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Forewordvi
Foreword
Biological specimens collected, 
processed, and stored under opti-
mal conditions increasingly provide 
a necessary foundation for cancer 
research. Information obtained from 
such samples opens opportunities 
to learn more about the causes, 
prevention, and treatment of the 
disease. International comparisons 
made possible by the study of sam-
ple collections from different parts of 
the world are also invaluable in the 
pursuit of the evidence base for can-
cer control.
However, the above-mentioned 
opportunities are accompanied by 
many challenges and potential pit-
falls. At times, pragmatic decisions 
have to be made in response to the 
constraints faced when conducting 
clinical or population-based studies. 
These constraints may be techni-
cal, may relate to infrastructure or 
finance, or may be ethical, legal, 
or social in nature. Being unaware 
of these types of risk to successful 
biobanking can place important sci-
entific advances in jeopardy.
In this context, it is a great plea-
sure to introduce this publication 
from the International Agency for 
Research on Cancer (IARC). The 
purpose of the text is to provide 
clear and practical advice on the 
common practices needed to create 
and maintain biobanks, recognizing 
that the circumstances faced by the 
curators of biobanks vary across 
the world. The international coop-
eration that went into formulating 
these Common Minimal Technical 
Standards provides confidence that 
the content is realistic, while at the 
same time maintaining the minimal 
standards needed in order for the 
biospecimens to be valid and to 
yield the reliable research data be-
ing sought. In providing this Fore-
word, I would like to place on record 
my thanks to all authors and review-
ers who have contributed to this final 
product, as well as to all the contrib-
utors to Common Minimum Techni-
cal Standards and Protocols for Bio-
logical Resource Centres Dedicated 
to Cancer Research, known as the 
“Green Book”, published by IARC in 
2007.
In publishing this book, my hope 
is for a balanced focus, not only on 
what goes into a biobank but also on 
what comes out. There is a risk that 
biobanks remain untouched or un-
derexploited, a deposit that is rarely 
put to work for the common good. 
While this book aims to ensure that 
what goes into a biobank is of high 
quality and well managed, it has as 
its ultimate objective to drive the use 
of those same biospecimens in re-
search. This will involve the analysis 
of biospecimens, but to maximize the 
benefits it will also require linkage to 
other well-documented epidemio-
logical and clinical data sets. In this 
period of spiralling numbers of can-
cer cases and costs of cancer care, 
the failure to use stored samples to 
answer critical research questions is 
indefensible.
In conclusion, I trust that readers 
will find this publication to be a sup-
port to successful biobanking and 
will find herein one important foun-
dation for cancer research in the 
21st century.
Dr Christopher P. Wild
Director, International Agency 
for Research on Cancer
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Preamble
The International Agency for 
Research on Cancer (IARC) pub-
lished Common Minimum Technical 
Standards and Protocols for Biologi-
cal Resources Centres Dedicated 
to Cancer Research, known as the 
“Green Book”, in 2007. The recom-
mendations and protocols in that 
publication were largely based on 
guidelines, procedures, and docu-
mentation on biorepositories devel-
oped by several working groups, 
institutions, regulatory bodies, and 
organizations, including the World 
Health Organization.
However, biobanking has devel-
oped at a rapid pace over the years, 
driven mainly by the push for person-
alized medicine, the need for high-
quality biological resources and as-
sociated data for scientific research, 
and technological advancement of 
analytical platforms for molecular 
and genetic research. These devel-
opments have enabled the collec-
tion and analysis of large numbers 
of biospecimens in combination with 
epidemiological and clinical data 
collected across populations and in-
volving multiple biobanks.
In response to these develop-
mental changes and to promote col-
laborative projects, a wide range of 
biobanking stakeholders are estab-
lishing approaches and mechanisms 
for the harmonization of resources, 
including data. These stakehold-
ers include international organiza-
tions, societies, and institutions, 
such as the United States National 
Cancer Institute (NCI), the Interna-
tional Society for Biological and En-
vironmental Repositories (ISBER), 
the European, Middle Eastern and 
African Society for Biopreserva-
tion and Biobanking (ESBB), and 
the Biobanking and BioMolecular 
resources Research Infrastructure–
European Research Infrastructure 
Consortium (BBMRI-ERIC). Their 
activities include the improvement of 
biobanking protocols and standards 
to provide high-quality samples and 
to adequately address ethical, legal, 
and social issues (ELSI).
This IARC Technical Publica-
tion includes guidelines and recom-
mendations for biobanks not only in 
high-income countries but also in 
low- and middle-income countries 
(LMICs). The recommendations are 
based on validated and/or evidence-
based guidelines, taking into account 
the current knowledge of biobanking 
practices and standards resulting 
from projects such as Standardisa-
tion and Improvement of Generic Pre-
analytical Tools and Procedures for In 
Vitro Diagnostics (SPIDIA), BBMRI–
Large Prospective Cohorts (BBMRI-
LPC), and the International Geno-
mics Consortium (IGC), as well as the 
European Committee for Standard-
ization (CEN) Technical Specifica-
tions for molecular in vitro diagnostic 
examinations and International Or-
ganization for Standardization (ISO) 
norm 15189 (ISO, 2012). ISO 15189 is 
currently under revision (https://www.
iso.org/obp/ui/#iso:std:iso:15189:ed-
3:v2:en), and the working groups 
of the Technical Committee of ISO 
276  (http://www.iso.org/iso/home/ 
standards_development/list_of_iso_
technical_committees/iso_technical_ 
committee.htm?commid=4514241) 
are dealing with biobanking qual-
ity issues, including terminology, 
bioresearch, bioprocessing, pre- 
analytical methods, isolation of 
viii
analytes, and data processing and 
integration.
This book also includes sections 
on sample sharing, ELSI, and harmo-
nization guidelines important to sup-
port collaborative research efforts 
that make use of biological materi-
als. In particular, the section on open 
access deals with the principles of 
sharing and provides recommenda-
tions for biobanks in relation to sam-
ple and data sharing, which is key to 
establishing research collaboration. 
The section on governance provides 
guidelines on governance structures 
for biobanks for transparent and ef-
fective running of the facilities. Tem-
plates for informed consent and Ma-
terial and Data Transfer Agreements 
are available in the Annexes section.
This new book also benefits 
from the experience and knowl-
edge gained by IARC from coordi-
nating the LMICs Biobank and Co-
hort Building Network (BCNet) and 
managing an international biobank, 
which contains diverse collections 
of specimens and data drawn from 
studies across the world, including 
the European Prospective Inves-
tigation into Cancer and Nutrition 
(EPIC) collection.
The guidelines and recommen-
dations are applicable to biobanks 
operating in different geographical 
locations, and although the book’s 
focus is on biobanks dedicated to 
cancer research, the principles and 
guidelines outlined here are also 
applicable to non-cancer biobanks.
Table 1 presents a list of the 
main sources of information used 
to develop the recommendations 
presented in this book. Whenever 
appropriate, the book indicates ref-
erences and links to more extensive 
documentation and protocols.
Table 1. Guidelines, procedures, and documentation on biobanks
Title Authors/origin
Tissue banking for biomedical research National Cancer Centre Singapore
Biorepository protocols Australasian Biospecimen Network (ABN)/Australia
Standardizing tissue collection and quality control procedures for a 
European virtual frozen tissue bank network
European Human Frozen Tumour Tissue Bank (TuBaFrost)
Human tissue and biological samples for use in research: operational 
and ethical guidelines
Medical Research Council (MRC)/United Kingdom
2012 Best practices for repositories: collection, storage, retrieval, and 
distribution of biological materials for research
International Society for Biological and Environmental Repositories 
(ISBER)/International
NCI best practices for biospecimen resources National Cancer Institute (NCI)/USA
Guidance on regulations for the transport of infectious substances World Health Organization (WHO)/International 
United Nations recommendations on the transport of dangerous goods, 
model regulations, 19th revised edition
United Nations Economic Commission for Europe (UNECE)/
International 
Recommendation Rec(2006)4 of the Committee of Ministers to Member 
States on research on biological materials of human origin
Council of Europe Committee of Ministers
Collection, transport, preparation, and storage of specimens for 
molecular methods: approved guideline
Clinical and Laboratory Standards Institute (CLSI)/USA
The Human Proteome Organization Human Proteome Organization (HUPO)
Case studies of existing human tissue repositories: “best practices” for 
a biospecimen resource for the genomic and proteomic era
RAND Corporation/USA
Biological resource centres: underpinning the future of life sciences and 
biotechnology
Organisation for Economic Co-operation and Development (OECD)/
International
OECD best practice guidelines for biological resource centres Organisation for Economic Co-operation and Development (OECD)/
International
Standard operating procedure for the collection of fresh frozen tissue 
samples
European Organisation for Research and Treatment of Cancer 
(EORTC)
Abbreviations ix
ACD acid citrate dextrose
BBMRI-ERIC  Biobanking and BioMolecular resources Research Infrastructure–European Research 
Infrastructure Consortium
BBMRI-LPC BBMRI–Large Prospective Cohorts
BCNet LMICs Biobank and Cohort Building Network
BRIF Bioresource Research Impact Factor
BRISQ Biospecimen Reporting for Improved Study Quality
CEN European Committee for Standardization
CO2 carbon dioxide
CSF cerebrospinal fluid
DBS dried blood spot
DEPC diethylpyrocarbonate
DIN DNA integrity number
DMSO dimethyl sulfoxide
DNA deoxyribonucleic acid
DR disaster recovery
dsDNA double-stranded DNA
DTA Data Transfer Agreement
EDTA ethylenediaminetetraacetic acid
ELSI ethical, legal, and social issues
EPIC European Prospective Investigation into Cancer and Nutrition
ESBB European, Middle Eastern and African Society for Biopreservation and Biobanking
EU European Union
FBS fetal bovine serum
FFPE formalin-fixed, paraffin-embedded
GA4GH Global Alliance for Genomics and Health
gDNA genomic DNA
HBV hepatitis B virus
HIV human immunodeficiency virus
IARC International Agency for Research on Cancer
IATA International Air Transport Association
ICAO International Civil Aviation Organization
Abbreviations
xISBER International Society for Biological and Environmental Repositories
ISO International Organization for Standardization
IT information technology
LIMS laboratory information management system
LMICs low- and middle-income countries
LN2 liquid nitrogen
MIABIS Minimum Information about Biobank Data Sharing
miRNA microRNA
MTA Material Transfer Agreement
NCI United States National Cancer Institute
NIH United States National Institutes of Health
OCT optimal cutting temperature
OECD Organisation for Economic Co-operation and Development
P3G Public Population Project in Genomics and Society
PCR polymerase chain reaction
QA quality assurance
QC quality control
QMS quality management system
qPCR quantitative PCR
R&D research and development
RIN RNA integrity number
RNA ribonucleic acid
rRNA ribosomal RNA
RT-PCR reverse transcription PCR
SOPs standard operating procedures
SPREC Sample PREanalytical Code
ssDNA single-stranded DNA
TNM tumour–node–metastasis
TuBaFrost European Human Frozen Tumour Tissue Bank
UNECE United Nations Economic Commission for Europe
UV ultraviolet
WHO World Health Organization
Section 1. Glossary and definitions 1
S
EC
TI
O
N
 1
S
EC
TI
O
N
 1
section 1. 
Glossary and definitions
Aliquot
Aliquoting is a process in which a 
specimen is divided into separate 
parts, which are typically stored as 
individual samples. The term “ali-
quot” may also be used as a noun 
to denote a single sample. It is ad-
visable to store aliquots in separate 
containers, to minimize loss due to 
unexpected equipment failure.
Analyte
A substance or chemical constituent 
that is determined in an analytical 
procedure.
Annotation
Additional information associated 
with a particular point in a document 
or other piece of information.
Anomaly
An unexpected event occurring with-
in the quality management system, 
Unless otherwise defined in an-
other context in this book, important 
terms are defined below.
Some of the definitions are ac-
cording to the 2012 International So-
ciety for Biological and Environmen-
tal Repositories (ISBER) guidelines 
(ISBER, 2012). 
It should be noted that the Inter-
national Organization for Standard-
ization (ISO) standards that are cur-
rently under development and will be 
released within 2 years (ISO/TC 276 
Biotechnology) will include a section 
on biobanking definitions.
Adverse event
Any event that caused harm or had 
the potential to cause harm to any 
biobank personnel or visitors, in-
cluding but not limited to breach of 
security of the premises and its con-
tents, or harm to biospecimens or 
data integrity or linkage.
usually detected by staff of the area 
in which the event occurred, which 
may result in non-compliance with 
the quality management system or 
with the requirements of the user.
Anonymization
The process in which identifying 
information or details are re- 
moved from the data collected with 
a sample, so that the sample donor 
remains anonymous.
Associated data
The clinical, pathological, and epide-
miological information related to pa-
tients who provided a sample. The 
information relates to characteristics 
of the sample, the study participant, 
and biological experiments that can 
be used to generate knowledge.
Autopsy
The postmortem examination of 
2that can affect human health. It can 
also include substances harmful to 
animals.
Biological resource
A collection of biological specimens 
and associated data that are ac- 
quired for a defined purpose. The 
custodian of the collection is re-
sponsible for the management of the 
biological resource. Biological re-
sources may be stored in a biobank 
or laboratory and in databases, de-
pending on the number of samples, 
the volume of information, and the 
governance structure of the biobank.
Biological safety hood
A cabinet designed to provide a mi-
crobe-free work environment, which 
enables work on samples in an 
isolated area.
Biorepository
See “Biobank”.
Coding
Substituting a code for personally 
identifying information in such a way 
that linkage is only possible through 
a key.
Cold chain
A temperature-controlled supply chain.
Cold ischaemia
The condition of a tissue sample af-
ter its removal from the body until its 
stabilization or fixation.
Collection
The practice or technique of collect-
ing a specimen, or a specific sam-
ple or group of samples, that has 
been isolated for future research 
purposes.
Consignee
Any individual, agency, institution, 
or organization that receives speci-
mens and assumes responsibility for 
storing, dispensing, and tracking the 
disposition of specimens.
organs and tissues of a body, to de-
termine cause of death or pathologi-
cal conditions.
Biobank
Infrastructure for the collection, ar-
chiving, and storage of biospeci-
mens and their associated data, and 
the procedures and related servic-
es connected to the biospecimens 
and associated data. The services 
include informing individuals who 
are approached to participate in a 
study, obtaining their consent, col-
lecting and processing specimens 
for secure long-term storage, ac-
cessing and retrieving specimens 
appropriate for analysis, processing 
for preparation of biomaterials (e.g. 
DNA, RNA, proteins), quality con-
trol, and packaging and shipping of 
specimens. Many types of biobank 
are relevant to cancer research. 
They include, among others, tumour 
and tissue biobanks for specimens 
and data obtained in the course of 
normal clinical procedures; special-
ized collections of specimens and 
data developed in the context of 
clinical trials, mechanistic studies, 
or diagnostic or prognostic studies; 
and collections of specimens and 
data developed in epidemiologi-
cal studies and biomarker studies. 
Biobank samples include tissues, 
blood, cell lines, DNA, and pro-
teins derived from individuals with a 
history of hereditary or familial 
cancer. Biobanks are also known as 
biorepositories.
Biobanking
The process of storing material or 
specimens and associated data for 
future use.
Biohazard
An organism, or a substance de-
rived from an organism, that poses 
a threat to (primarily) human health. 
This can include medical waste and 
samples of a microorganism, virus, 
or toxin (from a biological source) 
Container
An enclosure for one or more units 
of a specimen or specimens.
Controlled areas
Restricted work areas of low micro-
bial and particulate content in which 
non-sterile materials are prepared.
Custodian
The person responsible for the 
management of a biological re-
source. The custodian works with 
other key stakeholders in the man-
agement of the resource, including 
the tracking of all relevant documen-
tation for the resource, and is re-
sponsible for ensuring that policies 
on access to the resource are in 
place and are implemented accord-
ing to appropriate guidelines.
Database
A structured collection of records 
or data that is stored in a computer 
system so that a computer program 
or a person using a query language 
can consult it to answer queries.
Dehydration
The removal of water from a tissue.
De-identification
A process that ensures that a per-
son’s identity cannot be connected 
with information or samples donated 
by them.
Desiccant
A desiccant is a hygroscopic sub-
stance that induces or sustains a 
state of dryness (desiccation) in its 
vicinity. Commonly encountered 
pre-packaged desiccants are solids 
that absorb water.
Deviation
An intentional or unintentional event 
that departs from a set procedure or 
normal practice.
Dewar
A specialized container that holds 
Section 1. Glossary and definitions 3
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liquefied gases. A dewar may also 
be referred to as a dewar flask or 
dewar vessel, or a liquid nitrogen 
tank.
Distribution
A process that includes receipt of 
a request for specimens, selection 
of appropriate specimens, and 
final inspection, in conjunction with 
subsequent shipment and delivery 
of specimens to another biobank, 
specimen collection centre, or 
laboratory.
Donor
A person who donates or gives an 
organ, blood, or blood products to 
another person.
Dry ice
Solid-phase carbon dioxide (CO2). 
CO2 solidifies at −78.5  °C.
End user
A health-care practitioner, scien-
tist, or laboratory staff member who 
performs an appropriate procedure, 
test, or archival function.
Error
A deviation from a standard operat-
ing procedure (SOP) during speci-
men retrieval, processing, testing, 
quarantining, labelling, storage, or 
distribution that might adversely 
affect the specimen.
Ethical, legal, and social issues 
(ELSI)
The ethical, legal, and social issues 
associated with the development 
and operation of a biobank.
Identifier
Information (e.g. name, social se-
curity number, medical record 
number, or pathology accession 
number) that would enable the iden-
tification of the subject. For some 
specimens, this information might 
include the taxon name and the 
collection number.
Incident
Any unplanned occurrence that 
deviates from standard operating 
procedures (SOPs) or applicable 
government laws and regulations 
during specimen retrieval, process-
ing, labelling, storage, or distribution 
that may affect subsequent use of 
those specimens.
Individual
The person who is the subject of pro-
tected health information.
Informed consent
A decision to participate in research, 
taken by a competent individual 
who has received the necessary in-
formation; who has adequately un-
derstood the information; and who, 
after considering the information, 
has arrived at a decision without 
having been subjected to coercion, 
undue influence, inducement, or 
intimidation.
Institution
The body responsible for speci-
men collection and archiving that 
commits itself to the development, 
management, and long-term main-
tenance of a biobank. Although the 
organizational nature of such insti-
tutions may vary widely, they are 
primarily clinical cancer centres, 
academic medical centres, research 
institutes closely associated with 
clinical centres, or central organiza-
tions dedicated to the management 
of biobanks.
Institutional review board (IRB)
See “Research ethics committee 
(REC)”.
Label
Any written, printed, or graphic mate-
rial on or affixed to a specimen con-
tainer or package.
Liquid nitrogen (LN2)
Coolant used to cool and store 
samples. Nitrogen becomes liquid 
at −196   °C. Samples stored in the 
vapour phase of liquid nitrogen are 
−190 °C and warmer, depending on 
the distance from the liquid phase.
Liquid nitrogen tank
See “Dewar”.
Lyophilized
Dehydrated for storage by conver-
sion of the water content of a frozen 
specimen to a gaseous state under 
vacuum. Also called “freeze-dried”.
Material Transfer Agreement (MTA)/ 
Data Transfer Agreement (DTA)
An agreement or contract that gov-
erns the transfer of research materi-
als and/or data between two organi-
zations, when the recipient intends to 
use them for research purposes. It 
defines the rights and obligations of 
the provider and the recipient with 
respect to the use of the materials 
and/or data.
Monitoring system
A system that monitors the temper-
ature and environmental conditions, 
including alarms, in conjunction with 
remote access, security features, 
and electronic data storage.
Participant
A person who takes part in a trial. 
Participants must usually meet cer-
tain eligibility criteria.
Patient
A person who receives medical at-
tention, care, or treatment.
Pre-analytical data
Factors that may have an impact on 
the integrity of the sample during the 
collection, processing, and storage 
processes. These data include infor-
mation on the treatment of the sam-
ple, including the conditions and the 
duration of the treatment.
Preservation
The use of chemical agents, alterations 
4in environmental conditions, or oth-
er means during processing and 
storage to prevent or retard bio- 
logical or physical deterioration of a 
specimen.
Procedure
A series of steps that, when followed 
in order, are designed to result in a 
specific outcome.
Processing
Any procedure used after specimen 
collection but before distribution, 
including preparation, testing, and 
releasing the specimen to inventory 
and labelling.
Pseudo-anonymization
The process whereby identifiable 
personal information is anonymized, 
but in such a way that the per- 
sonal identifiers are replaced by one 
pseudonym, which can be linked 
across multiple data records without 
revealing the identity of the person.
Quality
Conformance of a specimen or pro-
cess with pre-established specifica-
tions or standards.
Quality assurance (QA)
An integrated system of manage-
ment activities involving planning, 
implementation, documentation, as- 
sessment, and improvement to 
ensure that a process or item is of 
the type and quality needed for the 
project.
Quality control (QC)
The system of technical activities that 
measures the attributes and perfor-
mances of a process or item against 
defined standards, to verify that the 
stated requirements are fully met.
Quality management system (QMS)
The organizational structure, pro-
cedures, processes, and resourc-
es needed to implement quality 
management.
Re-identification
A reversible process that allows 
data from which identifiers have 
been removed, and replaced by 
a code, to be re-identified and 
linked to a specific individual by, for 
example, using the code or linking 
different data sets.
Removal
See “Retrieval”.
Repository
An entity that receives, stores, pro-
cesses, and/or disseminates speci-
mens, as needed. This term encom-
passes the physical location as well 
as the full range of activities associ-
ated with its operation. A repository 
may also be referred to as a bio- 
repository or a biobank.
Research ethics committee (REC)
A board, committee, or other group 
formally designated by an institution 
to review the ethical, legal, social, 
scientific, and financial implications 
of biomedical research involving 
humans as subjects, to approve 
the initiation of the research, and to 
conduct periodic reviews of such re-
search. In some countries, this body 
is known as an institutional review 
board (IRB) or a research ethics 
board (REB).
Retrieval
The removal, acquisition, recov-
ery, harvesting, or collection of 
specimens.
Safety
Processes, procedures, and tech-
nologies to ensure freedom from 
danger or harm.
Sample
A single unit containing material 
derived from one specimen.
 
Shipping manifest
A written description of the contents 
of a shipped package.
Snap-freezing
The process by which the temper- 
ature of samples is lowered very rap-
idly to below −70 °C using dry ice or 
liquid nitrogen.
Specimen
A specific tissue sample, blood sam-
ple, and so on taken from a single 
subject or donor at a specific time.
Standard operating procedures 
(SOPs)
A set of detailed written instructions 
to achieve uniformity of the perfor-
mance of a specific function.
Storage
Maintenance of specimens under 
specified conditions for future use.
Subject
A living or deceased individual who 
is the source of the specimen in ac-
cordance with established medical 
criteria, procedures, and privacy reg-
ulations. In some countries, the term 
“Donor” or “Individual” may be used 
in the same context as “Subject”, 
especially in the context of human 
specimens.
Traceability
The ability to locate a specimen dur-
ing any step of its donation, collec-
tion, processing, testing, storage, 
and disposition.
Warm ischaemia
The condition in which the tissue 
is deprived of its normal blood 
supply, containing oxygen and nu-
trients, while the tissue is at body 
temperature.
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The role of biobanks in biological 
research in general and their impact 
on medical, societal, and economic 
issues have been discussed in two 
reports from the Organisation for 
Economic Co-operation and Devel-
opment (OECD) (OECD, 2007, 2009). 
The OECD publications address the 
importance, justification, and sustain-
ability of developing biobanks for re-
search. In 2014, the Biobanking and 
BioMolecular resources Research 
Infrastructure–European Research 
Infrastructure Consortium (BBMRI- 
ERIC), an umbrella organization for 
biobanking in Europe, was estab-
lished to provide a focal point for 
biobanking activities in Europe and 
to provide fair access to quality-con-
trolled human biological samples and 
associated data for cross-biobanking 
research (van Ommen et al., 2015; 
Mayrhofer et al., 2016).
2.1 Importance of biobanks
2.1.1 Biobanks are critical for 
cancer research
Human biological specimens have 
been used for many decades for 
translational purposes in cancer re-
search, to investigate disease patho-
genesis, to test scientific hypotheses, 
and to assess biomarkers identified 
in experimental studies. The advent 
of new technologies opens unprec-
edented opportunities to assess the 
status of the human genome and its 
expression, the complex networks of 
interactions between biomolecules, 
and the functional and clinical con-
sequences of their alteration (NCI, 
2016).
Therefore, studies on human 
specimens are also becoming critical 
for the process of discovering new 
mechanisms involved in causing can-
cer or in determining its progression, 
resistance or response to treatment, 
and clinical outcome (Riegman et al., 
2006a). 
Biobanks are the foundation of 
three rapidly expanding domains of 
biomedical science:
•  molecular and genetic epidemiolo-
gy (aimed at assessing the genetic 
and environmental basis of cancer 
causation in the general population 
as well as in families);
•  molecular pathology (aimed at de-
veloping molecular-based classifi-
cation and diagnostic procedures 
for cancers); and
•  pharmacogenomics/pharmacopro-
teomics (aimed at understanding 
the correlation between an in-
dividual patient’s genotype or 
phenotype and response to drug 
treatment).
section 2. 
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62.1.2 Biobanks are important 
for developing personalized 
medicine and/or precision 
medicine
With conventional diagnostic meth-
ods, risk factors of importance, as 
well as the opportunity to prevent 
diseases that may emerge later, are 
often overlooked when the focus is on 
the symptoms manifested. Collecting 
and analysing biological specimens 
is a necessary procedure for pathol-
ogy-based diagnosis and to enable 
patients to benefit from the applica-
tions of molecular and genetic cancer 
research.
Personalized medicine and pre-
cision medicine are transforming di-
agnosis in medicine and are leading 
towards patient-centred and multifac-
eted diagnostics (Hall et al., 2011).
Personalized medicine is an 
emerging practice of medicine that 
uses an individual’s genetic and en-
vironmental profile to guide decisions 
made about the prevention, diagno-
sis, and treatment of disease. This 
concept has been refined and its 
scope expanded to include the ap-
proaches, decisions, and practices in 
medical facilities, resulting in the new 
term “precision medicine”.
Precision medicine is defined 
by the United States National Insti-
tutes of Health (NIH) as “an approach 
to disease treatment and prevention 
that seeks to maximize effectiveness 
by taking into account individual var-
iability in genes, environment, and 
lifestyle” (Precision Medicine Initiative 
Working Group, 2015). In precision 
medicine, genomic and epigenomic 
analyses with associated data can be 
used to define individual patterns of 
disease and susceptibility. Perform-
ing molecular-based assessments 
may become a systematic require-
ment at different stages of patient 
follow-up, potentially leading to bet-
ter individual prevention, diagnosis, 
prognosis, treatment, and monitoring.
2.1.3 Biobanks have an 
impact on biotechnological 
and medical innovation
In the continuum from laboratory dis-
covery to medical application, bio-
banks play a key role in life science 
research and development (R&D). 
Progress in medicine depends on 
innovation, development, and the 
translation of laboratory findings into 
clinical practice. Access to human 
biological specimens and associat-
ed data is often a prerequisite for 
such R&D advances.
Therefore, the development of 
high-quality biobanks with innovative 
research platforms has accelerated 
and facilitated this translational pro-
cess. This is due mainly to techno- 
logical advances and reductions in 
the cost of information technology 
(IT), used for data storage and for the 
assembly, evaluation, and analysis of 
large numbers of samples, as well as 
increases in analytic capabilities and 
the drastically reduced costs of DNA 
sequencing, with results available 
within a shorter time frame. Simi-
lar advances in mass spectrometry 
have drastically lowered the cost and 
expanded the ability to characterize 
proteins and the metabolites present 
in biological samples.
2.1.4 Importance of 
networking and exchanges 
between biobanks
Cancer is a burden faced by people 
across the globe. Occurrence and 
mortality rates vary in different parts 
of the world. In addition, studies of 
many rare forms of cancer are limited 
by the difficulty of recruiting a suffi-
cient number of cases within any sin-
gle collection centre, or even within 
one country.
Networking, or harmonizing, of 
biobanks can encourage the col-
lection of higher-quality samples 
and data, enable larger research 
projects to take place, and reduce 
duplication of effort (Yuille et al., 
2008; Harris et al., 2012). For can-
cer biobanks, networking can en-
able the study and classification 
of rare cancers; a cancer type is 
considered rare if fewer than 5 cas-
es are diagnosed in a population of 
10 000, and rare cancers make up 
at least 20% of new cancer cases 
(ESMO, 2010; van Ommen et al., 
2015; Mayrhofer et al., 2016).
Networking implies a multidirec-
tional flow of information, expertise, 
and biological materials between 
cancer centres and research insti-
tutions and requires the adoption 
of common technical standards for 
specimen collection, storage, and 
annotation, and for data collection 
and management. Biobanks have 
an important role in facilitating such 
exchanges and in providing logis-
tics and infrastructure for multi- 
centre research projects involving 
cancer centres, academic medical 
centres, and diagnostic and health- 
care facilities. Biobank networks 
involved in the collection, process-
ing, storage, and dissemination of 
biological specimens can range 
from small operations with single 
projects in research or university 
laboratories to large operations in 
hospital, academic, or commercial 
biobanks. National, regional, and 
international networks are also de-
veloping to provide resources from 
diverse populations. For example, the 
Low- and Middle-Income Countries 
(LMICs) Biobank and Cohort Building 
Network (BCNet), coordinated by the 
International Agency for Research 
on Cancer (IARC), has established 
a virtual catalogue to document the 
resources of its members.
The operational model and gov-
ernance of networks depend on their 
focus and mission. One such model is 
the federated model, where the bio-
banks maintain their samples and 
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contribute to a common network 
project when necessary. Another 
model is the project-based model, 
where the biobanks collect samples 
for a specific project (Vaught et al., 
2009).
Several factors can contribute to 
the success of a biobank network. 
They include:
•  well-defined goals, effective coor-
dination, and funding mechanisms;
•  efficient communication between 
the relevant medical disciplines and 
the global scientific community;
•  standard operating procedures 
(SOPs), compatible informatics 
systems, and harmonized informed 
consent and material transfer poli-
cies and procedures; and
•  tools to enable de-identified, up-
to-date follow-up and retrieval of 
information and clinical data on 
participants.
These tools are key to the suc-
cess of biobank networks.
The European Prospective In- 
vestigation into Cancer and Nu-
trition (EPIC) study, a popula-
tion-based study that was initiated 
in the 1990s and coordinated by 
IARC, is an example of an effec-
tive networked project. The project 
involved partners from 10 European 
countries and 23 EPIC centres, and 
each centre collected biospecimens 
and data. Blood samples and as-
sociated data, including lifestyle 
and dietary information, were col-
lected at baseline. Blood samples 
from participants in eight out of the 
10 European countries are kept in 
the IARC central biobank. For two 
Scandinavian countries, blood sam-
ples are kept locally.
Although EPIC has a central 
biobank for the baseline samples, 
the tissue samples from individu-
als who develop cancer are kept at 
the centre, and this forms the EPIC 
federated biobank.
The EPIC study has provided 
opportunities for researchers to 
investigate lifestyle and cause of 
death (Bergmann et al., 2013) as 
well as dietary intake in relation 
to mortality among people who 
develop different types of cancer, 
such as colorectal cancer (Alek-
sandrova et al., 2014) and prostate 
cancer (Rohrmann et al., 2013), 
and other diseases, such as is-
chaemic heart disease (Crowe et 
al., 2012).
2.1.4.1 Tools for effective 
networking
Several important tools have been 
developed in recent years for effec-
tive networking and resource sharing 
between biobanks. Some examples 
are the following (see also Sec-
tion 3.8).
•  The Minimum Information about 
Biobank Data Sharing model 
(MIABIS 1.0 and MIABIS 2.0). MIABIS 
1.0 recommends the minimum data 
items and the format of the items 
required to enable the exchange 
of biological samples and data, 
and required to initiate collabora-
tions between biobanks (Norlin et 
al., 2012). MIABIS 2.0 provides an 
ontology that represents the admin-
istrative entities and includes data 
about the biobanks where specific 
specimens of interest are stored; 
this ontology can be helpful to an-
swer research-relevant questions, 
such as those about the scope and 
curation status of the specimens 
and the contact information for cu-
rators of biobanks (Brochhausen et 
al., 2013).
•  The Sample PREanalytical Code 
(SPREC) (Lehmann et al., 2012) 
identifies and records the main 
pre-analytical factors that may have 
an impact on the quality of sampled 
clinical fluids and solid biospeci-
mens and their simple derivatives 
during collection, processing, and 
storage. However, the SPREC tool 
may be less important with the re-
lease in 2015 of the European Com-
mittee for Standardization (CEN) 
norms (CEN/TS 16826, 16827, and 
16835) (CEN, 2015) and with the 
new ISO 276 standards, which will 
become available within 2 years.
•  The CEN norms deal with the stan- 
dardization of the entire process 
of sample handling, from primary 
sample collection to analysis. They 
are based on studies undertaken to 
determine the important influenc-
ing factors. The Technical Specifi- 
cations draw on the effort to codify 
and standardize the different steps 
in the pre-analytical phase.
2.1.4.2 Visibility and 
standardized citation schemes
Being part of an international network 
and contributing to a global catalogue 
of available resources, with the pos-
sibility of creating population-based 
biobanks, provides opportunities 
for biobanks to benefit from the ex-
periences and tools developed for 
networks. Increased participation in 
research will result in an increase 
in the visibility of biobanks and their 
recognition as an important part of 
research infrastructure. These at- 
tributes can serve to augment the con-
fidence of researchers and donors in 
the institutions and countries that the 
established resources are managed 
effectively and used optimally.
Recently, a programme of guide-
lines for reporting bioresource use 
and standardized citation schemes 
has been established to formal-
ly recognize the efforts involved in 
generating, maintaining, and sharing 
high-quality bioresources.
Two current initiatives aim to put 
in place standardized procedures for 
formally recognizing the contributions 
of biobanks in research through ci-
tations in scientific publications: the 
Citation of BioResources in Journal 
Articles (CoBRA) guidelines for the 
reporting of bioresource use in re-
search articles (Bravo et al., 2015) 
and the Bioresource Research Im-
pact Factor (BRIF), a standardized 
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8citation scheme. Biobanks joining 
the BRIF citation scheme will have 
increased visibility and will benefit 
from participation in network projects 
(Cambon-Thomsen et al., 2011).
The formal recognition of the role 
of biobanks in scientific research will 
encourage sharing of biological re-
sources and will increase the visibility 
of biobanks both nationally and inter-
nationally.
2.2 Issues in developing 
biobanks and using stored 
specimens
Developing and using the resources 
in a biobank requires the active in-
volvement of many professionals and 
has ethical and legal implications. 
Section 3.1 is dedicated to putting 
these ethical, legal, and social issues 
(ELSI) into perspective. However, it 
is useful to highlight some of the key 
documents and principles that can 
guide decision-making when estab-
lishing a biobank. Key documents 
include the following:
•  the WMA Declaration of Taipei on 
ethical considerations regarding 
health databases and biobanks 
(WMA, 2016);
•  the WMA Declaration of Helsinki, 
which provides the general frame-
work in which questions relating to 
medical research can be addressed 
(WMA, 2013);
•  the more specific guidance issued 
by the OECD: Guidelines on Human 
Biobanks and Genetic Research 
Databases (OECD, 2009) and Best 
Practice Guidelines for Biological 
Resource Centres (OECD, 2007);
•  best practice principles outlined 
by organizations such as the Unit-
ed States National Cancer Insti-
tute (NCI) (NCI, 2016) and ISBER 
(ISBER, 2012);
•  guidance from the Global Alliance 
for Genomics and Health (GA4GH) 
(GA4GH, 2016) and the Public  Pop-
ulation Project in Genomics and So-
ciety (P3G) (P3G, 2016); and
•  European Union (EU) legislation, in-
cluding the General Data Protection 
Regulation (European Commission, 
2016).
Another useful approach derives 
rights and responsibilities from a set 
of four ethical principles guiding bio-
medical research: respect for autono-
my, non-maleficence (to do no harm), 
beneficence (to do good), and justice 
(Beauchamp and Childress, 2013). 
Protecting the rights of individuals 
arising from these principles includes 
the development of appropriate 
methods to obtain informed consent 
from a potential participant and the 
development of research protocols 
that are fully compatible with the 
principles of beneficence, non-ma-
leficence, and justice. The institu-
tions and investigators that develop 
and manage biobanks also have a 
responsibility to protect personal 
data, ensure biological and environ-
mental safety, and make collections 
accessible and available for reuse for 
research purposes under (the con-
sented) defined conditions. Access 
requests should take into account the 
non-renewable nature of the speci-
mens in setting priorities for scientific 
use, and the distribution of specimens 
for research should be governed by 
the use of clear and documented Ma-
terial Transfer Agreements (MTAs). 
These rights and responsibilities are 
further defined and addressed in the 
remainder of this book.
2.3 Principles for sustainable 
biobanks
Developing a biobank is expensive. 
Added to the maintenance and run-
ning costs, this can place financial 
strain on underresourced institutions. 
These constraints are a significant 
obstacle to developing biobanks 
in low- or middle-income countries 
and for the long-term sustainability 
of biobanks worldwide. Overcoming 
these obstacles requires a signifi-
cant concerted effort of national and 
international solidarity. The public 
sector (local and national govern-
ments and international bodies and 
organizations) has a responsibility 
to contribute to the funding of the 
basic infrastructure of biobanks, be-
cause of the important contribution 
of biobanking to research on global 
health and diseases. In contrast, the 
responsibility for the development 
and maintenance of sustainable and 
usable resources lies primarily with 
the institutions.
Institutions and the public sector 
should make provision for:
• infrastructure
• maintenance of infrastructure
• equipment
• running costs
• trained personnel
• data management systems
•  quality management systems (QMSs)
• procedures to deal with ELSI.
In addition, users of the biobank-
ing infrastructure facilities should con-
tribute through cost reimbursement, 
for the financial and structural sus-
tainability of biobanks. Thus, biobanks 
should establish user fees for access 
to human specimens, data, and ser-
vices, to cover the costs of collecting, 
annotating, storing, retrieving, and 
processing the delivered biospeci-
mens. However, human biospecimens 
should not under any circumstances 
be commercialized. Regardless of the 
role of industry in core funding, which 
is a matter of debate with serious im-
plications, the legal responsibility and 
custodianship of the specimen collec-
tion and storage must remain within 
institutions. This is because people 
who agree to provide their samples 
donate to the institution and not to 
researchers or individuals, and the 
samples will remain in the primary 
institution after the research project 
ends or the researcher leaves the 
organization. To ensure continuity in 
the management of the samples, the 
institution should nominate another 
person who will assume primary re-
sponsibility for the samples.
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In defining mechanisms for sus-
tainability or stability, there is a need 
to develop safeguards for preserva-
tion of participant confidentiality and 
protection against improper use of 
human biospecimens and data. In 
addition, the stability of biobanks re-
lies heavily on the value of the stored 
resources, in terms of their quality 
and scientific relevance and the use 
of the samples.
Financial forecasts have demon-
strated that the actual costs associ-
ated with biobanking are significantly 
higher than recognized by researchers 
and funding bodies (Matharoo-Ball 
and Thomson, 2014). Cost recovery 
is essential for biobank sustainability 
and stability. Although each institu-
tion will have to decide on the cost-re-
covery model that will best serve its 
purposes, common elements to be 
considered include costs related to 
personnel, equipment, supplies, and 
service contracts.
The models should be consid-
ered in the context of relationships 
between the users, funding agen-
cies, academia, and universities, 
and possibly also industry partners. 
Contingency plans in case of unex-
pected incidents and inadequate 
supporting infrastructure, such as 
flood or fire disasters, interruption 
in electricity supply, and poor Inter-
net connectivity, should be included 
in any model.
2.4 General considerations 
for establishing a biobank
Several factors must be taken into ac-
count when setting up and running 
a biobank. A detailed description of 
these requirements is provided in the 
2012 Best Practices for Repositories: 
Collection, Storage, Retrieval, and 
Distribution of Biological Materials 
for Research, developed by ISBER 
(ISBER, 2012). Some aspects of 
particular importance in setting up 
a biobank for cancer research are 
highlighted here.
2.4.1 Institutional commitment
Many factors contribute to the deci-
sion to establish and run a biobank. In 
practice, the process often starts with 
the willingness of medical doctors 
and scientists to develop a resource 
useful for diagnosis, prognosis, and 
research purposes. However, the 
establishment of a biobank must not 
rely only on individual action but also 
requires a clear commitment by the 
host institution, which also needs to 
ensure that collections are developed 
within appropriate legal, ethical, clin-
ical, scientific, and technical guide-
lines, to provide historical continuity in 
specimen management and record- 
keeping. Finally, the biobank should 
ensure that the stored materials can 
be made available for research.
The purpose of the biobank must 
be clearly formulated and document-
ed. In case of loss of funding or other 
adverse events that may prevent the 
institution from maintaining its com-
mitment, it is the responsibility of 
the institution to take the necessary 
steps, depending on the applicable 
legal/ethical requirements. There may 
be an obligation to destroy the sam-
ples or to transfer the collected spec-
imens and data to another institution 
that will take over the commitment 
for the long-term maintenance of the 
resources. There may be specific 
obligations related to such a transfer.
2.4.2 Ethical, legal, and social 
issues (ELSI) and governance
ELSI considers local, national, and 
international cultural, legal, social, 
and ethical norms. For example, the 
EU Data Protection Directive states 
that under EU law, personal data can 
be gathered legally only under strict 
conditions, for a legitimate purpose 
(European Commission, 1995). Fur-
thermore, people or organizations 
that collect and manage personal in-
formation must protect it from misuse 
and must respect certain rights of the 
data owners, which are guaranteed 
by EU law.
However, there are conflicting 
data protection rules in different 
countries, which need to be observed 
during international exchanges. 
Therefore, common EU rules have 
been established to ensure that per-
sonal data have a high standard of 
protection everywhere in the EU. The 
EU Data Protection Directive also 
provides specific rules for the trans-
fer of personal data outside the EU, to 
ensure the best possible protection of 
data when they are exported abroad.
ELSI and governance recom-
mendations relating to governance 
structures, informed consent, data 
protection, return of results and inci-
dental findings, and data and sample 
sharing are presented in Section 3.1.
An important governance issue 
to highlight when establishing and 
maintaining biobanks relates to pub-
lic engagement programmes and 
the establishment of clear channels 
of communication with partners and 
stakeholders. Therefore, transparen-
cy in procedures and operations is 
critical, and clear descriptions of the 
roles and responsibilities of person-
nel should be communicated to part-
ners and stakeholders. Given that 
participation is voluntary and that most 
biobanks operate on a non-economic 
basis, biobanks need public trust 
and support. It has become common 
practice for large-scale population 
biobanks to engage in consultation 
with the public and other stakehold-
ers before the biobank is established 
(UK Biobank Ethics and Governance 
Council, 2015, 2016). Methods of 
communication could include, for ex-
ample, consultation with community 
representatives, focus group meet-
ings, workshops, interviews, public 
meetings, polls, and surveys. Public 
consultation is particularly important 
when ethnic or cultural minorities are 
approached to participate in biobank 
collections. Section 3.1 provides fur-
ther information on transparency and 
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communication with key stakehold-
ers, and Section 3.1.2.5 describes 
community engagement in relation 
to the consent process.
2.4.3 Biobank management 
and staffing
Biobanks should be adequately 
staffed, and the personnel selected 
for these tasks must be well quali-
fied and have an appropriate level 
of specialized training. The biobank 
should be placed under the overall 
supervision of a biobank manager 
with sufficient training, experience, 
and seniority to fulfil the scope of the 
activities of the biobank. The manag-
er is responsible for operations, in-
cluding compliance with appropriate 
regulations, and has a critical role in 
receiving, processing, and respond-
ing to requests for access to stored 
specimens. The manager can act 
as a technical advisor to the access 
committee during the review of ac-
cess applications.
Running a biobank requires ded-
icated staff members for specimen 
processing and storage and for data 
management. The job description, 
tasks, and reporting system of all 
supervisory and technical staff mem-
bers must be documented. This is 
of particular importance in instanc-
es where biobank staff members 
also perform other tasks within the 
institution (e.g. pathology service 
or service activities in molecular 
biology). Staff members must have 
adequate educational backgrounds, 
experience, and training to ensure 
that assigned tasks are performed 
in accordance with the biobank’s 
established procedures. Updated 
training should be conducted on a 
periodic basis for personnel, in ac-
cordance with applicable regulations 
and roles within the biobank.
Other personnel who are not nec-
essarily staff members of biobanks 
but should be aware of the purpose 
and goals of obtaining high-quality 
bioresources are clinicians, research-
ers, technicians, nurses, surgeons, 
pathologists, and anaesthetists. The 
involvement of a pathologist in this 
process is crucial to ensure that 
patient care is not compromised 
(NCI, 2016).
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3.1 Ethical, legal, and social 
issues (ELSI) and governance
This section provides advice on 
developing an internal governance 
system for biobanks. It references 
recommendations and best prac-
tices of international organizations, 
including OECD (2007, 2009), ISBER 
(2012), GA4GH (2016), and NCI 
(2016), among others. However, the 
background of law and guidance is 
continually developing and should be 
monitored. For example, the new EU 
General Data Protection Regulation 
(European Commission, 2016) has 
implications for patients’ rights in 
medical research, CEN norms, and 
ISO standards.
Governance, in the context of bio-
banks, is not one-size-fits-all. During 
the establishment of a biobank, gov-
ernance systems should be designed 
to take into account the biobank’s 
scope and the context in which it 
operates (Laurie, 2011). A good inter-
nal governance system should:
•  ensure that the biobank remains 
faithful to its purpose, encour-
aging trust between the various 
stakeholders;
•  be guided by a set of overarching 
principles when making decisions, 
including being transparent, ac-
countable, consistent, proportion-
ate, efficient, coordinated, equita-
ble, and fair; and
•  be dynamic and able to adapt over 
time.
The internal governance ap-
proaches introduced in this section 
are based on a good governance 
structure or framework (Section 3.1.1) 
and documentation on:
•  informed consent (Section 3.1.2);
•  data protection, confidentiality, and 
privacy (Section 3.1.3);
•  return of results and incidental find-
ings (Section 3.1.4); and
•  access to and sharing of samples 
and data (Section 3.1.5; see also 
Annex 1).
Further sections consider quality 
(Section 3.4) and records manage-
ment (Section 3.6).
Good governance includes en-
gaging with the public during the 
establishment of a biobank and 
throughout the life-cycle of the bio-
bank. Therefore, the approach to 
public engagement must be con-
sidered from the outset. In addition 
to engaging with participants, the 
biobank may need to engage with 
the scientific community, research-
ers, patient groups, and/or the wid-
er public using a variety of meth-
ods, for example by consultation 
on study designs and policies, in-
volvement on committees, or publi-
cation and outreach. Good biobank 
governance also includes a strong 
commitment to researchers, ensur-
ing quality, efficiency, and trans-
parency of service. Therefore, the 
section 3.
Recommendations 
for biobanks
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following recommendations should 
be put into practice in collaboration 
with project principal investigators.
3.1.1 Governance framework
A good governance framework 
should define the organizational 
structure of the biobank, for daily 
management and oversight of its 
strategic policy. This framework usu-
ally includes lists and descriptions 
of the biobank’s personnel, commit-
tees, and policies that are required 
to enable the correct functioning of 
the biobank. The level of policies 
and procedures governing the bio-
bank should be scalable to its na-
ture, size, and available resources. 
For example, smaller biobanks may 
have more limited policies, whereas 
larger biobanks will need to develop 
a detailed protocol and procedures.
The policies are usually stipulat-
ed in a governance document that 
describes the objectives and scope 
of the biobank, the organizational 
structure, the scientific and eco-
nomic strategy of the biobank (which 
will be articulated in an annually up- 
dated business plan), and contingen-
cy plans in the event of closure. The 
governance document also includes 
policies on data protection and pri-
vacy as well as the procedures gov-
erning specific operational activities 
of the biobank.
Defining the structure and man-
date of committees and describing 
policies is an effective way to en-
sure adherence to proper gover- 
nance. However, if there are too 
many committees or policies, or if 
they are ill-defined, this can impede 
procedures and cause delays.
3.1.1.1 Governance organization
The biobank should have a structure 
of committees and appropriately quali-
fied personnel in relevant roles to over-
see its governance. The size, type, 
and number of committees and their 
composition will vary depending on the 
size and purpose of the biobank. Care-
ful consideration should be given when 
participants, patient groups, or public 
representatives are asked to serve 
on biobank committees. Their roles 
on the committee should be clearly 
communicated, and training should 
be provided. The following types of 
committee may be considered (Fig. 1).
Fig. 1. Sample committee structure for internal biobank governance.
Scientific oversight committee Ethics oversight committee
Laboratory safety and biosecurity committee Data and sample access committee
Public engagement committee Quality management committee
Operations or management committee
Biobank executive committee or steering group
Other committees:
Essential Strongly recommended Optional
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Executive committee or steering 
group
All biobanks should have an execu-
tive committee or steering group. The 
responsibilities of this committee may 
include overall management, defin-
ing strategic objectives, monitoring 
progress, revising and/or adopting 
policies, and developing a commu-
nications strategy. This committee 
may also conduct an annual review 
meeting to consider the QMS.
Ethics oversight (or advisory) 
committee
The ethics oversight committee ad-
vises the executive committee on 
strategy, developments, and proce-
dures relating to ethical oversight, in-
cluding legal and policy issues. The 
committee could include, for exam-
ple, ethicists, scientific researchers, 
medical experts, lawyers, social sci-
entists, and members of the public 
or participant organizations. In some 
cases, this committee may be part of 
a larger infrastructure, such as a local 
hospital ethics committee. In some 
countries, this committee may be a 
legal requirement.
Laboratory safety and biosecurity 
committee
All biobanks should establish, or have 
access to, a committee on laboratory 
safety, which may also consider gen-
eral health, safety, and security issues.
Data and sample access committee
Biobanks should consider establish-
ing a data and sample access com-
mittee, to oversee access requests, 
monitor related procedures, and en-
sure that participants’ interests are 
protected and biobank protocols 
are followed. In some cases, this 
committee is external to the biobank 
and is composed of independent 
members.
Operations or management 
committee
The role of the operations or man-
agement committee is to support the 
executive committee for the strate-
gic decisions of the biobank and to 
provide expertise in all aspects of 
biobanking operations (e.g. safe-
ty; quality and efficiency, including 
processing, storage, and distribution 
of biospecimens).
Larger biobanks may require 
additional committees, such as the 
following.
Scientific oversight (or advisory) 
committee
This committee would provide scien-
tific feedback to the executive com-
mittee, advise on scientific strategy 
and current developments, consider 
the pertinence of new collections, or 
advise on procedures. Membership 
should include relevant profession-
als. In some biobanks, this commit-
tee could be combined with an ethics 
oversight committee. In some coun-
tries, this committee may be a legal 
requirement.
Public engagement committee
This committee could help biobank 
personnel and associated research-
ers to better understand public opin-
ion. For some larger biobanks, ad-
visory panels of study participants 
meet regularly and provide feedback 
on new projects and review study 
materials, newsletters, and ques-
tionnaires. Examples are the Avon 
Longitudinal Study of Parents and 
Children (ALSPAC) teenage advisory 
panel (UK Biobank Ethics and Gov-
ernance Council, 2009) and the NIH 
Precision Medicine Initiative Cohort 
Program subcommittee, which has 
significant participant representation 
(Precision Medicine Initiative Work-
ing Group, 2015).
In terms of personnel, the bio-
bank should have clear reporting 
lines and accountability, with doc-
umented levels of authority and 
responsibility associated with each 
role. Clear responsibilities for staff 
members enable the biobank man-
agement to ensure that the biobank’s 
activities comply with ethical and 
legal requirements (OECD, 2009). An 
organizational chart and list of staff 
members and their responsibilities 
should be developed, alongside an 
organizational plan, which defines the 
organization and management of the 
biobank and its relationship to exter-
nal parties. Roles and responsibilities 
should be clearly defined, to establish 
who has legal responsibility in relation 
to the biobank, who has day-to-day op-
erational responsibility, and who is act-
ing as the custodian of the resources.
Specific roles within the biobank 
will depend on the institutional con-
text but may include the following.
•  A designated director, who is re-
sponsible for implementing biobank 
policies. The roles and responsibili-
ties of this person in their institution 
should be clearly defined.
•  A biobank coordinator or manager, 
who reports directly to the steering 
group. To eliminate conflicts of in-
terest, it is recommended that the 
biobank manager is not an  active in-
vestigator or a biobank  user. The bi-
obank manager may  also be desig-
nated the custodian of the resource, 
with the following responsibilities:
- establishing procedures;
-  ensuring that ethical guidelines are 
adopted and respected;
-  implementing the decisions of the 
relevant committees in relation to 
the control, access, and use of the 
material;
-  maintaining close collaborations 
with principal investigators;
-  distributing information about the 
biobank and related research; 
and
-  other responsibilities, which 
should be defined in advance.
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•  A biobank quality manager, who is 
responsible for the QMS and for 
periodic review of all SOPs, and 
has overall responsibility for quality 
control (QC) and quality assurance 
(QA).
•  A data steward, who is responsible 
for data protection and privacy.
3.1.1.2 Documentation: plans, 
policies, and procedures
Documentation requirements in-
clude plans, policies, and specific 
SOPs. The documents should be 
compatible with international stan-
dards such as the ISO standards 
for biobanking and the CEN norms 
that articulate how activities of the 
biobank are to be performed (see 
Section 3.4 for more details about 
ISO and CEN). Some general prin-
ciples in relation to these docu-
ments should be followed:
•  Documents should be developed 
in the context of a QMS, which in-
cludes document version control.
•  Documents should be developed 
in the context of an up-to-date risk 
assessment undertaken alongside 
a procedure that takes into account 
risks to the health and safety of 
people.
•  Documents should include a time 
frame for review and revision; 2 
years is a recommended time 
frame (NCI, 2016).
•  To facilitate cooperation between 
biobanks, documents should ad-
here to internationally accept-
ed technological standards and 
norms, ensuring that these are 
clearly referenced (OECD, 2009).
•  High-level policies, including data 
and sample access policies and 
terms of reference of committees, 
should be publicly and freely avail-
able, for example on a website.
•  Biobanks should consider imple-
menting monitoring strategies 
with scheduled audits to ensure 
that policies and procedures are 
followed.
•  Researchers should submit re-
ports annually and at the end of 
their projects, including informa-
tion on publications and patent 
applications (OECD, 2009).
•  The biobank should maintain a sys-
tem for reporting adverse events, 
anomalies, and non-compliance 
with the QMS; this reporting sys-
tem supports corrective and pre-
ventive actions and enables any 
relevant documents to be updated 
(CCB, 2014).
A critical document is the bio-
bank programme document (or 
biobank protocol), which contains 
information about the scientif-
ic rationale, scope, design, and 
strategy for the biobank. Other 
biobank plans, policies, and proce-
dures should be developed in line 
with this protocol. The biobank’s 
mission should be clearly outlined 
in terms of its purpose, the types 
of research or other users sup-
ported (scope), and the types of 
samples and data collected. Ad- 
ditional considerations include 
which services are provided (e.g. 
specific research assays, storage of 
samples) and whether legacy sam-
ples can be incorporated into the 
biobank. This protocol and associ-
ated key biobank documents should 
be approved by a research ethics 
committee, and renewed approval 
should be required if the documents 
are amended (OECD, 2009).
An annually updated business 
and continuity plan or model is es-
sential, especially if the biobank is 
planning to charge for use of the 
resources (Vaught et al., 2011). 
The business plan should include a 
strategy for both medium-term and 
long-term sustainability. A budget-
ing or costing exercise will assist 
in the development of such a plan.
All biobanks should also devel-
op a quality management policy 
and a policy on access to samples 
and data from the biobank (see 
Annex 1).
Additional policies to consider 
include:
•  a governance policy, containing in-
formation about the biobank’s gover- 
nance structure and the responsibil-
ities of management (OECD, 2009);
•  a retention policy, covering bio-
specimen availability and wheth-
er collections can be shared or 
destroyed;
•  a policy on storage options;
•  a safety policy for staff and visitors;
•  a policy on transportation of 
material;
•  a policy on disposal of material and 
biosafety and biosecurity;
•  policies covering ethical issues, 
including information on the pro-
tection of the confidentiality and 
privacy of participants (see Sec-
tion 3.1.3), informed consent, return 
of results and incidental findings, 
and so on;
•  a policy on the intellectual proper-
ty generated from the use of the 
resources and research results;
•  a publication policy, governing pub-
lications arising from the use of the 
biobank; and
•  policies on how the termination of 
the biobank would be handled.
Guidelines recommend that ac-
companying SOPs should be put in 
place to govern all biobank activities: 
recruitment; consent; staff training; 
biosafety; the collection, receipt, 
processing, and storage of samples; 
sample QC; laboratory QA; partici-
pant de-identification; data collection, 
recording, storage, and management; 
data protection; the monitoring, cali-
bration, maintenance, backup, and 
repair of equipment; the procurement 
and monitoring of supplies (dispos-
ables and reagents); the distribution 
and tracking of samples; records 
and documentation; reporting of 
non-conformity and complaints; and 
disaster management.
All staff members should be 
trained in the procedures at the 
biobank, and this should be 
documented.
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•  Good governance involves considering structures and documentation from the outset.
•  The biobank should, at a minimum, have an executive committee or steering group and have (or have 
access to) a laboratory safety and biosecurity committee.
•  A scientific oversight committee, an ethics oversight committee, an operations or management committee, 
and a data and sample access committee are strongly recommended.
•  Other committees are optional, depending on the size and scope of the biobank, including a public 
engagement committee and a quality management committee.
•  In terms of personnel, it is critical that clear reporting lines and accountability exist, with documented 
levels of authority and responsibility associated with each role. An organizational chart should be made 
and communicated to all biobank staff members.
•  Key biobank personnel may include a director of the biobank.
•  Other personnel should include a biobank coordinator or manager, who reports directly to the steering 
group. A biobank quality manager and a data protection officer are also strongly recommended.
•  A critical document is the biobank protocol, which includes information about the scientific rationale, scope, 
design, and strategy for the biobank. The protocol and associated documents should be approved by an 
independent research ethics committee.
•  A business plan or model that considers long-term sustainability and provides a continuity plan is essential, 
especially if the biobank is planning to charge for use of the resources.
•  All biobanks are strongly advised to develop a quality management policy and a biobank access policy, 
based on the model of the biobank.
•  Extensive guidance is provided on other policies and SOPs that may be implemented, depending on the 
context of the biobank.
Key points: biobank governance
3.1.2 Informed consent
The approach to informed consent is 
a key consideration when establishing 
a new biobank, and a policy should 
be developed (see Section 3.1.1.2). 
Requesting appropriate informed 
consent has become a cornerstone 
for the collection of samples and data 
for use in research, and is supported 
by relevant guidance and legislation. 
This section presents recommenda-
tions to assist a biobank in developing 
a consent policy and associated doc-
umentation, and covers the following 
areas (see also Annex 2):
•  types of consent;
•  what information to provide to po-
tential participants;
•  potentially ethically or legally chal-
lenging issues;
•  what to consider during the process 
of requesting consent;
•  what to consider if the country or the 
research area would benefit from 
community engagement in relation 
to the consent process;
•  what to do if the potential partici-
pant does not fully understand the 
language of the researcher who is 
administering the consent;
•  what to do if the potential partici-
pants do not have the legal capacity 
to consent for themselves;
•   considerations when including  sam-
ples or data from deceased partici-
pants in the biobank;
• the continuing nature of consent;
•  when participants might need to be 
re-contacted to request new or up-
dated consent; and
•  how to approach withdrawal of 
consent.
3.1.2.1 Types of consent
Many biobanks use a broad consent, 
which allows patients or research par-
ticipants to consent to a broad range 
of uses of their data and samples. 
Although broad consent allows for a 
broad range of research activities, it is 
regarded by research ethics commit-
tees as specific enough to be consid-
ered “informed”, because guidance is 
provided on the nature of the future 
undetermined research uses (e.g. 
research on breast cancer and as-
sociated conditions). It is important to 
note that broad consent forms usually 
contain a series of statements spe- 
cific to the biobank, and not state-
ments related to specific research 
projects. Table 2 outlines the differ-
ent types of consent associated with 
biobanks and sample collections, 
together with key points about each 
approach and notes on information to 
be provided to participants.
Further guidance on designing 
and implementing a broad informed 
consent is provided in Annex 2.
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Type/subtype of 
consent
Uses Key points Information to be provided to 
participants
Consent waiver Existing collections An ethics committee agrees that existing samples 
and anonymous data can be used for research or 
biobanking without a new/updated consent.
Consent waivers should be an exceptional measure 
for high-value collections. If a similar collection can 
be prospectively obtained, this should be done.
None
Opt out Leftover clinical 
samples from 
treatment when 
expected uses are 
low-risk
New uses of existing 
collections
This approach needs specific review by an ethics 
committee.
Part of the participant’s routinely taken sample and 
anonymous data can be used for research, unless 
the participant takes action to opt out.
This approach should not be used for collection of 
additional/new samples for research projects or 
biobanking.
Information on the biobank should 
be available to the participant 
population, with details of how 
to opt out (e.g. information 
sheets given directly to patients, 
leaflets distributed with hospital 
appointments, and clearly visible 
posters).
Opt in, with subtypes
Specific consent Research projects 
involving sample 
collection that are 
complicated for 
the participant to 
understand, including 
clinical trials
Consent forms usually contain a series of 
statements specific to the project.
Restricts samples and data to the specific research 
project described.
Ethics approval is needed.
Information is provided that refers 
to one research project or a linked 
group of projects.
Specific and 
broad consent
Used for specific 
projects or activities 
(e.g. surgical treatment 
or clinical trials) 
involving sample 
collection when there 
is a future plan for 
biobanking
The consent form for a specific project or trial 
includes provision on the addition of participant 
data and samples to a biobank.
The consent form for surgical treatment should 
include a clause on adding any remaining samples 
and anonymized clinical data to a biobank.
May restrict use for biobank to anonymized 
samples and data.
Ethical and scientific approval will be required 
for future biobanking or research with samples 
collected via this route.
An existing biobank must have ethics approval for 
samples to be accepted via this route and should 
have standard approved wording to include on the 
consent forms and information sheets.
Information on the intended 
biobanking activity should be 
included in the project information 
sheet, plus information in other 
relevant sections of the information 
sheet, if possible.
For surgical treatment, information 
about the biobank should be 
provided (see advice for “Opt out” 
above, including posters, etc.).
Broad consent Used when samples 
are taken for the 
purpose of a biobank
For multiple sampling 
events and multiple 
projects
This approach provides information and choice to 
participants about the biobank’s activities.
The consent forms usually contain a series 
of statements specific to the biobank, and not 
statements related to specific research projects.
Ethical approval is mandatory for this approach.
Ethical and scientific review is usually needed before 
distribution of samples and data to researchers.
Topics for a biobank information 
sheet are included in Annex 2.
Dynamic consent Used when (multiple) 
samples are taken 
for the purpose of a 
biobank, or a research 
project
When the scope of the 
biobank or project may 
change over time
When the biobank 
envisages regular 
contact with 
participants
The consent process and continuing communication 
with the participant usually happen via an IT-based 
infrastructure. The platform can be used for other 
communications relating to the study.
If the biobank enables this, the participant can opt 
in or out of parts of the biobank’s planned research 
and amend this over time, and find out which 
projects their samples have been used in.
Ethical approval is needed for this approach.
Through the use of an IT system, 
the participants themselves can 
choose how much information they 
wish to receive, i.e. in-depth or brief 
information.
The information can cover both the 
biobank’s scope and information on 
the governance of the biobank.
More in-depth information could be 
provided on potential uses of the 
samples, to enable participants to 
opt in or out of certain uses.
IT, information technology.
Table 2. Types of consent and key considerations
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3.1.2.2 What information to 
provide to potential participants
Information about the biobank and 
biobanking activities is usually pro-
vided to potential participants using 
a participant information sheet in 
conjunction with a consent form (in 
some cases, these two documents 
together are called the informed con-
sent form). The information provided 
will vary depending on the nature of 
the biobank and the type of consent 
requested. Further details are provid-
ed in Table 2 and Annex 2.
3.1.2.3 Potentially ethically or 
legally challenging issues
The following potential uses of sam-
ples and data are examples of issues 
that may be considered ethically or 
legally challenging:
•  transfer of samples or data across 
national borders; it is important to be 
aware of regional and national reg-
ulations, such as the EU Data Pro-
tection Directive of 1995 (Article 26) 
(European Commission, 1995) and 
the EU-U.S. Privacy Shield adopted 
by the EU Commission on 12 July 
2016  (http://ec.europa.eu/justice/
data-protect ion/ internat ional - 
transfers/eu-us-privacy-shield/ 
index_en.htm);
•  use of samples in experiments in-
volving animals;
•  creation of cell lines from the sam-
ples, including stem cell lines;
•  use of samples and data by com-
mercial researchers;
•  research linked to reproduction, 
including use of embryos;
•  return of individual research results 
and incidental findings (this is an im-
portant topic that warrants exten-
sive discussion, which is beyond the 
scope of this document); and
•  research into high-penetrance 
genes linked to disease.
When information sheets and 
consent forms are being developed, 
the biobank should consider whether 
it may be involved in any potentially 
challenging uses and include infor-
mation about these in the informa-
tion sheet and/or the consent form 
as appropriate, in addition to the 
core elements usually included as 
part of a consent form. The consent 
form should provide the participant 
with a means to opt out of uses that 
the participant feels are ethically 
questionable. The consent form may 
also require specific opt-in provisions 
if they are legally required by national 
or regional laws; an example is 
transfer of data outside of Europe, 
according to the EU Data Protection 
Directive (European Commission, 
1995). A means to opt out of certain 
uses should be provided by the bio-
bank only if this is recordable (i.e. in a 
database), actionable (i.e. when dis-
tributing the samples for research), 
and practicable (e.g. given the num-
ber of participants or the number of 
samples distributed).
3.1.2.4 What to consider during 
the process of requesting 
consent
It is important to consider the fol-
lowing aspects during the consent 
process.
•  Where possible, the information 
sheet should be distributed ahead 
of the meeting with the potential 
participant.
•  The potential participant must be 
given adequate time to read and 
consider the information sheet and 
should be offered the option to de-
cide and give consent at a later visit 
if required.
•  The person administering the con-
sent process must be convinced of 
the capacity of the potential partici-
pant to give consent. If they are not 
convinced, Section 3.1.2.6 (on par-
ticipants without the legal capacity 
to consent) may be applicable. Al-
ternatively, the potential participant 
may require assistance in reading 
the form.
•  The person requesting consent 
should not coerce the potential 
participant in any way.
•  The person requesting consent 
should encourage open discus-
sion and give the potential par-
ticipant the opportunity to ask 
questions.
•  The person requesting consent 
should ensure that the potential 
participant is informed about their 
right to withdraw consent, about the 
risks and benefits of participating in 
the project, and about any other im-
portant issues.
3.1.2.5 What to consider if the 
country or the research area 
would benefit from community 
engagement in relation to the 
consent process
The consent process needs to be 
appropriate for the local cultural con-
text, and in some cases this means 
that wider community engagement 
is appropriate (H3Africa, 2013). In 
cases where wider community en-
gagement is needed, consultation on 
the biobank’s consent processes and 
documents should take place with the 
wider community, local leaders, and 
professionals. The requirement for 
community involvement in the con-
sent process may also be specified 
in local ethical or legal guidance. In 
some of these cases, prior consent, 
assent, or permission may need to 
be obtained from community, tribal, 
or family leaders (Nuffield Council 
on Bioethics, 2002). In all cases, the 
potential research participant must 
be approached for consent and must 
have the right to refuse participation.
3.1.2.6 What to do if the 
potential participants do not 
have the legal capacity to 
consent for themselves
This category of participant is of-
ten called “vulnerable people”, and 
careful consideration must be given 
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to how recruitment will be conduct-
ed (WMA, 2013, 2016). Recruitment 
of “vulnerable” participants must re-
spect the requirements in the Decla-
ration of Helsinki that all vulnerable 
groups and individuals should receive 
specifically considered protection, 
that the research is responsive to the 
health needs of this group and can-
not be carried out in a non-vulnerable 
group, and that this group will benefit 
from the research.
Three types of participant com-
monly identified as vulnerable are:
•  mentally incapacitated adults;
•  adults in emergency care situations; 
and
•  minors/children.
In the case of mentally incapaci-
tated adults, a legally authorized rep-
resentative can provide consent on 
their behalf. If the participant made 
legally approved provisions about re-
search participation before they were 
incapacitated or if they assigned a 
legal representative, these should 
be respected. The participant should 
be involved as much as possible in 
the decision to participate, and any 
resistance or objections should be 
respected.
In the case of research taking 
place in an emergency clinical sit-
uation where consent has not been 
obtained, requirements will differ by 
country and may include:
•  the local ethics committee explicitly 
approving the recruitment pathway;
•  another medical professional au-
thorizing the involvement of the 
participant;
•  the known wishes or objections of 
the participant being respected; and
•  a maximum time limit being im-
posed for participant involvement 
without consent.
Consent should be requested 
from the participant if the participant 
regains legal capacity.
In the case of research involving 
children, they should take part in the 
consent process in accordance with 
their age and maturity, and assent to 
participate (rather than consent). In-
formation and consent materials can 
be designed for different age groups 
to aid understanding of the research. 
Any objection from the child should 
be respected (Hens et al., 2011). 
The assent process is based on the 
age and maturity of the child and on 
any applicable local laws or ethical 
guidance on the matter. In addition 
to the assent of the child, the child’s 
parent(s) or an appropriate legal rep-
resentative must provide consent on 
the child’s behalf. It is also good prac-
tice to re-contact child participants 
once they reach the local legal age of 
maturity, to request consent, if possi-
ble (CIOMS, 2002; Hens et al., 2011).
3.1.2.7 Considerations when 
including samples or data from 
deceased participants in the 
biobank
Consent requirements will vary 
depending on whether the biobank 
intends to request consent for sam-
ples and data from potential partici-
pants before their death (for example, 
for a brain biobank) or request the 
samples and data after the partici-
pants’ death. Local legislation will 
dictate the applicable consent and 
legal requirements. Some legal or 
practical constraints may exist for 
biobanks accessing medical records 
after the participants’ death. Uses 
of the samples and data, collected 
before or after death, that fall outside 
the scope of the original consent will 
require approval by a research ethics 
committee (Tassé, 2011).
Where samples are to be col-
lected for research after death, local 
institutional, ethical, and legal guide-
lines to obtain consent must be fol-
lowed, and the individual’s wishes 
expressed before death, if they are 
known, should be respected. The 
consent procedure may be built into 
existing procedures for postmortems 
or for clinical use of postmortem 
samples for organ or tissue trans-
plants, which may differ markedly 
from country to country.
3.1.2.8 The continuing nature of 
consent
If the participant has given prior writ-
ten consent, they should always be 
asked to confirm (verbally and/or tac-
itly, as appropriate) their agreement 
to donate samples to the biobank, 
and they should always have the 
opportunity to ask questions, before 
additional sampling (e.g. blood, biop-
sy, aspirate, bronchial brushings) or 
data collection is performed. Where 
possible, the verbal consent should be 
recorded electronically or noted and 
stored with the original consent form. 
The participant may decline to provide 
further samples or data at any time. 
This does not invalidate the consent 
to use any previous samples or data 
given to the biobank, unless notice of 
withdrawal of consent is given.
3.1.2.9 When participants might 
need to be re-contacted to 
request new or updated consent
Several situations may arise where 
the biobank may need to re-contact 
the participants to request new or 
updated consent, apart from con-
tact to request additional data and/
or samples for the purposes of the 
same project. These situations may 
include children reaching the age of 
maturity and temporarily incapacitat-
ed participants regaining legal capac-
ity (see Section 3.1.2.6), and in such 
cases full informed consent should 
be requested (Burke and Diekema, 
2006). Another situation is when the 
information provided in the initial con-
sent form and information sheets is 
modified or updated (e.g. if the scope 
of the biobank changes). In this case, 
re-contact of participants to request 
an updated consent may be required, 
given the changing conditions of 
their participation (Wallace et al., 
2016). An appropriate research ethics 
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committee  should decide whether 
re-consent is required or whether a 
waiver can be applied.
A general guideline is that be-
fore re-contact is established, a 
participant’s options with respect to 
re-contact should be checked, be-
cause participants should be given 
the option not to be re-contacted 
(see Annex 3).
3.1.2.10 How to approach 
withdrawal of consent
At any time, participants can with-
draw consent for the biobanking and 
use of their samples or data without 
giving a reason. It is crucial for the 
biobank to present withdrawal op-
tions to participants in the consent 
form or information sheets. This may 
not mean guaranteeing to destroy 
all samples and data; for example, 
the withdrawal options may stipulate 
that samples and data already re-
leased or used in analyses are not 
retrievable. Examples of withdrawal 
options include the following.
•  “No further use” option: the bio-
bank will destroy all samples and 
data from the participant and will not 
contact the participant again.
•  “No further contact” option: the 
biobank will no longer contact the 
participant directly by any means 
but can continue to use samples 
and data already collected and can 
continue to access the participant’s 
medical records if necessary.
•  “No further access” option: the bio-
bank will not contact the participant 
or access the participant’s medical 
records but can continue to use 
samples and data already collected.
The biobank should also clearly 
communicate to participants when it 
is impossible to destroy parts of the 
samples or data. Examples include 
being unable to destroy:
•  samples and data already distribut-
ed for research or used in analyses; 
and
•  data needed for audit purposes or 
already archived.
•  Consider local legal or ethical requirements that are applicable to the consent process.
•  Distribute the consent materials to the participant in advance whenever possible. The form should be 
written in a language that is understandable to the participant.
•  Give participants adequate time to read the form, understand the information, and consider possible 
participation.
•  The person requesting consent should ensure that the participant fully understands what is required of them.
•  The person requesting consent should encourage open discussion with the potential participant and should 
not coerce them to participate in the project.
•  The rights of the participant and the risks and benefits of participating in the project should be explained 
to potential participants.
•  The withdrawal options should be explained.
Key points: informed consent
3.1.3 Data protection, 
confidentiality, and privacy
This section briefly outlines recom-
mendations about the protection of 
biobanks’ data and about the con-
fidentiality and privacy of the parti- 
cipants’ data. Legislation and guid-
ance on these issues vary between 
countries and, where they exist, may 
also be complemented by local site 
requirements.
In the EU, the General Data Pro-
tection Regulation (European Com-
mission, 2016) replaces the Data 
Protection Directive (European Com-
mission, 1995) and unifies data pro-
tection for individuals in the EU. The 
processing of personal data outside 
the EU is also an important com-
ponent of EU privacy and human 
rights law.
Other examples of privacy and 
security policies are those of the 
Confederation of Cancer Biobanks 
(CCB, 2014) and GA4GH (GA4GH, 
2015b).
At a European level, the changing 
data protection regulations and re-
quirements in relation to the EU-U.S. 
Privacy Shield should be taken into 
account. The biobank must develop 
a strategy and have an IT framework 
and policies in place for managing 
data collected alongside the samples 
in line with the commitment undertak-
en with participants.
Methods to ensure data protec-
tion, confidentiality, and privacy are 
discussed in Section 3.3.4 and Sec-
tion 3.6. The biobank should consider 
using de-identification methods, such 
as coding or pseudo-anonymization 
associated with a procedure to store 
codes. Explanations of these terms 
are provided in Section 1 and in Ap-
pendix 1 of the privacy and security 
policy of GA4GH (GA4GH, 2015b).
Examples of particular issues for 
data protection and privacy for bio-
banks include the following.
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•  Access to medical records. When 
possible, staff members should 
be bound by a professional code 
of practice with high standards of 
ethical behaviour. The participant 
should be asked for permission to 
access their medical records and 
should be informed where these 
data are held in an encrypted, 
non-identifiable format at the bio-
bank (CCB, 2014).
•  Data protection mechanisms when 
biobanks share data with other 
biobanks or provide data for trans-
lational research. Privacy and 
confidentiality of data must be guar-
anteed, while facilitating access.
•  Participants should also be in-
formed, in the informed consent, 
about what data will be shared and 
3.1.4 Return of results and 
incidental findings
This section presents the issues 
with respect to research results: 
summary results, individual results 
from baseline assessment, and in-
dividual research results. The prin-
cipal investigator and the biobank 
have collective responsibility for 
deciding whether to return research 
results to participants. The deci-
sion-makers should consider the 
how data will be shared, and how 
their privacy and the confidentiality 
of the data will be protected.
•  Research involving genetic data 
and next-generation sequencing 
data may lead to concerns about 
(i) whether data can identify individ-
uals and/or family members, and 
(ii) whether to return results 
from this type of analysis (see 
Section 3.1.4).
•  The inclusion of medical images in 
biobanks (e.g. scans and histology 
slides) poses specific challenges 
for de-identification, because iden-
tifying data are usually embedded 
within the images, which by them-
selves may not be identifying.
In terms of confidentiality, all 
staff members with access to con-
balance between the duty of care 
to participants, the ethical and legal 
requirements to return results, and 
the logistical and technical ability of 
the biobank to return results in an 
appropriate manner. Factors to con-
sider include whether the biobank 
no longer has contact with the pa-
tient, the ease of re-identifying the 
participants and finding out whether 
they have chosen to be informed, 
the potential cost implications of 
providing re-testing or counselling to 
fidential data should have a duty 
of professional secrecy (OECD, 
2007). Staff members, consultants, 
or committee members without 
such a duty must be asked to sign 
a confidentiality agreement. Ac-
cess to personal data should be 
limited, and access to any data 
should be restricted to those data 
needed for the research project or 
other use. Data can be separated 
into different databases according 
to type. The biobank should keep 
specimen metadata in a linked 
but separate database from the 
patients’ medical records and de-
mographic information, to keep 
data safe and confidential. Regular 
audits of the data systems must be 
implemented.
participants, if required, and whose 
responsibility this is.
One toolkit is the framework on 
the feedback of health-related find-
ings in research (Medical Research 
Council and Wellcome Trust, 2014).
3.1.4.1 Generalized, non-
individual study results
According to best practices, re-
search results can be published 
on the biobank website or via a 
•  Inform participants about any data protection and privacy issues (e.g. sending information abroad, intention 
to share data).
•  Use a method to protect privacy, such as de-identification, coding, or pseudo-anonymization, and consider 
how this affects re-contact and return of results.
• Develop a policy or procedure that describes the process of re-identifying participants.
• Coded data and codes should be stored separately.
• Put in place robust data systems and audit trails.
• Manage, limit, and trace rights of access to information systems.
•  Limit physical access (e.g. store paper documents in rooms with limited access), and implement electronic 
security procedures where possible.
• Respect participants’ consent options during access, use, and transfer of data.
•  Consider what data or combinations of data will not be made available, because of confidentiality or privacy 
reasons.
Key points: data protection and privacy
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ences is during the consent pro-
cess. The information sheet and 
consent form should provide poten-
tial study participants with informa-
tion and give them the opportunity 
to choose whether they wish to re-
ceive individual research results. 
The protocol must provide a way 
for participants to later change their 
preferences.
3.1.4.4 Results of genetic tests 
and next-generation sequencing
Returning the results of genetic tests 
or next-generation sequencing should 
involve offering a clinical-grade vali-
dation and making available clinical 
expertise or genetic counselling. Rec-
ommendations about which genetic 
test results to return are provided, for 
example, in the American College 
of Medical Genetics and Genomics 
(ACMG) recommendations for report-
ing of incidental findings in clinical 
exome and genome sequencing 
(Green et al., 2013) and in the Geno-
mics England project (https://www. 
genomicsengland.co.uk/taking-part/
results/).
3.1.4.5 Results of imaging 
studies and scans
Imaging biobanks are defined by the 
European Society of Radiology as 
3.1.4.3 Individual research 
results
Individual research results fall into 
two categories.
•  Results that can be anticipated be-
cause they are in line with the aims 
of the research. The method for 
handling these can be considered 
during the evaluation of the sample 
request.
•  Incidental findings that are not linked 
to the aims of the research. The 
method for returning these to the bio-
bank can be addressed in the MTA.
In both cases, the biobank 
will need procedures for evaluat-
ing the validity of such results, as 
well as the period of validity, and 
for returning these results to the 
participants, including re-iden-
tification and re-contact of the 
participant if the participant has 
indicated in the consent form 
that they wish to be re-contact-
ed (UK Biobank Ethics and Gov- 
ernance Council, 2015). The scope 
of the results to be returned and 
how they are to be returned should 
be defined in advance with relevant 
experts and the ethics committee 
(Thorogood et al., 2014), taking into 
account that biobank participants 
have the right to choose not to know 
research results. The ideal time to 
ask about an individual’s prefer- 
newsletter (CCB, 2014). These are 
summary results of research using 
samples and/or data from the bio-
bank and cannot be connected back 
to a specific individual.
The participant should be given 
the option during the consent pro-
cess to receive these publications, 
and researchers using samples and 
data should commit in the MTA to 
providing the report of research re-
sults to the biobank.
3.1.4.2 Individual results from 
tests conducted during sign-up 
or registration
Some biobank studies request par-
ticipants, after they give consent, 
to undergo initial testing (baseline 
assessments), such as blood pres-
sure measurements, lung function 
tests, and vision tests. In addition, 
biological samples may be routinely 
tested for infectious diseases, such 
as HIV, hepatitis B, and hepatitis 
C, before storage in the biobank. 
Biobanks should consider whether 
they will return the results of these 
tests, and this should be clearly in-
dicated in the participant consent 
materials. These tests should not 
be used as incentives for the par-
ticipants to sign up, and it should be 
made clear that they are not part of 
health checks.
•  The return of research results to the biobank by researchers using samples and/or data should be addressed 
in the MTA. Return of research results to the participant should be covered in the consent form.
•  Individual research results should be validated using clinical techniques before being returned to the 
participant.
•  Individual research results should be returned to the participant only if a relevant clinical support structure 
can be made available to the participant (e.g. in the case of genetic results, a genetic counsellor should 
be made available).
•  Decisions about whether to return individual research results to participants should consider the balance 
between the validity of the results, the duty of care to participants, and the logistical and technical ability 
of the biobank to return results in an appropriate manner.
•  Biobank participants should be given the opportunity to choose whether they wish to receive research 
results, and they should give consent for the return of results.
Key points: return of results
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and the policy should be publicly 
available (CCB, 2014). See Annex 
1 for the IARC access policy; oth-
er examples include those of the 
National Cancer Research Institute 
(NCRI, 2009) and P3G (Harris et 
al., 2012).
Evaluation of requests should be 
based on the notion of proportional-
ity, balancing risks against benefits, 
and ensuring that the intended use 
follows the biobank’s protocol and 
priorities and the consent provided 
by the participants (Mallette et al., 
2013). In general, samples should 
be shared in a fair, transparent, and 
equitable manner (Chen and Pang, 
2015). In the case of scarce sam-
ples, a decision could be made to 
provide samples to projects more 
closely aligned with the aims and 
strategy of the biobank. The re-
searcher should sign an MTA/DTA 
(see Section 3.1.5.5), which will 
include the obligations of the re-
searcher, before receiving the sam-
ples and/or data.
3.1.5.2 Principles for international 
specimen exchanges
The legal aspects of sample shar-
ing vary between countries, and an 
assessment should be made to en-
sure that the relevant legal regimes 
are compatible with those of the 
biobank and the consent. Where ap-
plicable, the participant should also 
have given consent for the transfer 
of data between countries. Exam-
ples of legal requirements are the 
EU-U.S. Privacy Shield principles, 
which deal specifically with transfer 
of data from Europe to the USA (see 
Section 3.1.2.3), and the new EU 
General Data Protection Regulation 
(see Section 3.1.3).
Finally, if there are any doubts 
in relation to privacy implications 
when samples or data are to be 
transferred internationally, a data 
privacy impact assessment can be 
performed before such transfer 
one of the largest directories for 
biobanks in Europe. The directory 
currently contains more than 6 mil-
lion samples with associated data, 
which can be accessed for collabo-
ration (BBMRI-ERIC, 2016).
Researchers requesting ac-
cess to the biobank’s resources 
should do so by applying to the 
biobank and following its access 
policy and access procedures (see 
Section 3.1.5.1). Furthermore, the 
biobank should assess and review 
the type of data requested by the 
researcher. For example, the bio-
bank cannot, without explicit prior 
consent, disclose participant-iden-
tifiable data to researchers. This 
should be addressed in any agree-
ment between the researcher and 
the biobank (such as an MTA or 
Data Transfer Agreement [DTA]; 
see Section 3.1.5.5). In all cas-
es, a section stipulating that the 
researcher may not attempt to 
re-identify any participants should 
be included. In general, the policy 
on disclosing data must consider 
which identifiers will be removed 
from the participant’s record to en-
sure that privacy is protected. Par-
ticular care should be taken with 
regard to data that may not direct-
ly lead to re-identification but, in 
combination with other data, could 
do so.
3.1.5.1 Access to stored 
materials and data for research 
purposes
The biobank should develop an 
access policy and access pro-
cedures, in line with its protocol 
(Section 3.1.1). The policy and pro-
cedures should describe the admin-
istrative and approvals process for 
applying for and obtaining access 
to samples or data, comprising 
an overview of applicable restric-
tions and obligations. A procedure 
should exist to ensure that the ap-
plicants are bona fide researchers, 
“organised databases of medical 
images and associated imaging bio- 
markers (radiology and beyond) 
shared among multiple research-
ers, and linked to other bioreposi-
tories” (European Society of Radi-
ology, 2015). Specialized facilities 
and biobanks that also conduct 
imaging studies such as scans are 
particularly likely to discover inci-
dental findings. The Royal College 
of Radiologists provides guidance 
on the management of incidental 
findings detected during research 
imaging (RCR, 2011).
3.1.4.6 Results about children
If the biobank includes biological sam-
ples from children, the biobank needs 
to evaluate whether it has a stronger 
responsibility to return results in this 
case because the participants are 
children (Hens et al., 2011). It must 
also consider what action to take if 
the results become available after the 
child comes of age, because the orig-
inal consent was not the child’s, and 
whether the parents have the right to 
receive all information about the child 
(see Section 3.1.2.6).
3.1.5 Access to and sharing of 
samples and data
A catalogue of biological material 
should be published, to optimize 
the use of resources and ensure 
the transparency of biobank activi-
ties. Optimally, each sample should 
be listed, with associated access 
conditions and consent elements 
(OECD, 2009).
In some cases, funders may re-
quire specific data sharing policies 
to be designed and implemented 
(Kaye and Hawkins, 2014; Kosseim 
et al., 2014). Intended sample and 
data sharing should be included on 
the participant information sheets 
and consent forms (GA4GH, 2015a).
To facilitate data and sample 
sharing, BBMRI-ERIC has created 
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3.1.5.4 Intellectual property and 
ownership
Intellectual property policies vary 
across institutions, but the bio-
bank should define an intellectual 
property policy. 
Aspects of this policy should 
be defined in the MTA/DTA (see 
Section 3.1.5.5), as well as own-
ership of biological samples.
3.1.5.3 Collaboration with the 
private sector
Collaboration with the private sector 
must adhere to the same require-
ments and obligations with respect to 
data and sample sharing. It is impor-
tant for the possibility of sharing sam-
ples and data with the private sector 
to be specifically mentioned in the in-
formed consent and information sheet 
(European Commission, 2012a).
(GA4GH, 2015b). For further infor-
mation on the legal requirements 
related to international sample 
sharing, researchers can use the 
Human Sample Exchange Regula-
tion Navigator (hSERN) tool, avail-
able at http://www.hsern.eu/.
Special attention should be given 
to the transfer of samples to or from 
countries with poor or non-existent 
regulatory frameworks (Chen and 
Pang, 2015).
•  As a general rule, no ownership of biological samples exists, and the biobank should assign ownership or 
custodianship based on national and institutional guidelines.
•  The biobank should develop a procedure for sharing samples and data that is in line with its protocol and 
with the consent provided by the participants.
•  The biobank should develop a policy on potential benefit sharing (sharing of benefits received by the biobank 
through the sharing of samples and/or data) or collaboration with the contributing community.
•  The biobank should develop an intellectual property policy.
Key points: data and sample sharing
3.1.5.5 Material Transfer 
Agreement (MTA)/Data Transfer 
Agreement (DTA)
An MTA, a DTA, or a similar agree-
ment should be put in place before 
the transfer of samples and/or data 
between organizations (ISBER, 
2012). An MTA/DTA is a legally bind-
ing document that governs the condi-
tions under which the samples and/
or data can be used (see Annex 4).
The MTA/DTA outlines the type 
of samples and/or data to be trans-
ferred, the purpose of the transfer, 
and all restrictions or obligations 
that relate to the use of the samples 
and data (NCI, 2011; ISBER, 2012; 
NCI, 2016). These restrictions and 
obligations must be in line with the 
conditions of the informed consent, 
ethics approval, and biobank gov-
ernance attached to the samples 
and/or data. The agreement may in-
clude a statement that the samples 
and data have received appropriate 
ethics approval and consent.
The agreements should include 
specific aspects relating to the bio-
bank’s policies and provisions that 
bind the researcher to:
•  use the samples and data in line with 
the biobank access approval given;
•  adhere to applicable laws, regula-
tions, and guidance;
•  not further distribute the samples 
or data;
•  dispose of, or return, the samples 
and data after use;
•  guarantee confidentiality and data 
protection;
•  not attempt to re-identify partici-
pants;
•  inform the biobank of any issues 
with the data or samples;
•  provide traceability of samples;
•  return research results in the form 
of individual results, raw data, an 
interim/final report, relevant publi-
cations, or patent applications;
•  cite or acknowledge the biobank in 
publications, patents, or other doc-
uments, or include a citation in any 
published work to a specific publi-
cation describing the biobank; and
•  respect intellectual property terms.
An example of an MTA is pro-
vided in Annex 4. Other examples 
include those of Knoppers et al. 
(2013) (online supplementary ma-
terial), NCI (NCI, 2016), the Na-
tional Cancer Research Institute 
(NCRI, 2009), the Association of 
Research Managers and Adminis-
trators (ARMA, 2016), and Belgian 
Co-ordinated Collections of Micro- 
organisms (BCCM, 2016).
3.2 General safety precautions 
required for working in a 
biobank
The primary, basic requirement of 
a biobank is general safety. This in-
cludes protection of people and of 
the environment against biological 
and chemical hazards. The man-
agement of these risks should be 
based on a general implementation 
of a precautionary principle similar 
to those used in laboratories and 
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handling and means of protection, 
must be given to personnel before 
they work in a biobank, and should 
be repeated on a regular basis.
There are also risks associated 
with the use of chemical fixatives 
and solvents used in tissue process-
ing. In addition, electrical safety is an 
important concern. Freezers must be 
properly wired to adequate sources 
of electrical supply, and grounded.
Work in a biobank also entails 
several occupational hazards typ-
ical of the laboratory environment. 
These risks must be taken into ac-
count before setting up a biobank, 
and their prevention must be inte-
grated into all aspects of the SOPs 
of the biobank.
3.2.2 Biological hazards
Laboratory biosafety requires the 
implementation of good laboratory 
practices and procedures as well as 
the proper use of safety equipment 
and facilities, to prevent unintention-
al exposure to microorganisms and 
toxins, or their accidental release.
All biological specimens should 
be considered as potentially infec-
tious. They should always be han-
dled with great care to avoid poten-
tial exposure. Their collection and 
processing represents a source of 
hazard both for the person who is 
the source of the specimens and 
for the staff members involved in 
these processes. It is recommend-
ed that potentially infectious sam-
ples should be handled under a 
biological safety hood to minimize 
exposure of laboratory staff. The 
risk group of the samples held in a 
biobank should be determined, and 
the biobank should comply with the 
biosafety levels corresponding to 
the risk group of the samples.
Immunization of biobank staff 
members is recommended when 
appropriate vaccines are available. 
In particular, immunization against 
hepatitis B virus (HBV) is mandatory 
of LN2 from several relief valves, 
causing white-out conditions in a 
matter of a few seconds. This leads 
to a drop in visibility to almost zero, 
and the oxygen level in the area de-
creases below what is necessary to 
sustain life. Personnel must evacu-
ate immediately.
Oxygen-level sensors should al-
ways be used when LN2 containers 
are used in a biobank. LN2 expands 
to 650 times its original volume at 
room temperature, causing a form 
of explosion hazard if evaporation 
is restricted. Storage areas must 
be well ventilated. Plastic and glass 
containers can easily explode if liq-
uid is trapped when the container is 
removed from the LN2.
Protective safety equipment must 
be worn when handling LN2. Heavy 
gloves, a face shield, and a protec-
tive garment should always be worn 
(Fig. 2). Protective shoes are also 
recommended. Safety notices and 
protocols must be clearly displayed in 
the biobank area. Appropriate train-
ing on the risks of LN2, including safe 
clinical settings, and should be em-
bodied in a general safety manage-
ment plan.
3.2.1 General laboratory 
safety
In addition to biosafety, biobanks 
must follow strict general safety reg-
ulations and procedures in relation 
to chemical, physical, and electrical 
safety. The use of liquid gases such 
as liquid nitrogen (LN2) for cryopre- 
servation poses a serious source 
of hazard. Where LN2 refrigeration 
is used, an adequate supply of re-
frigerant must be maintained. The 
supply maintained on-site should be 
at least 20% more than the normal 
refill use, to allow for emergency 
situations.
Handling LN2 has serious safety 
implications. Skin contact with LN2 
can cause severe frostbite.
When bulk storage and pip-
ing systems are used, blockage of 
relief valves and/or overpressure 
may lead to simultaneous leakage 
Fig. 2. Equipment for safe handling of liquid nitrogen: (a) individual oxygen 
detector, (b) knitted gloves, (c) cryogenic gloves, and (d) face shield.
a
c
b
d
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•  reporting protocols;
•  investigation reports; and
•  recommendations and remedies.
Adoption of these security re-
quirements is important for bio-
banks that store pathogenic or toxic 
biospecimens.
3.3 Infrastructure and storage 
facilities
The biobank infrastructure and stor-
age system depend on the type of 
material being stored, the required 
storage conditions, the anticipated 
period of storage, the intended use 
of the materials, and the resources 
available for purchasing the stor-
age equipment. The storage infra-
structure also depends on the avail-
able resources and support to the 
biobank (Mendy et al., 2013). The 
storage system is fundamental to 
maintaining high sample quality.
The data and databases re-
lated to biospecimen annotation, 
quality, storage location, and use, 
including the patients’ clinical and 
epidemiological information, are 
important attributes of biobank in-
frastructure.
The collection, storage, uses, 
and management of data linked to 
biospecimens are discussed in Sec-
tion 3.6 and Section 3.8.2.
2006, the World Health Organiza-
tion developed the publication Bio-
risk Management: Laboratory Biose-
curity Guidance, which defines the 
scope and applicability of “labora-
tory biosecurity” recommendations, 
narrowing them strictly to human, 
veterinary, and agricultural laborato-
ry environments (WHO, 2006).
Laboratory biosecurity mea-
sures should be based on a compre-
hensive programme of accountabil-
ity for valuable biological material 
that includes:
•  assessment of biosecurity risks;
•  restricted and controlled access;
•  containment-in-containment archi-
tecture;
•  regularly updated inventories with 
storage locations;
•  identification and selection of per-
sonnel with access;
•  plan of use of valuable biological 
material;
•  clearance and approval process-
es; and
•  documentation of internal and 
external transfers within and be-
tween facilities and of any inactiva-
tion and/or disposal of the material.
Institutional laboratory biosecu-
rity protocols should include how 
to handle breaches in laboratory 
biosecurity, including:
•  incident notification;
for staff members involved in col-
lecting and processing human blood 
or tissues. Other significant risks are 
posed by exposure to hepatitis C vi-
rus (HCV) and HIV as well as to the 
prion that causes Creutzfeldt–Jakob 
disease. Other pathogens can also 
represent a serious hazard.
Further sources of biological risk 
have been identified. Recommen-
dations for laboratory practices in 
a safe working environment have 
been provided by the United States 
Centers for Disease Control and 
Prevention (CDC) in Guidelines for 
Safe Work Practices in Human and 
Animal Medical Diagnostic Labora-
tories (Miller et al., 2012).
3.2.3 Biosecurity
Laboratory biosecurity describes 
the protection of, control of, and ac-
countability for valuable biological 
materials, to prevent their unautho- 
rized access, loss, misuse, theft, or 
intentional release.
The scope of laboratory biose-
curity is broadened by addressing 
the safekeeping of all valuable bio-
logical materials, including not only 
pathogens and toxins but also sci-
entifically, historically, and econom-
ically important biological materials, 
such as collections and reference 
strains, pathogens and toxins, vac-
cines and other pharmaceutical 
products, food products, genetically 
modified organisms, non-pathogen-
ic microorganisms, extraterrestrial 
samples, cellular components, and 
genetic elements.
Biosecurity can also refer to pre-
cautions that should be taken to pre-
vent the use of pathogens or toxins 
for bioterrorism or biological war-
fare. Securing pathogens and toxins 
at research and diagnostic laborato-
ries cannot prevent bioterrorism but 
can make it more difficult for poten-
tial terrorists to divert material from 
a legitimate facility so as to build a 
biological weapon (OECD, 2007). In 
•  Type, number, aliquots, and sizes of biospecimens.
•  Storage containers.
•  Storage temperature and conditions.
•  Frequency of access to biospecimens.
•  Requirements for identification of biospecimens.
•  Availability of storage space.
•  Requirements for temperature monitoring.
•  Associated data.
•  Financial and operational sustainability.
Key points: creating a biobank
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for morphological analysis, mor-
phology-related methods, and im-
munohistochemistry. It may also 
be used as an alternative method 
to preserve tissues at relatively low 
cost when adequate freezing proce-
dures and storage facilities are not 
available. Paraffin blocks and histo-
logical slides may be stored in light- 
and humidity-controlled facilities at 
22  °C (Figs. 3 and 4).
Tissue fixed according to strict 
protocols may be used for DNA ex-
traction. The DNA is usually frag-
mented but remains suitable for poly-
merase chain reaction (PCR)-based 
analysis of short DNA fragments. 
However, fixed tissue is of limited 
usefulness for RNA extraction.
RNAlater is a commercial aque-
ous, non-toxic tissue storage reagent 
that rapidly permeates tissues to sta-
bilize and protect cellular RNA at room 
temperature. RNAlater eliminates the 
need to immediately process tissue 
samples or to freeze samples in LN2 
for later processing. Tissue pieces 
can be harvested and submerged in 
RNAlater for storage for specific pe-
riods without jeopardizing the quality 
or quantity of RNA obtained after 
subsequent RNA isolation.
available on the principles of cryopre- 
servation (Cryo Bio System, 2013) 
and on the optimal temperature 
for selected biomarkers and me-
tabolites (Hubel et al., 2014). The 
process of thawing may also influ-
ence cellular structure or metabolite 
analyses.
Specimen freezing can be per-
formed, for example, by placing 
the specimen in a sealed (but not 
airtight) container and immersing 
the container in the freezing me-
dium. The ideal medium for rapid 
freezing is isopentane that has 
been cooled to its freezing point 
(−160  °C). To achieve this, the 
vessel containing the isopentane 
should be placed in a container 
of LN2. The freezing point approx-
imately corresponds to the mo-
ment when opaque drops begin to 
appear in the isopentane. Direct 
contact of the specimen with LN2 
should be avoided because this 
can damage tissue structure.
3.3.1.2 Other fixation and 
preservation methods
Formalin or alcohol fixation and par-
affin embedding is the best method 
3.3.1 Storage conditions
Biospecimens should be stored 
under stabilized conditions to meet 
the requirements of potential future 
use in research. In selecting the bio-
specimen storage temperature, it 
is essential to consider the type of 
biospecimen, the intended period of 
storage, the frequency of use of bio-
specimens, the biomolecules and 
analyses of interest, the intended 
purpose of the sample, and whether 
the goals include preserving viable 
cells. Other factors that should be 
considered include the humidity lev-
el, the light intensity in the facilities, 
access to a continuous power sup-
ply, and backup systems in case of 
freezer breakdowns, loss of power, 
and other emergencies.
3.3.1.1 Cryopreservation
Cryopreservation is the recommend-
ed standard for preservation of human 
biological samples for a wide range of 
research applications. The challenge 
of tissue preservation is to be able to 
block, or at least slow down, intracellu-
lar functions and enzymatic reactions 
while at the same time preserving the 
physicochemical structures on which 
these functions depend.
Cryopreservation is a process in 
which cells or whole tissues are pre-
served by cooling to ultra-low subzero 
temperatures, typically −80  °C (freez-
er) or −196   °C (LN2 phase). At these 
low temperatures, most biological ac-
tivity is effectively stopped, including 
the biochemical reactions that would 
lead to cell autolysis. However, due 
to the particular physical properties 
of water, the process of cryopreser-
vation may damage cells and tissue 
by thermal stress, dehydration and 
increase in salt concentration, and 
formation of water crystals. Specific 
applications (e.g. proteomics or stor-
age of primary cell cultures) may re-
quire more complex cryopreservation 
procedures. General information is 
Fig. 3. Paraffin-embedded tissues.
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LN2 vapour-phase containers 
with LN2 in the base of the tank can 
maintain samples below Tg (the crit-
ical glass-transition temperature, 
i.e. −132  °C), and submersion in LN2 
guarantees a stable −196 °C temper-
ature environment for all samples. 
Vapour-phase storage is preferred 
over liquid-phase storage, because 
it avoids some of the safety hazards 
inherent in liquid-phase storage, in-
cluding the risk of transmission of 
contaminating agents (Fig. 6). The 
design of the tank is critical to main-
tain a sufficient amount of LN2 in the 
vapour phase.
Liquid-phase storage needs less 
frequent resupply of LN2 and thus af-
fords better security in case of a cri-
sis in LN2 supply. Closed LN2 tanks 
can maintain samples at below 
−130  °C for several weeks without 
the need to refill the LN2 tank. The 
initial investment and the availability 
and cost of LN2 can be major draw-
backs. Also, safety hazards inherent 
in the use of LN2, such as burning 
or oxygen deficit risks, should be 
managed. When LN2 tanks are 
used, oxygen-level sensors must 
be used, and they should be cali-
brated every few years. The use of 
3.3.2.1 Liquid nitrogen storage
LN2 facilities contain LN2 in liquid- 
phase tanks (Fig. 5) and vapour-phase 
containers (Fig. 6). Cryogenic storage 
using LN2 is an effective long-term 
storage system, because its ex-
treme ultra-low temperatures slow 
down most biological, chemical, and 
physical reactions that may cause 
biospecimens to deteriorate.
PAXgene tissue fixation is in-
creasingly used for tissue preser-
vation. PAXgene tissue systems 
are formalin-free solutions for the 
simultaneous preservation of histo-
morphology and biomolecules and 
the purification of high-quality RNA, 
DNA, microRNA (miRNA), pro-
teins, and phosphoproteins from the 
same sample. Tissue specimens 
are collected, fixed, and stabilized 
with the PAXgene tissue fixation 
and stabilization products. PAX-
gene-fixed tissue can be processed 
and embedded in paraffin similarly 
to formalin-fixed tissue, and biomol-
ecules can be extracted (Gündisch 
et al., 2014).
3.3.2 Biospecimen storage 
infrastructure
Two types of storage systems are 
used for biospecimen storage: 
ultra-low-temperature (or low-tem-
perature) storage systems and am-
bient-temperature storage systems. 
“Ultra-low temperature” can be de-
fined as temperatures below −80 °C 
(e.g. LN2), and “low temperature” 
as temperatures between 0  °C and 
−80 °C.
Fig. 5. Liquid nitrogen facility with LN2 tanks.
Fig. 4. Histological slides.
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ever, the compressor technology 
requires constant electrical power 
to maintain subzero temperatures, 
so a backup power system and an 
emergency response plan are need-
ed. Whether samples warm up sig-
nificantly during power outages or 
freezer breakdowns depends on 
the temperature, type, and volume 
of the stored biospecimen, the am-
bient conditions of the environment 
where the freezers are stored, and 
the design and maintenance of the 
freezer.
Ambient temperature and hu-
midity influence temperature sta-
bility considerably if doors are left 
open for prolonged periods, for ex-
ample for sample loading, or if frost 
forms in the freezer, racks, or sam-
ples. Overheating of compressors 
may shorten their lives. Mechanical 
freezers and refrigerators should 
be positioned with sufficient air flow 
around the units and preferably in 
rooms that are air-conditioned or 
have equipment for extraction of 
the hot air generated by the com-
pressors. Regular cleaning and 
as low as −140  °C. Mechanical freez-
ers, which generally require a lower 
initial investment than LN2 tanks and 
provide easy access to biospeci-
mens, can be installed if appropriate 
electrical power is available. How-
protective equipment – in particu-
lar, face shields, cryogenic gloves, 
and individual oxygen detectors – 
should be mandatory, and this 
equipment should be easily acces-
sible (Fig. 2). Appropriate training 
in the safe handling of LN2 must be 
provided, and this should be includ-
ed in an SOP describing the po-
tential health hazards and required 
safety precautions.
3.3.2.2 Mechanical freezers
Mechanical freezers are used for 
a variety of storage systems with 
temperatures ranging from low- 
temperature to ultra-low-temperature 
conditions, including −20  °C, −40  °C, 
−70  °C to −80  °C, and −150  °C, and 
come in a wide range of sizes and 
configurations (Figs. 7 and 8).
Ice crystals may form in biolog-
ical samples at temperatures be-
tween 0 °C and −40  °C, and protein 
activity may persist until −70  °C or 
−80  °C; therefore, freezer temper-
atures should preferably be below 
−80  °C. Cascade compressor tech-
nologies may produce temperatures 
Fig. 7.  Freezer facility.
Fig. 6. Tank for storage in vapour-phase liquid nitrogen.
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the longevity of biospecimens be-
ing stored is enhanced if they are 
stored below ambient temperature, 
due to biomolecular degradation 
that can occur at high ambient tem-
peratures. Storage at 4  °C can be a 
temporary storage solution as an in-
termediate step before preparation 
for ultra-low-temperature storage or 
before sample processing. For re-
frigerators, as for mechanical freez-
ers, it is important to maintain and 
monitor the temperature in the re-
quired operating range and to have 
a backup power system.
3.3.2.4 Ambient-temperature 
storage
If a biobank does not have mechan-
ical freezers or cryogenic storage 
equipment, because of practical 
or financial reasons, then specif-
ic biological storage matrices may 
be used for long-term maintenance 
of some biological components 
at room temperature. Formalin-, 
PAXgene-, or ethanol-fixed, par-
affin-embedded tissues and ly-
ophilized samples can be stored 
at ambient temperatures. Dried 
samples, such as blood spots on 
filter paper, can be stored at ambi-
ent temperature (Figs. 11 and 12). 
There are also some new tech-
niques for storage of DNA at am-
bient temperature, for example in 
mini-capsules after dehydration. 
A mini-capsule consists of a glass 
vial containing the sample, en-
closed in a stainless steel shell with 
a cap. The mini-capsule is sealed 
by a laser, which welds the junction 
between the shell and the cap un-
der an anhydrous and anoxic inert 
atmosphere.
Biological storage matrices 
should be evaluated before use to 
ensure that they are appropriate for 
downstream applications. Temper-
ature, humidity, and oxygen levels 
should be controlled to avoid mould 
growth and microbial contamination.
breakdown and/or to alert person-
nel in case this happens. Some of 
the freezers (approximately 10%) 
should be kept empty and cool to 
be used as a backup system.
3.3.2.3 Refrigerators
Refrigerators are commonly used 
for samples that can be maintained 
at  ambient  temperature.  However, 
maintenance of freezers should 
be planned; this should consist, at 
a minimum, of cleaning filters and 
removing ice around the door and 
seals. Freezers should be equipped 
with alarms set at about 20  °C 
warmer than the nominal operat-
ing temperature of the unit. An in-
dependent temperature monitoring 
system should be in place (Figs. 9 
and 10), to prevent freezer failure or 
Fig. 8. Freezer racks.
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a system should have the capacity to 
run for a sufficient time to allow the 
restoration of the power supply (typ-
ically 48–72 hours) and should be 
tested regularly (Fig. 16). Enough 
fuel should be available on-site to 
run the generator for several days. 
The fuel should also be tested to en-
sure its quality.
Biobanks with LN2 facilities 
should have an LN2 supply stock 
traceability and for the updating of 
biobank catalogues.
All biobanks require a constant 
source of electrical power. Given that 
the commercial electrical power grid 
is likely to fail at some point, a backup 
power system is required. This backup 
system should operate independently 
from the grid and from any other facil-
ities. The most common type of back-
up power is a diesel generator. Such 
3.3.3 Storage services, 
access, and security
Biobanks should have dedicated 
storage facilities that are not shared 
with other activities, for the safety 
and security of biospecimen col-
lections. Sufficient air conditioning 
must be provided for air circulation 
and to maintain the ambient tem-
perature at 22   °C or below, to pre-
vent excess freezer wear and early 
failure. Rooms that contain LN2 
tanks should be equipped with ap-
propriate air flow systems to avoid 
the accumulation of N2 in case of 
leakage, coupled with an oxygen- 
level alarm system, to monitor N2 
release from the tanks. In gener-
al, storage facilities and equipment 
should be monitored by appropriate 
alarm systems (Figs. 13 and 14).
Biobanks should be equipped 
with a system that adequately limits 
access to authorized staff members 
and protects against intrusion by 
unauthorized individuals (Fig. 15). 
In principle, only people assigned 
to biobank activities should have 
access to the storage facility and 
biospecimens, and all materials 
added or withdrawn should be doc-
umented. The documentation of 
sample movement is important for 
Fig. 11. Room-temperature storage 
facility.
Fig. 12. Box of samples stored at 
room temperature.
Fig. 9. Temperature monitoring  
system.
Fig. 10. Graph of temperature log obtained from monitoring system.
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men-associated clinical data (Sec-
tion 3.8) that have been input into 
a separate system. Although it is 
not essential for the specimen-asso-
ciated data to be in the same data-
base as the biobank-specific data, it 
is important for the clinical data to 
be easily accessible via a link or a 
regular import. There may be logis-
tic concerns in directly accessing 
hospital IT systems, and careful 
attention should be given to this 
during the planning of the biobank IT 
infrastructure.
The IT infrastructure should 
also be part of the QMS, and the 
records stored in the system should 
be checked for veracity. QC checks 
should include the verification of 
biospecimen locations to assess the 
concordance between physical stor-
age and database location.
3.3.4.1 IT functionality
The biobank management software 
must guarantee the management of 
different functions and data related 
to biobanking activities (see Sec-
tion 3.8). It is fundamentally impor-
tant that there is a method to track 
each sample throughout the bio-
bank process and to document the 
actions that have been carried out 
on the sample.
will enable the preservation of a set 
of samples in the case of adverse 
events in one location. For multicen-
tre studies, it is recommended that 
each recruitment centre retain a set 
of aliquots at the place of collection, 
with the second set transported to a 
central location that is accessible to 
all recruitment centres.
3.3.4 Basic informatics 
infrastructure
The biobank informatics infrastruc-
ture needs to contain hardware and 
software that are sufficient to address 
the functional requirements of the 
biobank, record and store the infor-
mation acquired during each biobank 
process (see Section 3.8), and pro-
vide an electronic method for records 
management (see Section 3.6). It is 
important that the hardware and soft-
ware infrastructure is designed in such 
a way that it not only meets these ca-
pacity and traceability requirements 
but also meets the requirements for 
security, data protection, and privacy 
(see Section 3.1.3).
One challenge that persists 
for IT solutions is importing speci-
from which to refill the LN2 tank 
(Figs. 17 and 18). Adequate back-
up capacity for low-temperature 
units must be maintained. The total 
amount of backup storage required 
for large biobanks must be deter-
mined empirically but will typically 
be 10% of the total freezer capacity 
for mechanical freezer storage. Be-
cause LN2 storage is safer than us-
ing mechanical freezers, the backup 
capacity for LN2 storage could be 
less than 10% (ISBER, 2012).
Every facility should use basic 
security systems; these must be 
monitored and alarms must be re-
sponded to 24 hours a day, 7 days 
a week by people who can take the 
necessary action to respond to an 
alarm within a time frame that pre-
vents or minimizes loss or damage 
to biospecimen collections. Sys-
tems should allow for calls to other 
key staff members from a list of staff 
telephone numbers if the first per-
son fails to acknowledge the alarm.
Whenever possible, it is recom-
mended to consider splitting stored 
biospecimen collections into two 
sets of aliquots, with each set stored 
in a different location. This strategy 
Fig. 13. A tank fitted with a monitoring device, which shows the level of 
liquid nitrogen inside the tank.
Fig. 14. Video monitoring in liquid 
nitrogen facilities.
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tabase containing this information 
should be updated in real time as a 
biospecimen is moved within or out 
of the biobank.
In addition to IT software to re-
cord the information at each point of 
the biobanking process, there need 
to be software solutions to docu-
ment information about monitor-
ing of storage infrastructure and to 
report alarms about adverse events.
It is also recommended that the 
biobank software record informa-
tion about operations and opera-
tors. This should include informa-
tion about the standard and regular 
measures taken to calibrate and 
repair biobank instruments.
The management of these func-
tions is fundamental to provide 
high-quality samples.
3.3.4.2 Software solutions
As biobanking evolves in terms of 
the types of samples that are col-
lected, archived, and stored and 
the downstream use of the sam-
ples, there continues to be a need 
to develop informatics tools for the 
management of biobanks. Different 
options may be considered depend-
ing on the needs, financial resourc-
es, and IT resources of the specif-
ic biobank. For the rapidly growing 
field of biobanking, commercial 
software solutions are increasingly 
available. Recently, open-source 
systems have emerged, and some 
have been selected by European 
biobanks (Kersting et al., 2015). 
However, commercial and open-
source solutions mainly cover par-
ticular aspects and require adapta-
tion to respond to the requirements 
of the individual biobank.
An alternative to commercial and 
open-source systems may be the de-
velopment of a dedicated in-house 
system, noting that the internal cost 
of maintaining a development team 
for modifications and maintenance 
can be considerable (Voegele et al., 
corded in the IT system are correct-
ly tracked and maintained, and are 
recoverable in the event of erroneous 
modifications.
Semantic interoperability, in par-
ticular, presents a significant chal-
lenge for biobanking and IT support.
The specific location of every 
stored aliquot relating to a sample 
should be tracked. The biobank da-
Documentation related to sample 
collection (informed consent, partic-
ipant information sheet, sample col-
lection protocol), sample processing, 
sample sharing (MTA and DTA), and 
shipment (proof of shipment and deliv-
ery) must be appropriately referenced 
in the IT system (see Section 3.6). 
The IT system requires a backup 
process to ensure that all data re-
Fig. 15. Controlled access in a secured room.
Fig. 16. Power generator.
Section 3. Recommendations for biobanks 33
they must also guarantee the confi-
dentiality of sample records.
Data security systems should 
be adequate to ensure confiden- 
tiality and safety. Electronic records 
should be adequately protected 
through regular backups on appropri-
ate media. Intrusion-proof manage-
ment systems should include solutions 
such as dedicated servers, secure 
networks, firewalls, data encryption, 
and user authentication through verifi-
cation of user names and passwords.
All computers used by biobank 
personnel should be password-pro-
tected and have automatic timeout 
mechanisms. The biobank man-
agement software should also be 
password-protected and should 
have different user profiles to permit 
different levels of access. Each bio-
bank staff member should have an 
individual user ID, to provide com-
plete traceability of all actions per-
formed on biobank data.
The protection of personal infor-
mation and individual data associated 
with specimen collection is a funda-
mental requirement of a biobank. This 
should be achieved through the use 
of safe, structured bioinformatics sys-
tems. Personal identifiers should be 
replaced by codes, and all individual 
data stored in the biobank manage-
ment system should be protected with 
the same stringency as patient clinical 
files. This also applies to data that are 
considered to be sensitive. Commu-
nication to third parties of data files 
containing personal information and 
identifiers should be strictly prohibited 
unless it is required by law or explic-
it permission to do so was granted. 
Examples of methods of coding 
are provided in Appendix 2 of the 
privacy and security policy of GA4GH 
(GA4GH, 2015b).
3.3.4.4 Biobank networking 
infrastructure
The facilitation of scientific net-
working is an important aspect of 
engineers, and technicians (Voegele 
et al., 2013).
3.3.4.3 Data management and 
informatics security
Biobank management systems must 
permit access to sample data in or-
der to stimulate collaboration, but 
2010). On a larger scope, a laborato-
ry information management system 
(LIMS) enables the management not 
only of the biobank but also of the 
entire sample life-cycle workflow. 
Electronic laboratory notebooks are 
also a solution for the management 
of procedures performed in a labora-
tory, and can be used by scientists, 
Fig. 17. Liquid nitrogen supply stock tank.
Fig. 18. Liquid nitrogen piping.
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banks adhere to standards for use of 
samples and data to ensure seman-
tic interoperability between different 
systems and different biobanks, and 
this in particular presents a significant 
challenge for biobanking and IT sup-
port (see Section 3.8, Section 3.5, and 
Section 2.1.4).
biobank develop a website to pre-
sent its operations to the scientific 
community, in addition to an online cat-
alogue with information on the nature, 
characteristics, and quality of its biolog-
ical samples. Networking to facilitate 
exchange and access to an increased 
number of samples requires that bio-
IT infrastructure. Networking can 
increase biobank use and therefore 
is an important element of biobank 
sustainability. Publication of data 
on the Internet can greatly increase 
the visibility of the biobank and its 
ability to participate in biobank net-
works. It is recommended that a 
•  IT systems must correspond with biobanking activities and processes.
•  IT systems must ensure complete traceability of samples and data.
•  Data security systems should be adequate to ensure confidentiality and safety.
•  Access to IT systems must be managed so that they can be accessed only by authorized personnel.
•  Data and combinations thereof should only be made available based on consent and requirement.
•  IT systems should have a method of coding to de-identify individual data to protect privacy.
•  IT systems must also include biobank monitoring.
•  The biobank management system must permit some level of data publication, such as an online catalogue, 
to stimulate collaboration.
•  Cost, functionality, maintenance, and interoperability must be considered when evaluating the selection 
of software solutions: commercial, open-source, or developed in-house.
Key points: IT systems
3.3.5 Basic storage disaster 
recovery – monitoring, 
backup, and additional 
storage
Biobanks require a disaster recov-
ery (DR) plan to protect their assets, 
biological material, and associated 
data. The ability to respond to a 
disaster and protect the integrity 
of the samples and data directly 
affects their quality.
In its most simple terms, DR 
entails taking all necessary steps 
to ensure that, in the event of a 
disaster, the loss caused by the 
disaster is kept to an acceptable 
level and operations can return to 
normal as smoothly and as quick-
ly as possible. DR encompasses 
all processes, policies, and proce-
dures for recovery or continuation 
of infrastructure operation after a 
natural or human-caused disas-
ter, and must include planning for 
key personnel, facilities, and data 
recovery. DR plans are not a one-
size-fits-all solution; in order for DR 
plans to work, they need to address 
the needs of the specific biobank.
The best possible DR planning 
for biological materials and data 
is to ensure that there are dupli-
cated aliquots stored in two or 
more locations. The more distinct 
these locations are in terms of ge-
ographical area and reliance on the 
same utilities (power, generator, 
LN2, carbon dioxide [CO2] supply, 
ambient-temperature control, and 
other elements that pertain to the 
functioning of the biobank storage 
infrastructure), the better the ability 
of one of the locations to withstand 
a particular disaster. Although this 
strategy will avoid unnecessary 
loss in case of adverse events in 
one location, this approach has 
three difficulties.
•  There needs to be enough of the 
original specimen to produce two 
identical aliquots (in the presence 
of tumour heterogeneity, this is 
questionable for tumour tissue 
samples).
•  Additional logistics are involved in 
regular transportation of the fresh 
and/or frozen samples to ensure 
that the biobank has the same con-
tent at each location.
•  Retrieval of samples from the dupli-
cate locations involves increased 
costs and time delays.
Retrieval of samples from du-
plicate locations is hampered by 
increased distances (preferable 
for the DR plan) and transportation 
facilities (couriers, transportation in-
frastructure). Preventive measures 
such as different methods of stor-
age or reducing the specimen to its 
basic derivative components, such 
as nucleic acids, will provide oppor-
tunities for innovative storage meth-
ods. Also, nucleic acids are more 
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needed to collect the lost material 
again, considering the availability 
of such samples and their asso-
ciated data as well as the effort 
required by personnel, the equip-
ment to be used, and the consum-
ables. Samples from longitudinal 
studies acquire more value over 
time as their associated samples 
and data accumulate, and there-
fore the cost of replacing them in-
creases with time.
•  Carry out a risk analysis to eval-
uate the potential disasters, the 
probability of each type of disas-
trous event occurring, and the im-
pact each event would have on the 
biobank. The risk analysis makes 
it possible to prioritize the events 
that need to be addressed. Then, 
based on the resources available, 
it can be decided how to address 
each event.
•  Calculate the response times in 
the event of a disaster. Response 
times are critical because they di-
rectly affect the potential loss of 
samples, and they must be cal-
culated based on the acceptable 
loss and the time needed to either 
return to normal functioning or mit-
igate the problem caused by the 
adverse event.
•  For each type of disaster, calculate 
a maximum response time to en-
sure the integrity of the conserved 
samples, such as either fixing a 
broken freezer so that it returns to 
its desired temperature before it 
has reached critical temperature, 
or moving the samples to a dif-
ferent location before their quality 
is compromised. This calculation 
must take into consideration the 
different reactions of the contain-
ers and the different effects of 
temperature change on each 
sample type stored (tissue, blood, 
plasma, serum, DNA, RNA).
•  Assign people to be on call to re-
spond to any alarms at all times 
(24 hours a day, 7 days a week); 
it is essential that they are able to 
•  Automatic LN2 filling systems are 
most affected by faulty sensors 
and faulty transfer pipes.
•  Monitoring systems are most af-
fected by electricity supply, Inter-
net connectivity, wireless connec-
tions, and telephone lines.
Events such as a power outage 
or power fluctuations can be low 
priority if there is a way to mitigate 
or avoid the problem by providing 
either an uninterrupted power sup-
ply or a backup diesel generator. 
The backup generator should be 
able to start automatically, needs to 
have the capacity to run for a suf-
ficient time to allow the restoration 
of the power supply (typically 48–72 
hours), and should not be affected 
by the adverse event that caused 
the power outage.
It is always important to consider 
the cascading effect of a single event. 
An example is a fault in the air con-
ditioning system that causes the bio-
bank’s ambient temperature to rise. 
This temperature rise, in turn, caus-
es the mechanical freezers to need 
CO2 to maintain their temperature of 
−80  °C. If the CO2 supply is depleted 
by the time the ambient temperature 
returns to an acceptable level, then the 
temperature of the mechanical freez-
ers will also rise, potentially leading 
to damage of the samples they 
contain.
A complete DR plan requires the 
following steps.
•  Categorize the stored samples 
in order of priority. In case of an 
emergency, high-priority samples 
will be moved to an external facility 
before lower-priority samples.
•  Evaluate the acceptable downtime 
(the time during which the biobank 
is inaccessible).
•  Evaluate the acceptable loss (the 
number of samples and their as-
sociated data that can be lost). 
The acceptable loss should be 
considered in terms of delays to 
research, and by evaluating how 
much time and money would be 
stable once extracted from tissue, 
and therefore are more resistant to 
temperature fluctuations and permit 
longer response times.
A similar situation relates to 
biobank data: saving the data con- 
temporaneously at two distinct sites 
would guarantee the same safe-
guards to the data. This is potentially 
more feasible than storing samples 
in separate locations, because du-
plicating and transferring data is an 
easier task and does not necessar-
ily require physical transportation. 
However, where continual data 
transfer is not feasible, periodic 
backups should be carried out, with 
backups stored off-site to reduce 
loss of data.
Each biobank infrastructure DR 
plan should contain an evaluation 
of the events and elements that can 
affect the biobank, the probability of 
these occurring, and the means to 
address them. These can be either 
natural events (e.g. earthquakes, 
hurricanes, storms, floods, fires, 
plane crashes, excess temperatures 
and humidity) or human-caused 
events (e.g. breakdown of a sin-
gle freezer, breakdown of multiple 
freezers, power outage or power 
fluctuations, CO2 outage, air con-
ditioning breakdown, air extraction 
breakdown, inaccessible room due 
to gas leak). Only those elements 
that affect the biobank, either direct-
ly or indirectly, should be considered 
in the individual plan.
Apart from faults with a single 
container (caused by blown fuses, 
battery discharges, blocked refill 
valves, broken compressors, bro-
ken covers or doors, or worn seals), 
external events will affect each bio-
bank to a different extent.
•  Biobanks with −80   °C freezers are 
most affected by electricity supply, 
CO2 supply, biobank room temper-
ature, dusty conditions, humidity, 
and air conditioner faults.
•  LN2 biobanks are most affected by 
LN2 supply.
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lists must be presented in the form 
of SOPs, so that in the event of 
a disaster, action can be taken 
immediately.
The DR plan should be part 
of the QMS and should be re-
viewed annually to guarantee that 
it responds adequately to the bio-
bank’s evolution. The DR plan 
must be tested as extensively as 
possible using simulated scenar-
ios and should be updated regu-
larly as the biobank infrastructure 
changes.
units must be maintained (10% 
is the best practice). The total 
amount of backup storage required 
for large biobanks must be deter-
mined empirically. Typically, the 
minimum should be the capacity 
of a single container (where there 
are different sizes, this should be 
calculated based on the capacity 
of the largest freezer) or, for large 
biobanks, 10% of the total contain-
er capacity (NCI, 2016).
•  Prepare a detailed list of actions 
for each evaluated event. These 
respond and carry out the DR plan 
within the allocated time.
•  Carry out simulation exercises 
to ensure effective training of the 
people assigned to respond.
•  Specify methods for transporting 
samples without affecting their 
quality and integrity, in case the 
samples need to be moved.
•  Ensure that backup facilities are 
available, in case samples need 
to be moved from the current 
biobank or freezer. Adequate back-
up capacity for low-temperature 
•  Categorize the stored samples in order of priority, to facilitate the relocation process if the samples or 
equipment need to be moved to an external facility in case of an emergency.
•  Calculate the acceptable downtime and the response times in the event of a disaster.
•  Carry out a risk analysis to evaluate the potential disasters and the acceptable loss.
•  List the actions for each evaluated event, and design SOPs as part of the QMS, along with adequate 
simulation exercises, training, and review.
•  Prepare an on-call list of people on standby in case of an emergency.
•  Ensure that adequate backup storage capacity is available, in case samples need to be transferred.
Key points: disaster recovery plan
3.4 Quality
Biobanks are key for the develop-
ment of clinically useful biomarkers 
of disease and disease progression, 
for discovering and monitoring new 
drugs, and for understanding the 
mechanisms of cancer and related 
diseases. All of these possibilities 
are underpinned by the availability 
of high-quality, well-annotated sam-
ples of diseased and control tissue, 
blood, and other biological materials 
and associated data.
The availability of high-quality 
samples is also important to demon-
strate to funders of biobanks and 
to the research community that the 
facility provides a good return on 
their investments in sample and 
data collection, which will accelerate 
progress in cancer research.
The scientific and technical man-
agement of the biobank infrastruc-
ture and resources – such as storage 
facilities, pre-analytical processing 
tools, trained personnel, robust gov-
ernance, and policy management – 
is central to maintaining quality and 
determines the relevance and suc-
cess of a biobank.
The key components that can af-
fect the quality of samples and data 
are presented in Fig. 19.
In general, biobanks should im-
plement systems that specify QC 
and QA for sample collection, pro-
cessing, storage, shipment, and dis-
position. Such systems are essential 
for maintaining a fit-for-purpose bio-
bank for cancer research. The ISO 
15189 standard currently referred 
to by biobanks (ISO, 2012) is based 
on ISO/IEC 17025 and ISO 9001, 
which provide general requirements 
for the competence of testing and 
calibration laboratories and for the 
QMS, respectively. They are not 
specific to biobanking processes 
and procedures. However, in 2015 
CEN published a series of Technical 
Specifications for molecular in vitro 
diagnostic examinations – Specifica-
tions for pre-examination processes, 
which are relevant for diagnostic lab-
oratories as well as biobanks. See 
Table 3 for a list of CEN Technical 
Specifications. It is recommended 
that these standards are used.
In addition, ISO is developing 
standards for biobanks and biore-
sources. The Technical Committee 
of ISO 276 (standardization in the 
field of biotechnology) will include:
•  biobanking terms and definitions;
•  biobanks and bioresources;
•  analytical methods;
•  bioprocessing; and
•  data processing, including annota-
tion, analysis, validation, compara-
bility, and data integration (Furuta 
and Schacter, 2015).
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Fig. 19. Overview of the key issues related to quality in biobanking.
Table 3. CEN Technical Specifications for molecular in vitro diagnostic examinations
Technical Specification Title
CEN/TS 16826-1:2015 Specifications for pre-examination processes for snap frozen tissue. Part 1: Isolated RNA
CEN/TS 16826-2:2015 Specifications for pre-examination processes for snap frozen tissue. Part 2: Isolated proteins
CEN/TS 16827-1:2015 Specifications for pre-examination processes for FFPE tissue. Part 1: Isolated RNA
CEN/TS 16827-2:2015 Specifications for pre-examination processes for FFPE tissue. Part 2: Isolated proteins
CEN/TS 16827-3:2015 Specifications for pre-examination processes for FFPE tissue. Part 3: Isolated DNA
CEN/TS 16835-1:2015 Specifications for pre-examination processes for venous whole blood. Part 1: Isolated cellular RNA
CEN/TS 16835-2:2015 Specifications for pre-examination processes for venous whole blood. Part 2: Isolated genomic DNA
CEN/TS 16835-3:2015 Specifications for pre-examination processes for venous whole blood. Part 3: Isolated circulating cell free 
DNA from plasma
CEN, European Committee for Standardization; FFPE, formalin-fixed, paraffin-embedded; TS, Technical Specification.
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3.4.2 Quality of tissue and 
derivatives
The procurement of tissue, both 
diseased (neoplastic, pre-neoplastic, 
and inflammatory) and normal, must 
always be carried out by, or under 
the supervision of, a pathologist. 
This permits a more accurate mac-
roscopic sampling followed by a 
microscopic confirmation. This is 
standard QA for tissue procurement 
(Hainaut et al., 2009).
3.4.2.1 Quality control of tissue 
(e.g. frozen section)
QC should be done during sampling 
in the grossing room on surgical 
samples using the frozen sec-
tion method. This is done by sam-
pling the area of suspected cancer 
reported on the identification of 
evidence-based biospecimen QC 
markers (Betsou et al., 2013). The 
findings are summarized in Table 4. 
Although the report provided evi-
dence for several quality biomark-
ers, their level of applicability and 
accessibility varies. In Table 4, 
only markers that scored highly for 
applicability and accessibility are 
included. These markers provide 
QC tools for assessing biospeci-
mens in relation to pre-analytical 
conditions. NCI’s Biorepositories 
and Biospecimen Research Branch 
has initiated the Biospecimen 
Research Network (http://biospeci 
mens.cancer.gov/researchnetwork/
projects/default.asp), which aims 
to stimulate original research and 
disseminate available data in bio-
specimen science.
Biobanks should have appropri-
ate QA and QC programmes with 
respect to equipment maintenance 
and repair, staff training, data man-
agement and record-keeping, and 
adherence to principles of good 
laboratory practice. All biobank op-
erations must be subject to regu-
lar audits. The timing, scope, and 
outcome of these audits should be 
documented.
3.4.1 Biospecimen quality 
biomarkers
Biospecimen quality biomarkers 
are useful to assess the quality of 
material before it is included in ex-
perimental platforms and to avoid 
the unnecessary use of biospec-
imens. In 2013, the ISBER Bio-
specimen Science Working Group 
Table 4. Identified biospecimen molecular diagnostic biomarkers, with QC scope and evaluation
QC tool Analyte type
Sample  
type QC scope
Applicability 
grade
Accessibility 
grade
Delay  
Consequence Reference
Transferrin 
receptor
Protein Serum Pre-centrifugation 
delay
1 1 8 h blood pre-centrifugation 
delay 
90% increase
De Jongh et al. 
(1997)
K+ Ion Serum Pre-centrifugation 
delay
1 1 1 day pre-centrifugation delay 
at 4  °C
200% increase
7 day pre-centrifugation delay 
at 4  °C
500% increase
Heins et al. 
(1995)
GM-CSF, IL-1α, 
G-CSF
Protein EDTA 
plasma 
± PI
Pre-centrifugation 
delay
1 1 2 h pre-centrifugation delay 
at RT
11–20-fold increase without PI
7–10-fold increase with PI
Ayache et al. 
(2006)
sCD40L Protein Serum Exposure to RT 1 1 12 h at 37  °C or 48 h at RT 
Complete degradation
Lengellé et al. 
(2008)
Vitamin E Vitamin EDTA 
plasma
Storage conditions 1 1 > 24 months at −20  °C 
> 90% decrease
Ockè et al. 
(1995)
MMP-7 Protein Serum Freeze-thawing 1 1 30 freeze–thaw cycles 
Loss of MMP-7
Chaigneau et al. 
(2007)
DUSP1 
expression
RNA Fresh 
prostatic 
tissue
Warm ischaemia 
time
1 1 Warm ischaemia 
14-fold upregulation
Lin et al.  
(2006)
p-Tyr, ERBB2 
(alias HER2; 
alias Neu)-
Tyr1248, PTK2 
(alias FAK)
Protein Breast 
tissue
Cold ischaemia 
time
1 1 24 h of cold ischaemia 
Complete denaturation of 
phosphorylated epitopes
De Cecco et al. 
(2009)
±, with or without; EDTA, ethylenediaminetetraacetic acid; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage 
colony-stimulating factor; IL-1α, interleukin 1 alpha; K+, potassium; MMP-7, matrix metalloproteinase-7; PI, protease inhibitors; QC, quality control; 
RT, room temperature; Tyr, tyrosine. 
Source: Adapted from Betsou et al. (2013), Copyright (2013), with permission from Elsevier.
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The qualification process con-
sists of the quantification of dsDNA 
and the assessment of its suitability 
for downstream applications, such 
as high-throughput next-generation 
sequencing. Microarray experiments 
may require nucleic acid samples 
with specific values of concentra-
tion, purity, and integrity, whereas 
quantitative PCR (qPCR)-based as-
says may accept samples with lower 
quality scores because the ampli-
cons are small (typically < 100 bp). 
Correctly interpreting data obtained 
from quantification and QC analysis 
is essential.
3.4.3.1 Methods for evaluating 
quality of nucleic acids from 
tissue
Spectrophotometers can measure 
absorbance and provide values for 
wavelengths of 260 nm, 280 nm, and 
230 nm. However, they lack the sen-
sitivity to measure small quantities 
of DNA. All nucleic acids (dsDNA, 
RNA, and ssDNA) absorb at 260 nm, 
and this method cannot distinguish 
between the various forms of nucle-
ic acid. For example, the amount of 
genomic DNA (gDNA) present in an 
RNA preparation or the amount of 
RNA present in a gDNA sample can-
not be determined. These contam-
inants contribute to the absorbance 
value, resulting in an overestimation 
of nucleic acid concentration. In 
addition, if samples are degraded, 
single nucleotides will also contrib-
ute to the 260 nm reading, and thus 
the nucleic acid concentration will be 
overestimated.
Fluorescent dye-based quantifi-
cation uses dyes that only fluoresce 
when bound to specific molecules, 
dsDNA, ssDNA, or RNA, and thus 
the concentration of the specific 
molecule can be measured. This 
makes the measurement more 
accurate for samples that contain 
nucleic acid contaminants or sam-
ples that are partially degraded. 
by the nucleic acid to the absor- 
bance of the contaminants. Aromatic 
amino acids absorb light at 280 nm, 
so absorbance measurements at 
that wavelength are used to estimate 
the amount of protein in the sample. 
Measurements at 230 nm are used 
to determine the amount of other 
contaminants that may be present in 
the samples, such as guanidine thio-
cyanate, which is common in nucleic 
acid purification kits. Typical require-
ments for A260/A280 ratios are 1.8–
2.2; A260/A280 of pure DNA is ~1.8, 
and A260/A280 of pure RNA is ~2. 
Requirements for A260/A230 ratios 
are generally > 1.7. The A260/A230 
ratio may also predict sample ampli-
fiability (the ability of the extracted 
sample to be amplified by PCR).
Acceptable ratios for purity vary 
with the downstream application. 
A230 is often constant for nucle-
ic acid purified using a specific kit, 
whereas the amount of nucleic acid 
can vary depending on the sample 
source. Thus, the A260/A230 ratio 
often decreases when small amounts 
of nucleic acids are isolated.
Integrity represents intactness 
or state of degradation. This is often 
presented as the DNA integrity num-
ber (DIN) and the RNA integrity num-
ber (RIN). The higher the RIN value, 
the better the integrity of the RNA. 
RNA is considered to be of high qual-
ity when the RIN value is ≥ 7. RNA 
with RIN values of 5 and 6 may be 
considered acceptable. Care must 
be taken when using instruments to 
determine these values, because the 
concentration of the sample can af-
fect the resulting value.
The quality of nucleic acid ex-
tracted from tissue can vary de-
pending on the sample source and 
the extraction method applied. 
Quality requirements can be very 
different depending on the dow 
stream application. Nucleic acids 
that are unsuitable for one applica-
tion may provide perfectly accept-
able results in another application. 
macroscopically, performing a rou-
tine frozen section, preparing a 
stained slide, and documenting the 
review data on the sample collec-
tion sheet. The following information 
should be provided, which defines 
the quality of the tissue sample:
•  frozen section performed (yes or no);
•  pathologist who performed frozen 
section review;
•  tumour confirmed;
•  percentage of tumour cells;
•  percentage of stromal and inflam-
matory cells;
•  percentage of surface occupied by 
necrosis; and
•  other comments.  
3.4.2.2 Methods for quality 
control of tissue sections for 
DNA/RNA extraction
Regardless of whether a frozen 
section is performed at the time of 
sampling, microscopic pathology 
review should be performed on the 
tissue sections taken for nucleic 
acid extraction. It is recommend-
ed that this is performed every 20 
sections of 5 µm, because of the 
potential heterogeneity in the sam-
ple. This is also recommended for 
sections taken from formalin-fixed, 
paraffin-embedded (FFPE) blocks.
3.4.3 Quality control of 
nucleic acids from tissue
The quality of a nucleic acid is based 
on quantity, concentration, purity, 
and integrity.
Concentration is calculated for 
DNA, RNA, and proteins using the 
ultraviolet (UV) absorbance read-
ing at a wavelength of 260 nm and 
a conversion factor based on the 
extinction coefficient for each nu-
cleic acid (A260 of 1.0 = 50 µg/mL 
for double-stranded DNA [dsDNA], 
40 µg/mL for RNA, and 33 µg/mL for 
single-stranded DNA [ssDNA]).
Purity is calculated from the 
ratio of the absorbance contributed 
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reporting of accidents, errors, 
complaints, and adverse events;
•  policies, procedures, and schedules 
for equipment inspection, mainte-
nance, repair, and calibration;
•  emergency procedures in case of 
failure of a refrigerator, freezer, or 
LN2 tank;
•  procedures for disposal of medical 
waste and other hazardous waste; 
and
•  policies and procedures describing 
the requirements of recruitment 
and training programmes for bio-
bank staff.
3.6 Records management
The importance of an adequate re-
cords management strategy cannot 
be overstated.
Documentation related to sam-
ple collection, sample processing, 
sharing of samples (MTA and DTA), 
and shipment of samples (proof of 
shipment and delivery) must be ap-
propriately maintained and archived 
in a traceable and secure manner. A 
backup system must be implement-
ed to guarantee appropriate mainte-
nance of all documents.
All documents and documen-
tation must be kept centrally and 
should include:
•  the SOP manual;
•  quality certifications;
•  personnel training records;
•  templates of forms and spread-
sheets;
•  documentation of biobank audits;
•  documentation of adverse events;
•  instrument calibration records;
•  maintenance and repair records;
•  signed informed consents;
•  signed collaboration agreements;
•  sample request forms;
•  signed MTAs and DTAs; and
•  shipping notes.
Similarly to SOPs, each form 
should have a unique number and 
title. All changes made to forms 
should be noted, dated, and signed 
to provide a trace of all modifications.
3.5 Contents of standard 
operating procedures (SOPs)
Biobanks should develop, docu-
ment, and regularly update policies 
and procedures in a standardized 
written format incorporated into an 
SOP manual that is readily avail-
able to all laboratory personnel. 
The SOP manual is a key part of 
the overall QMS of the biobank, is 
important to the success of biobank-
ing, and is a major contributor to the 
development of biomedical practice 
worldwide.
The SOP manual should specif-
ically include:
•  procedures for obtaining informed 
consent and withdrawal of consent 
from participants;
•  records management policies, 
including access control, a back-
up system, clinical annotation, 
and document maintenance and 
archiving;
•  policies and procedures for spec-
imen handling, including supplies, 
methods, and equipment;
•  laboratory procedures for speci-
men processing (e.g. collection, 
transportation, processing, ali-
quoting, tests, storage, and QC);
•  procedures for sharing and trans-
ferring specimens (access policy, 
MTA);
•  procedures for a business model 
and cost recovery, when applicable;
•  policies and procedures for ship-
ping and receiving specimens;
•  QA and QC policies and proce-
dures for supplies, equipment, in-
struments, reagents, labels, and 
processes used in sample retrieval 
and processing;
•  procedures for security in biobank 
facilities;
•  policies and procedures relat-
ed to emergencies and safety, 
including reporting of staff inju-
ries and exposure to potential 
pathogens;
•  policies and procedures for the 
investigation, documentation, and 
Although this method provides a 
more accurate concentration of the 
sample for the molecule of interest, 
it does not give an indication of the 
contamination of the sample.
Gel electrophoresis verifies the 
integrity of DNA and RNA mole-
cules by separating their fragments 
based on size and charge and thus 
estimating the size of DNA and RNA 
fragments.
The RIN is an algorithm for as-
signing integrity values to RNA 
measurements. The integrity of RNA 
is a major concern for gene expres-
sion studies and traditionally has 
been evaluated using the 28S/18S 
ribosomal RNA (rRNA) ratio. The 
RIN algorithm is applied to electro-
phoretic RNA measurements and is 
based on a combination of different 
features that contribute information 
about the RNA integrity to provide 
a robust universal measure. If RNA 
is purified from FFPE samples, the 
28S/18S rRNA ratio and the RIN val-
ue are not useful for assessing RNA 
quality.
The DIN determines the level of 
sample degradation using an algo-
rithm to evaluate the entire electro-
phoretic trace. The higher the DIN 
value, the better the integrity of the 
gDNA sample.
qPCR can be a useful technique 
in the QC of gDNA for downstream 
sequencing, because it simultane-
ously assesses DNA concentration 
and suitability for PCR amplification. 
However, this technique is labour- 
intensive and has higher costs.
Sequential use of spectropho-
tometric and fluorescence-based 
methodologies permits the cost-ef-
fective assessment of DNA quality 
for high-throughput downstream 
applications. This combination also 
enables the detection of impuri-
ties, and thus their removal from 
samples. This is particularly useful 
for samples such as FFPE sam-
ples that are available in limited 
amounts.
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cide the period for record retention 
depending on the type of record. 
Records pertaining to samples that no 
longer exist may be destroyed if the 
records are considered to no longer 
be valuable. Records pertaining to 
samples that were withdrawn should 
be destroyed in a secure manner. 
Records pertaining to instruments may 
be destroyed once the instrument has 
been retired. The destruction of records 
should be carried out in a manner in 
line with the security requirements of 
the record.
shelves, racks, and boxes as 
well as each location within the 
container.
An IT solution (see Section 3.3.4) 
can provide a centralized system to 
maintain traceable records of sam-
ples. Where possible, hard copies of 
records should be scanned into an IT 
system to provide a backup.
All records should be archived 
for a period in line with institution-
al or local regulations, where they 
exist. Where there are no such reg-
ulations, the biobank should de-
All hard copies of records must be 
archived in a secure manner, to be ac-
cessed only by authorized personnel. 
All stored records should be stored in 
a manner that provides easy access 
for inspection by authorized personnel.
Each container, tank, freez-
er, refrigerator, or room-tempera-
ture storage cabinet should have a 
unique identifier. The hierarchy of 
each storage unit should be clearly 
defined, to enable stored samples 
to be located easily. A convention 
should be established for numbering 
•  Evaluate the available systems: commercial, open-source, or developed in-house.
•  Biobanking activities and processes must be documented.
•  Data security systems should be adequate to ensure confidentiality and safety.
•  Records management should be audited regularly (QA/QC).
•  Biobank management systems must also allow access to sample data, to stimulate collaborations.
•  Semantic interoperability is an important consideration.
•  Systems must ensure full traceability of samples, data, and documentation.
•  Documentation must be archived in a traceable and secure manner.
Key points: records management system
3.7 Specimen collection, 
processing, and storage
Many types of biological material can 
be stored for cancer research pur-
poses. The methods used to collect 
biospecimens will vary depending on 
what the intended end use is and how 
the specimens will be processed.
The recommendations present-
ed here are derived from multiple 
sources, such as international publi- 
cations and articles (Eiseman et al., 
2003), including the biorepository 
protocols of the Australasian Bio-
specimen Network. Although this 
book focuses on cancer research, 
the research community realizes 
that samples may also be used 
in other areas of research; the 
key issue is the importance of har-
monization of techniques and prac-
tices to facilitate multidisciplinary 
collaboration.
This section provides general 
advice about the collection of:
•  whole blood and derivatives
•  solid tissues
•  urine
•  buccal cells and saliva
•  bronchoalveolar lavage
•  bone marrow aspirate
•  cerebrospinal fluid
•  semen
•  cervical and urethral swabs
•  hair
•  nails.
3.7.1 Collection of blood or 
blood-derived products
Detailed instructions and protocols 
for the collection of blood or blood 
derivatives are provided in Section 4.
3.7.1.1 Blood
The following general guidelines 
should be considered.
•  All blood should be treated as po-
tentially infectious. Blood samples 
for research purposes should be 
collected at the same time as rou-
tine clinical blood samples, so as 
to limit discomfort to individuals. 
Blood should be collected from 
fasting individuals (i.e. after ab-
stinence from food, alcohol, and 
caffeine-containing beverages for 
8–12 hours).
•  Blood should not be collected after 
prolonged venous occlusion.
•  Tubes into which the blood is 
collected should be clearly labelled 
(Fig. 20).
•  For blood collection, the recom- 
mended order of draw is the following 
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heel-stick blood from newborns for 
metabolic disease screening. The 
903 paper is manufactured from 
100% pure cotton linters with no 
wet-strength additives. The critical 
parameters for collection of new-
born screening samples are blood 
absorbency, serum uptake, and 
circle size for a specified volume 
of blood. Blood spots archived for 
as long as 17 years, sometimes at 
room temperature, have also pro-
vided valuable sources of ampli- 
fiable DNA (Makowski et al., 1996) 
(Fig. 21).
Modified cards (IsoCode cards 
or FTA cards) have been devel-
oped. These consist of filter paper 
impregnated with a proprietary mix 
of chemicals that serves to lyse 
cells, to denature proteins, to pre-
vent growth of bacteria and other 
microorganisms, and to protect 
nucleic acids from nucleases, oxi-
dation, and UV damage. Room-tem-
perature transportation of such 
cards in folders or envelopes (by 
hand or by mail) has been common 
for years. The papers protect DNA 
in the samples for some years under 
ambient conditions. The main vari-
able is expected to be the quality 
of the storage atmosphere, particu-
larly the content of acid gases and 
free-radical-generating pollutants, 
although FTA paper can protect 
against such conditions (Smith and 
Burgoyne, 2004). Sample integrity 
is optimized when FTA cards are 
stored in a multi-barrier pouch with 
a desiccant pack. Whatman Protein 
Saver Cards are commonly used to 
collect dried blood spots for molecu-
lar and genomic studies and for the 
isolation of viruses (Mendy et al., 
2005) and bacteria (see Section 4).
3.7.1.3 Buffy coat
For DNA testing, if DNA cannot 
be extracted from blood within 3 
days of collection, the buffy coat 
may be isolated and stored at 
be used if DNA will be extracted 
or lymphoblastoid cell lines will 
be derived. Lithium heparin is not 
recommended for establishment of 
lymphoblastoid cell lines.
•  EDTA tubes are recommended if 
protein studies will be performed. 
The use of EDTA tubes results in 
less proteolytic cleavage com-
pared with the use of heparin tubes 
or ACD tubes.
•  For the preparation of plasma, the 
blood should be centrifuged as 
soon as possible. For the prepa-
ration of serum, the blood should 
be processed within 1 hour of 
collection.
•  The amount of blood collected 
should be justified when applying 
for ethical clearance.
•  A reduced volume of blood in a 
tube containing additives should 
be recorded to avoid confounding 
the results.
•  The time and date of blood collec-
tion and the time of freezing should 
be recorded, as well as any devia-
tions from the standard processing 
protocol.
•  Blood should be transported at 
room temperature or on melting 
ice depending on the particular ap-
plications. Samples to be used for 
proteomics assays should be pro-
cessed immediately at room temper-
ature, because cool temperatures 
can activate platelets and release 
peptides into the sample ex vivo.
•  Blood spot collection should be 
considered as an alternative to 
whole blood for validated tech-
niques when conditions necessi-
tate easier collection and cheap 
room-temperature storage. Differ-
ent types of collection cards are 
available (e.g. Guthrie cards, “fast 
transient analysis” [FTA] cards, 
IsoCode cards) (see Section 4).
3.7.1.2 Blood spots
Guthrie cards (Schleicher & Schuell 
903 filter paper) are used to collect 
(Calam and Cooper, 1982; CLSI, 
2007):
1. blood culture tube;
2. coagulation tube;
3.  serum tube with or without clot 
activator, with or without gel;
4.  heparin tube with or without 
plasma separating gel;
5.  ethylenediaminetetraacetic acid 
(EDTA) tube with or without sep-
arating gel;
6. glycolytic inhibitor.
•  For the preparation of plasma, 
blood may be collected into an 
EDTA tube, an acid citrate dex-
trose (ACD) tube, or a lithium hep-
arin tube.
•  Ideally, blood should be processed 
within 1 hour of collection. After 
that time, cell viability decreases 
rapidly, resulting in poor cell struc-
ture and degradation of proteins 
and nucleic acids.
•  Lithium heparin is generally used if 
cytology studies will be performed, 
but it is not recommended for pro-
teomics work.
•  PCR was clearly interfered with when 
heparinized blood (heparin 16 U/mL 
blood) was used as a source of 
template DNA (Yokota et al., 1999).
•  Either EDTA or ACD tubes can 
Fig. 20. Blood sample.
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tions of the tumour and adjacent 
apparently normal tissue and other 
areas of interest. Where possible, 
two or more samples of the tumour 
tissue should be taken, represent-
ing different areas, i.e. different 
macroscopic patterns in the body 
of the tumour. Normal tissue can 
be taken from a non-diseased re-
sected organ, but where the nor-
mal tissue is required for use as 
matched control, it should be tak-
en preferably > 10 mm from the 
diseased tissue.
•  If applicable, involved lymph nodes 
and metastases will also be col-
lected. Tissues must be sliced with 
sterile forceps and scalpel blades, 
and staff members must use ster-
ile gloves. The use of the same 
scalpel blade for normal and neo-
plastic areas should be avoided. If 
this is not possible, normal tissue 
should be collected before tissue 
from tumour areas.
•  Standard diagnostic processes usu- 
ally place surgical specimens in for-
malin after excision. Where fresh, 
vitally cryopreserved, or fresh fro-
zen samples are required, samples 
must be transferred as fresh spec-
imens. In this case, fresh speci-
mens should be placed in a closed 
container in a sterile cloth on wet 
ice for transportation from surgery 
to pathology. An alternative, which 
also permits a delay in the need for 
immediate processing, is to vacu-
um-pack the tissue.
•  Transfer of specimens on wet ice 
must be carried out as soon as 
possible, to minimize the effect of 
hypoxia on gene expression and 
degradation of RNA, proteins, and 
other tissue components. Transfer 
of vacuum-packed specimens is 
less time-critical; the samples may 
be stored for up to 115 hours in a 
4  °C refrigerator before and/or after 
transportation from the operating 
theatre, until processing. The tem-
perature of the specimen during 
transfer should be documented.
•  The collection of samples for re-
search should never compromise 
the diagnostic integrity of a spec- 
imen. Only tissue that is excess to 
diagnostic purposes should be col-
lected for research. It is the responsi-
bility of the pathologist to decide this.
•  The intact surgical specimen or 
biopsy sample should be sent to 
pathology.
•  Tissue bank staff members must 
be present in pathology, to collect, 
freeze, or fix the tissue as quickly 
as possible.
•  All materials and instruments 
should be prepared in advance. If 
a fresh sample is to be obtained, 
transport medium (RPMI 1640, 
10% fetal bovine serum [FBS], 
100 U/mL penicillin/streptomycin, 
100 U/mL amphotericin) should be 
prepared. If a sample is to be vital-
ly cryopreserved, cryopreserving 
solution should be prepared (RPMI 
1640, 10% dimethyl sulfoxide 
[DMSO], 20% FBS).
•  A pathologist should supervise 
the procurement of the tissue for 
research purposes. The patholo-
gist will examine the sample and, 
allowing adequate tissue for diag-
nostic purposes, will remove por-
−70 °C or below before DNA iso-
lation. Buffy coat specimens that 
are being used for immortaliza-
tion by Epstein–Barr virus should 
be transported frozen on dry ice 
(solid-phase CO2). RNA should be 
isolated from buffy coat within 1–4 
hours of specimen collection; al-
ternatively, RNA stabilization solu-
tion (e.g. RNAlater) should be used 
(see Section 4).
3.7.2 Collection of solid 
tissues
Solid tissues for research are col-
lected by biopsy or after surgical 
excision. Detailed procedures are 
presented in Section 4.
The following important points 
should be considered when plan-
ning tissue collection for research.
•  The collection of samples should 
be carefully planned with sur-
geons, clinical staff, and patholo-
gists. Collection of solid tissue for 
research from surgically excised 
tissue should always occur in the 
grossing room unless the standard 
procedure for clinical care permits 
collection in the operating theatre 
or nearby pathology suite.
Fig. 21. Card with dried blood spots.
S
EC
TI
O
N
 3
44
•  Each specimen conservation re-
ceptacle (tube) must be clearly 
labelled before it is placed in the 
biobank (see Figs. 24–26).
3.7.3 Collection of other 
specimens
3.7.3.1 Urine
Urine is easy to collect and is a 
suitable source of proteins, DNA, 
and metabolites. Urine should be 
routinely stored at −80 °C. Ambi-
ent-temperature storage before 
freezing should be kept to a mini-
mum (see Section 4).
3.7.3.2 Buccal cells
The collection of buccal cells is not 
difficult and does not require highly 
trained staff. Buccal cell collection 
is considered when non-invasive, 
self-administered, or mailed collec-
tion protocols are required for DNA 
analysis (Steinberg et al., 2002). How-
ever, buccal cells will yield only limit-
ed amounts of DNA compared with 
blood. Different methods of self-col-
lection are available, depending on 
the end-points and the analyses to be 
performed (Mulot et al., 2005).
Cytobrush
With this method, buccal cells are 
collected on a sterile cytobrush by 
twirling it on the inner cheek for 15 
seconds. The operation is repeat-
ed three times, on the two cheeks. 
The swabs are separated from the 
stick with scissors and transferred 
to a cryotube. The duration of the 
collection can influence the DNA 
yield. García-Closas et al. (2001) 
reported that cytobrushes produce 
DNA with good quality. Howev-
er, King et al. (2002) concluded 
that the mouthwash method of 
collecting buccal cells is superior 
for reactions that require long 
fragments.
be immersed directly in LN2, be-
cause of the potential formation 
of cryo-artefacts. When dry ice or 
LN2 is not readily available, tissue 
collection in RNAlater is a good 
alternative, provided that this tis-
sue is not required for diagnostic 
purposes and that permission has 
been given by the pathologist. Al-
ternatively, PAXgene can be used 
as a fixative that preserves nucle-
ic acids and morphology for histo-
pathological analyses (Viertler et 
al., 2012).
•  Where possible, it is advisable for 
a cryostat section to be taken, to 
prepare a haematoxylin and eo-
sin (H&E)-stained slide for review 
by the pathologist for confirmation 
and QC of the tissue sample be-
ing conserved. An indication of the 
cancer cellularity is important for 
tissue banking because it predeter-
mines the need for microdissection 
of tissue for nucleic acid extraction 
in next-generation sequencing.
•  FFPE tissue can be used for tar-
geted immunohistochemistry, fluo- 
rescence in situ hybridization 
(FISH), and next-generation se-
quencing and validation studies. 
RNA can also be extracted from 
FFPE tissue for gene fusion stud-
ies, next-generation sequencing, 
or quantitative reverse transcrip-
tion PCR (RT-PCR). The same 
procedure as for diagnostic tissue 
may be followed, with the samples 
placed in containers of different 
colours to identify them as sam-
ples for research purposes.
•  Care should be taken in the evalua-
tion of biopsy material for research, 
because the sample has a much 
smaller quantity of tissue and most 
of it may be needed for diagnostic 
purposes. When needed for diagno-
sis, the biopsy sample should follow 
the standard diagnostic process 
and be formalin-fixed and paraf-
fin-embedded. After the diagnostic 
process, any leftover material can 
be recovered for research.
•  It is recommended that surgical 
specimens or biopsy samples be 
preserved within 1 hour of exci-
sion. However, tissue subject to a 
delay up to 2 hours should still be 
collected (Eiseman et al., 2003). 
Detailed records should be kept of 
the timing of events from excision 
(or arterial clamping, in the case 
of larger specimens) to fixation or 
freezing.
•  All tissue should be treated as 
potentially infectious; the collec-
tion process should be carried out 
under the most aseptic conditions 
possible.
•  Each specimen collection recepta-
cle must be clearly labelled when 
multiple samples are being collect-
ed for the biobank.
•  Fresh tissue required for xeno-
grafting or for creation of cultures 
or cell lines must be placed in 
transport medium (RPMI 1640, 
10% FBS, 100 U/mL penicillin/
streptomycin, 100 U/mL ampho-
tericin). If this tissue is to be vitally 
cryopreserved, it should be placed 
in freezing medium (RPMI 1640, 
10% DMSO, 20% FBS). Because 
DMSO requires slow freezing, the 
tissue can be placed into a house-
hold −20 °C freezer for 30 minutes 
and then placed into −80 °C stor-
age overnight before final storage 
in LN2. A specific system to reduce 
the temperature of the tissue by 
1 °C per minute can also be used 
before the tissue is transferred.
•  Tissue required for expression 
profiling and other molecular pro-
filing, such as whole-genome se-
quencing or epigenetic studies, 
must be snap-frozen. Each tissue 
sample should be placed on card 
and covered with optimal cutting 
temperature (OCT) compound be-
fore vapour-freezing the sample 
by holding it over LN2. The sam-
ple can also be frozen by placing 
it into a container immersed in 
freezing medium (e.g. precooled 
isopentane). Tissue should never 
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the lowest efficiency for DNA yield, 
because of the small quantity of 
collected saliva. Moreover, some 
proteins are left in the solution of 
extracted DNA. Therefore, the DNA 
cannot be kept for long-term con-
servation. However, an advantage 
of this method of saliva collection is 
its low cost, because of the absence 
of an extraction step.
3.7.3.4 Bronchoalveolar lavage
The airways, and particularly the al-
veoli, are covered with a thin layer of 
epithelial lining fluid, which is a rich 
source of many different cells and 
of soluble components of the lung 
that help protect the lung from infec-
tions and preserve its gas-exchange 
capacity. Bronchoalveolar lavage 
performed during fibre-optic bron-
choscopy is the most common way 
to obtain samples of epithelial lining 
fluid (Reynolds, 2000). The cellular 
and protein composition of the epi-
thelial lining fluid reflects the effects 
of the external factors that affect the 
lung, and changes in this composi-
tion are of primary importance in the 
early diagnosis, assessment, and 
characterization of lung disorders 
as well as in the search for disease 
markers (Griese, 1999).
Bronchoalveolar lavage is clas-
sically performed by instillation of 
buffered saline solution divided into 
three or four aliquots (typically a 
total volume of 100–150 mL) through 
a flexible fibre-optic bronchoscope, 
after local anaesthesia. The first 
10 mL should be processed separate-
ly and is denoted as bronchial lavage. 
The rest of the lavage, denoted as 
bronchoalveolar lavage, should 
be pooled into a sterile siliconized 
bottle and immediately transported 
on ice to the laboratory. At the labo-
ratory, the total volume of the lavage 
is measured, and cells and proteins 
are separated by centrifugation. The 
lavage fluid should be frozen and 
stored at −80 °C until use.
Mouthwash
With this method, buccal cells are 
collected by rinsing the mouth for 10 
seconds with 10 mL of sterile water 
and expectorating the rinse into a 
50 mL centrifuge tube. This oper-
ation is repeated three times. The 
effect of lag time of storage at room 
temperature is observed for mouth-
washes, whereas cytobrushes are 
less sensitive to the lag time at room 
temperature.
Cytobrushes and mouthwashes 
are generally considered unsuitable 
for children, because cytobrushes 
are abrasive. Mouthwashes require 
participants to expectorate and may 
be aspirated or swallowed.
3.7.3.3 Saliva
Saliva is used as a biological fluid 
for the detection of different bio-
markers, such as proteins, drugs, 
and antibodies. Saliva meets the 
demand for a non-invasive, acces-
sible, and highly efficient diagnostic 
medium. The collection of saliva is 
non-invasive (and thus not painful), 
and a sample can easily be collect-
ed without a need for various de-
vices. Whole saliva is collected by 
expectoration into a provided tube, 
whereas for the collection of sub-
mandibular saliva and sublingual 
saliva, different ducts need to be 
blocked by cotton gauze. For the 
collection of parotid saliva, a parotid 
cup should be used (see Section 4).
Treated cards
These cards are treated to inhibit 
the growth of bacteria and kill virus-
es, thereby minimizing degradation 
of nucleic acids. Saliva is expecto-
rated into a sterile cup. The tip of the 
triangle of treated card is placed into 
the saliva, which is wicked onto the 
matrix. The treated card is air-dried 
and placed in a bag with a desiccant 
pack. Treated cards correspond to 
3.7.3.5 Bone marrow aspirate
The following paragraphs on bone 
marrow aspirate and cerebrospinal 
fluid are derived from the Austral-
asian Biospecimen Network recom-
mendations (see Table 1) and the 
publication Guidelines on Standard 
Operating Procedures for Microbiol-
ogy (Kumari and Ichhpujani, 2000). 
Bone marrow is the soft tissue 
found in the hollow interior of bones. 
In adults, the marrow in large bones 
produces new blood cells. There 
are two types of bone marrow: red 
marrow (also known as myeloid tis-
sue) and yellow marrow. In cancer 
research, red bone marrow from the 
crest of the ilium is typically examined.
Bone marrow should be collected 
by a doctor who is well trained in this 
procedure. Bone marrow should be 
aspirated by sterile percutaneous as-
piration into a syringe containing an 
EDTA anticoagulant, and the speci-
mens should be chilled immediately. 
Heparin is not recommended as an 
anticoagulant for molecular testing. If 
a specimen contains erythrocytes, it 
should be processed to remove the 
erythrocytes before freezing. The 
bone marrow samples should be 
fresh frozen and stored at −80 °C.
3.7.3.6 Cerebrospinal fluid (CSF)
Cerebrospinal fluid (CSF) originates 
from the blood. The choroid plexuses 
in the first, second, and third ventri-
cles of the brain are the sites of CSF 
production. CSF is formed from 
plasma by the filtering and secretory 
activities of the choroid plexus and 
the lateral ventricles. CSF circu-
lates around the brain and the spinal 
cord. It nourishes the tissues of the 
central nervous system and helps 
to protect the brain and the spinal 
cord from injury. It primarily acts as 
a water shock absorber. It totally 
surrounds the brain and the spinal 
cord, and thus absorbs any blow to 
the brain. CSF also acts as a carrier 
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drug use and to conduct criminal 
investigations (see Section 4). Hair 
should be kept in a sealable plastic 
bag, stored in the dark at room tem-
perature (Fig. 22).
3.7.3.10 Nails
Nail clippings may contain analytes 
of interest that were deposited dur-
ing the growth of the nail. Nail spec-
imens can be collected for drug, 
nutritional, poisons, and toxicity test-
ing (see Section 4) (Fig. 23).
3.8 Specimen annotations 
and data sets
Data associated with the biological 
specimens provide added value to 
the samples and increase the types 
of research for which the biospeci-
mens can be used. Specimen an-
notations provide basic information 
such as sample type, quantity, and 
current form (how the sample was 
stabilized and conserved), which 
can be used to evaluate the use 
of the sample in a specific assay. 
Specimen annotation also provides 
parameters that define the quality of 
be added to the sample, to avoid 
digestion by powerful proteases 
present in seminal fluid. To ensure 
complete separation of cell debris 
or occasional spermatozoa from 
seminal plasma, the sample can 
be centrifuged a second time. The 
sample should be stored at −80 °C.
3.7.3.8 Cervical and urethral 
swabs
The quality of collected cervical 
and urethral specimens depends 
on appropriate collection methods. 
Swabs, brushes, or other collection 
devices should be placed in a trans-
port medium, or transported dry in 
a sealed tube and resuspended in 
the transport medium upon arrival. 
The transport fluid may either be 
stored at −70 °C or below or immedi-
ately centrifuged, and the pellet pro-
cessed for DNA or RNA extraction 
(see Section 4).
3.7.3.9 Hair
Currently, hair analysis is used for 
purposes of assessing environmen-
tal exposures, such as exposure to 
mercury from eating fish. Hair anal-
ysis is also used to test for illegal 
of nutrients and waste products 
between the blood and the central 
nervous system.
CSF is a very delicate biolog-
ical material. Often, only small 
volumes of CSF are available for 
analysis, because of the difficulty 
of collecting CSF, and therefore it 
should be handled with care. Only a 
physician or a specially trained 
nurse should collect the speci-
men. After collection, the specimen 
should be transferred into a clean 
penicillin vial containing about 8 mg 
of a mixture of EDTA and sodium 
fluoride in the ratio of 1:2. Centri-
fuging CSF is recommended before 
freezing if the sample contains red 
blood cells or particulate matter. 
The specimen should be frozen and 
stored at −80 °C or in LN2. Do not 
delay freezing the CSF, because 
cells are rapidly lysed once the 
CSF is removed from the body.
3.7.3.7 Semen
Seminal fluid, which is the liquid 
component of sperm, provides a 
safe surrounding for spermatozoa. 
At pH 7.35–7.50, it has buffering 
properties, protecting spermato-
zoa from the acidic environment of 
the vagina. Seminal fluid contains 
a high concentration of fructose, 
which is a major nutriment source 
for spermatozoa during their journey 
in the female reproductive tract. The 
complex content of seminal plas-
ma is designed to ensure the suc-
cessful fertilization of the oocyte by 
one of the spermatozoa present in 
the ejaculate. Seminal plasma is a 
mixture of secretions from several 
male accessory glands, including 
the prostate gland, seminal vesicles, 
epididymis, and Cowper’s glands 
(Pilch and Mann, 2006).
After collection, the fresh ejac-
ulate should immediately be spun 
down at 4 °C to separate the sem-
inal fluid from the spermatozoa. 
Protease inhibitors should then 
Fig. 22. Hair sample. Fig. 23. Nail clippings.
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lected, stabilized, and preserved. It 
also contains clinical data associ-
ated with the patient.
•  Tier 2 comprises 19 elements of 
beneficial data, covering patient 
demographic information, times 
and temperatures, and methods of 
enrichment.
•  Tier 3 comprises 16 elements of 
nice-to-have data, pertaining to 
environmental conditions such as 
ischaemia, therapy, exposures, 
disease state, and storage con-
tainers and shipping parameters.
Tier 1 is now required for many 
journals.
MIABIS 2.0 represents the mini-
mum information required to initiate 
collaborations between biobanks. 
This standard currently comprises 
aggregated descriptive data, and 
not sample-specific data, to permit 
a harmonized exchange of sam-
ples and data among biobanks. The 
MIABIS standard pertains to de-
scriptive data of a biobank, col-
lection, and study, which include 
collection types and contact infor-
mation. It also includes aggregated 
data such as sex, age range, materi-
al type, data categories, and diseas-
es. MIABIS is the only standard to 
provide indications for this collective 
type of information. This information 
is useful when creating biobank cat-
alogues and inventories to provide 
visibility to available resources.
3.8.1 Annotations on patients/
individuals
It is important for the biobank to an-
notate the consent that is collected 
for the samples and data that be-
long to the patient. This information 
should include whether the consent 
or a waiver was used to permit the 
use of the sample or data in re-
search. It is important to indicate 
the scope of the permission, the 
type of research that can be per-
formed, information such as what 
types of entities can access the 
to classification systems, the version 
to which the value applies is also in-
dicated. As versions change, these 
values can be correctly interpreted 
or adjusted. One such example is 
the staging score used for defining 
the stage of a cancer. The require-
ment to indicate the scoring system 
also applies to values that may be 
retrieved using different assays. An 
example of this is the concentration 
value taken using a spectrophotome-
ter or a fluorescent dye-based quan-
tification. Other fields for which the 
situation may be similar are units of 
time (e.g. time to stabilization, time 
from diagnosis to collection, time 
from diagnosis to follow-up), which 
may be recorded in minutes, hours, 
days, months, or years, as well as 
units of measurement of size (e.g. 
millimetres, centimetres) or weight 
(e.g. nanograms, milligrams).
Systems already exist to address 
the need to standardize biobank- 
and sample-associated information.
The SPREC tool, in particular, 
addresses the pre-analytical data 
required and contains seven data 
fields and defined values for the 
definition of sample type and the 
processes of collection, stabiliza-
tion, and storage. There is a SPREC 
available for fluids and one for sol-
ids, to address the different collec-
tion and stabilization processes 
required. However, the SPREC sys-
tems will be replaced by CEN norms 
and ISO standards.
The Biospecimen Reporting for 
Improved Study Quality (BRISQ) 
standard covers pre-acquisition, 
acquisition, stabilization/preserva-
tion, storage/transportation, and QA 
measures (Moore et al., 2011). The 
elements in the BRISQ list are pri-
oritized into three tiers according to 
the relative importance of their be-
ing reported.
•  Tier 1 comprises 15 elements of 
necessary data, covering all sam-
ple types and including the manner 
in which the specimens were col-
the specimen and thus the quality of 
the downstream assay.
For biobanks wishing to share 
samples in large studies and for re-
search that requires samples from 
different sources, it is important 
that, as with all other elements of a 
biobank, the data are standardized 
or at least harmonized to permit 
effective aggregation.
Information to annotate the 
sample should be collected at each 
phase of the biobank/biospecimen 
processes:
•  consent;
•  donor/patient ID, sample ID;
•  collection (technique, date, time);
•  processing/stabilization;
•  conservation/storage;
•  for tissues: organ of origin;
•  for tissues: disease features (e.g. 
tumour, non-neoplastic);
•  quality parameters;
•  donor/patient-related data;
•  distribution/use; and
•  returned data.
It is important to determine a 
minimum data set, because this es-
tablishes a basic quality of all sam-
ples collected in the biobank (see 
Table 5). This should not, however, 
compromise the ability to collect ad-
ditional data for particular sample 
sets that may be useful in the future. 
The minimum data set must be as 
completely defined as possible, in-
dicating values for each of the fields 
in the data set, to reduce the het- 
erogeneity of sample-associated 
data and thus improve its quality.
One potential problem of data 
values involves different systems 
that use different date formats: DD/
MM/YYYY or MM/DD/YYYY or 
YYYY/MM/DD. Another problem for 
sample annotation is unfilled fields. 
It is important that a value for “not 
available” is defined, because blank 
fields can potentially be interpreted 
as zero and can provide incorrect 
evaluations when used in research.
During the creation of a data set, 
it is important that for data that refer 
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system functionality or through a 
parent ID field that relates initially 
to the donor data. This avoids re-
peating each donor data annota-
tion for each sample.
•  It is important to have a method 
to indicate participants for which 
different sample types are avail-
able. This should be done either 
within the database system func-
tionality or through a field to indi-
cate the availability of other types 
of samples related to the same 
case.
•  For all classification systems (on-
tologies) that are used to annotate 
samples, the version should be 
indicated.
•  All numerical values indicated 
should have associated units of 
measurement (e.g. months, days, 
hours, nanograms, microlitres).
•  All null values (not inserted) should 
have default values that are not 
zero.
•  Values lists for data fields avoid the 
introduction of error and are pref-
erable to free-text fields.
See Table 5 and Annex 5.
3.8.4 Specimen labelling and 
aliquoting
Each specimen should be labelled 
in such a manner that the labelling 
will survive all potential storage con-
ditions, in particular dry ice and LN2 
and potentially water bath.
Ink used on the label should be 
resistant to all common laboratory 
solvents. A minimum requirement is 
to print labels with a barcode (linear 
or two-dimensional), thus providing a 
direct link to database software and 
preventing human error in identifica-
tion. However, it is also essential to 
include human-readable indications 
of contents in case no barcode 
reader is available (Figs. 24–26). 
The barcode template should be 
documented. The software used for 
labelling should enable data import 
and export in standard formats and 
Not all of these data categories 
of participant-associated data are 
required for all studies, and even 
within a single category, different 
data fields will be required depend-
ing on the type of sample being col-
lected and the intended use of the 
sample.
3.8.2 Annotations on stored 
specimens
Obtaining and storing information 
about the stored specimens – in 
particular, the pre-analytical variables 
related to the collection, transpor-
tation, ischaemia times, stabiliza-
tion, and conservation of the spec-
imens – is mandatory in CEN and 
ISO. The data categories to consid-
er for sample-specific annotations 
are:
•  pre-acquisition;
•  collection;
•  processing/stabilization;
•  conservation/transportation; and
•  quality.
3.8.3 General recommendations 
for data sets
•  Wherever possible, the biobank 
should collect its data from existing 
clinical databases for patient-relat-
ed data. This avoids the need for 
duplicate input and reduces the 
possibility of human error. If the 
data are collected through a link 
between the biobank database 
and the clinical database, this may 
also permit tracking of additional 
clinical data over time.
•  Because it is not always possible to 
set minimum data sets common to 
multiple sample or disease types, 
macro fields should be set to in-
dicate the presence of such data 
(e.g. clinical data, epidemiological 
data, follow-up data).
•  All donor/patient-related data 
should be associated with each 
sample collected. This should be 
done either within the database 
sample (public, private), and wheth-
er there are geographical restric-
tions (local, national, international) 
on shipment of samples and data. 
In the era of personalized medicine 
and open access, it is also impor-
tant to record which participant- 
related data can be associated with 
the sample (clinical data, patho-
logical data, follow-up data) and, 
in particular, whether genetic data 
can be used and whether these 
data can be placed in public data-
bases (publication or research). It 
is vital to indicate whether a donor/
patient wishes to be re-contacted 
for further studies, whether they 
wish to be informed of incidental 
findings, and what should be done 
if any findings have hereditary 
implications.
For all samples, it is vital to 
have the diagnosis and pathological 
data. It is preferable that accepted 
nomenclature is used for diagno-
sis and classification systems are 
used for all pathology data, because 
they provide standard comparable 
parameters. One such example is 
the tumour–node–metastasis  (TNM) 
system for classification of malig-
nant tumours.
Participant-associated data are 
important, to provide additional val-
ue because they permit an extended 
evaluation of downstream assays. 
The more information can be col-
lected during the patient’s clinical 
care path, the more valuable the 
sample becomes. Some of these 
data categories are:
•  demographic information;
•  family history;
•  environmental exposure;
•  lifestyle;
•  diagnosis;
•  clinical data/medical history;
•  complete pathology report, includ-
ing immunohistochemical and mo-
lecular biology markers;
•  treatment;
•  follow-up/outcome; and
•  molecular/genetic characterization.
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Table 5. Example of IARC minimum data set for a study or collection in a biobank
Attribute Standard
1 Study details
1.1 Study ID MIABIS 2.0
1.2 Study name MIABIS 2.0
1.3 Description/objective MIABIS 2.0
1.4 Responsible unit
1.5 Responsible/principal investigator MIABIS 2.0
1.6 Sample manager
1.7 Study design MIABIS 2.0
1.8 Cancer type WHO name or ICD-O code
1.9 Other chronic disease BRISQ
2 Collaborators details
2.1 Contact person (collaborators)
– First name
– Last name
– Telephone number
– Email
– Contact institution
– Contact department
– Contact address
– Contact country
MIABIS 2.0
3 Collection details  
3.1 Collection start date  
3.2 Collection end date  
3.3 Collection centres
– Centre name
– Centre country
4 Ethical, legal, and social issues (ELSI)  
4.1 Ethical approval
– Date
– Reference
4.2 Informed consent  
4.3 Participant information sheet  
4.4 Material Transfer Agreement
– Date
– Reference
4.5 Other contract
– Date
– Reference
5 Donor/patient-related data  
5.1 Sample ID  
5.2 Parent sample ID (for aliquots and derivatives)  
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Table 5. Example of IARC minimum data set for a study or collection in a biobank (continued)
Attribute Standard
5.3 Informed consent
– YES/NO/NI (implying waiver)
– Type of consent
– Area of research
– Re-contact
– Return of results
– Access to medical data
– Possibility of publishing data
– Access to genetic data
5.4 Sex  
5.5 Age at collection  
5.6 Country and region of origin  
5.7 Basic diagnostic parameters (e.g. for cancer: individual TNM codes where 
possible; if not, then stage and always grade – for all, the version should be 
indicated)
 
5.8 Associated diagnostic parameters (CA125, CA19-9, etc.)  
5.9 Other diseases  
5.10 Disease status  
6 Biospecimen-related data
6.1 Biospecimen type  
6.2 Anatomical site: organ of origin or site of blood draw  
6.3 Collection mechanism: how the biospecimens were obtained  
6.4 Type of stabilization: the initial process by which the biospecimens were 
stabilized during collection
 
6.5 Biospecimen size  
6.6 Delay to preservation:
– Time between biospecimen collection and processing
– Time between biospecimen processing and cryopreservation
–  Warm ischaemia time for tissue: period between circulatory arrest  
and beginning of cold storage
SPREC
6.7 Temperature before preservation:
– Storage temperature before processing
– Storage temperature before cryopreservation
6.8 Type of long-term preservation: the process by which the biospecimens were 
sustained after collection
SPREC
6.9 Constitution of preservative: the make-up of any formulation used to maintain the 
biospecimens in a non-reactive state
 
6.10 Storage temperature for short-term storage: the temperature, or temperature 
range, at which the biospecimens were kept until distribution or analysis
 
6.11 Storage temperature for long-term storage SPREC
6.12 Freeze–thaw cycles: this field is for low-temperature storage and should 
account for the number of times the sample underwent a freeze–thaw cycle for 
processing; it should also account for any anomalies to the container containing 
the samples
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Attribute Standard
7 Categories of associated data collected  
7.1 Medical history data (e.g. history of other diseases, medications, family history  
of same cancer to first and second degree, family history of other cancers,  
family history of other diseases):
– Available or not?
– Which kind of data?
– Where are data kept?
– Who manages data?
7.2 Epidemiological and survey data (e.g. age, sex, exposure, anthropometric data, 
reproductive history, physical activity, tobacco status, alcohol consumption, 
occupational history, socioeconomic status, previous illness):
– Available or not?
– Which kind of data?
– Where are data kept?
– Who manages data?
7.3 Clinical data (e.g. clinical diagnosis, clinical presentation, comorbidities, 
biochemical data, immunophenotypic data, neoadjuvant therapy, disease status of 
patients, vital status of patients, clinical diagnosis, pathology diagnosis):
– Available or not?
– Which kind of data?
– Where are data kept?
– Who manages data?
7.4 Pathology data (e.g. pathology diagnosis, histological type, TNM, stage, grade, 
nuclear component, immunohistochemistry):
– Available or not?
– Which kind of data?
– Where are data kept?
– Who manages data?
7.5 Follow-up data (e.g. bioassays, treatment, disease progression, relapse, status – 
disease-free, alive with disease, dead from disease, dead from other causes):
– Available or not?
– Which kind of data?
– Where are data kept?
– Who manages data?
8 Shipment data saved for each sample  
8.1 Date of deposition  
8.2 Number of biospecimens shipped  
8.3 Shipment conditions  
8.4 Carrier  
8.5 Date of next shipment  
8.6 Number of biospecimens to be shipped  
8.7 Expected carrier  
BRISQ, Biospecimen Reporting for Improved Study Quality (Moore et al., 2011); ICD-O, International Classification of Diseases for Oncology; MIABIS 
2.0, Minimum Information about Biobank Data Sharing 2.0 (Brochhausen et al., 2013); SPREC, Sample PREanalytical Code (Lehmann et al., 2012); 
TNM, tumour–node–metastasis classification of malignant tumours; WHO, World Health Organization.
Table 5. Example of IARC minimum data set for a study or collection in a biobank (continued)
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Experts on the Transport of Dan-
gerous Goods, a committee of the 
United Nations Economic and Social 
Council (UNECE, 2015).
The International Civil Aviation 
Organization (ICAO) Technical In-
structions for the Safe Transport 
of Dangerous Goods by Air (ICAO, 
1986) are legally binding interna-
tional regulations. The Dangerous 
Goods Regulations incorporate the 
ICAO provisions and may add fur-
ther restrictions. The ICAO rules 
apply on all international flights. For 
national flights, i.e. flights within one 
country, national civil aviation au-
thorities apply national legislation. 
This is usually based on the ICAO 
provisions but may incorporate vari-
ations. State and operator variations 
are published in the ICAO Technical 
Instructions and in the IATA Dan-
gerous Goods Regulations (IATA, 
2015a; WHO, 2012).
Each person involved in the 
transportation of biospecimens 
classified as dangerous goods by 
IATA should undergo an initial train-
ing session followed by a refresher 
course every 2 years. This training 
space saving in the biobank storage 
facility. Consideration and attention 
should be given to the composition 
of plastic, potential interaction with 
some analytes, and resistance to ul-
tra-low storage temperatures.
3.9 Specimen shipping
Human biospecimens are con-
sidered to be “dangerous goods”, 
defined by the International Air 
Transport Association (IATA) as 
“articles or substances which are 
capable of posing a risk to health, 
safety, property or the environment”. 
According to United Nations regula-
tions, dangerous goods meet the 
criteria of one or more of nine Unit-
ed Nations hazard classes (DGI, 
2016). The relevant class for biolog-
ical specimens is Class 6, Division 
6.2: Infectious substances (IATA, 
2015b).
The shipping and dispatch of 
biospecimens is subject to inter-
national regulations. These regu-
lations, applicable to any mode of 
transport, are based on the recom-
mendations of the Committee of 
should be able to link with the bio-
bank management system.
Ideally, all specimens should 
be labelled with at least two hu-
man-readable forms of identification 
without revealing the identity of the 
donor. The anonymity of the donor 
must be guaranteed in all cases. Ra-
dio-frequency identification (RFID) 
is another option but is not in wide-
spread use for biobanking.
Information on the label should 
include the biobank’s unique iden-
tifier number, the name of the proj-
ect, the type of biospecimen, and/
or the number of the location within 
the storage system, with the same 
information repeated in the barcode 
if available.
After primary samples are pro-
cessed, derived products should be 
stored in appropriate and optimized 
containers. As technologies for 
analysing biospecimens improve, 
smaller volumes of sample are 
required. Therefore, the volume of 
aliquots should be adapted to avoid 
unnecessary freeze–thaw cycles.
A wide range of tubes of differ-
ent sizes, with or without a preprint-
ed barcode, are now available and 
affordable. Coloured caps can be 
used to distinguish between differ-
ent types of samples and to facilitate 
the retrieval of samples. More and 
more analysis platforms are using 
robots, and sample storage in SBS 
format containers is also important 
to consider, to facilitate downstream 
analyses. Otherwise, specific boxes 
must be used for appropriate stor-
age of SBS format tubes, allowing 
Fig. 24. Printed linear barcode.
Fig. 25. Printed two-dimensional bar- 
code.
Fig. 26. Pre-labelled tube with two- 
dimensional barcode.
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•  The primary receptacle is a water-
tight, leakproof receptacle contain-
ing the specimen, packaged with 
enough absorbent material to ab-
sorb all fluid in case of breakage.
•  The secondary packaging is a du-
rable, watertight, leakproof pack-
aging to enclose and protect the 
primary receptacle. Several pri-
mary receptacles may be placed 
in one secondary packaging, but 
sufficient additional absorbent ma-
terial should be used to absorb all 
fluid in case of breakage.
•  The outer packaging is the ship-
ping packaging, made of a suitable 
cushioning material, to protect the 
contents from outside influences 
while the package is in transit. An 
itemized list of contents must be 
enclosed between the secondary 
packaging and the outer packaging.
Appropriate insulation should 
be used. For example, for 8 °C to 
−20 °C, use gel packs; for −78.5 °C, 
use dry ice (Fig. 28); and if samples 
need to be kept at −150 °C, trans-
port them in a dry shipper containing 
LN2. Ensure that enough refrigerant 
is included to allow for a 24-hour de-
lay in shipping.
In-transit temperature monitor-
ing solutions that feature alarms as 
well as reporting are commercially 
available.
is for staff members involved in the 
preparation of documentation and 
also for those involved in packaging 
biospecimens.
3.9.1 Regulations
Infectious substances fall into two cat-
egories: Category A and Category B.
Category A comprises any in-
fectious substance that is transport-
ed in a form that, when exposure 
to it occurs, is capable of causing 
permanent disability or life-threat-
ening or fatal disease in otherwise 
healthy humans or animals. Catego-
ry A specimens include, but are not 
restricted to, specimens contami-
nated by highly pathogenic viruses 
(Ebola, Hantaan, Marburg, Lassa, 
etc.) or cultures of viruses such as 
dengue, HIV, or HBV. The proper 
shipping name for such substances 
is UN 2814: “Infectious substances 
affecting humans” or UN 2900: “In-
fectious substances affecting ani-
mals only”.
Category B comprises any infec-
tious substance that does not meet 
the above-mentioned criteria. Most 
human specimens, such as blood 
samples, tissues, saliva, exfoliated 
cells, or urine not contaminated by 
highly pathogenic viruses, will fall 
into Category B. The proper ship-
ping name for such substances is 
UN 3373: “Biological Substance, 
Category B”.
Biospecimens or derived prod-
ucts that have been specifically treat-
ed to neutralize infectious agents, or 
for which there is a minimal likeli-
hood that pathogens are present, 
are not subject to these regulations. 
The proper shipping name for such 
substances is “Exempt Human (or 
Animal) Specimens”.
3.9.2 Packaging
The basic triple packaging system 
applies to all substances. It consists 
of three layers, as follows (Fig. 27).
The triple packaging system also 
applies to “Exempt Human Speci-
mens”, such as Guthrie cards (which 
should be transported in watertight 
plastic bags) and histopathological 
slides (which need to be cushioned 
to prevent breakage). In all cases, 
desiccants should be used for sam-
ples that are sensitive to humidity.
3.9.3 Labelling of parcels
All outer packages must bear a Unit-
ed Nations packaging specification 
Fig. 27. The triple packaging system.
Fig. 28. Dry ice (−78.5  °C).
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specimens, from the study design 
to final laboratory analyses. This 
scheme underlines the central role 
of biobanks as the transfer structure 
between biospecimen collection 
and laboratory analysis. It also un-
derlines the fact that, in developing 
a study protocol, each step in this 
sequence of events must be clearly 
defined. The flow of information and 
biospecimens, as defined by pro-
tocols and procedures, will ensure 
the formation of a collection that 
contains traceable biospecimens 
and yields interpretable results. The 
biobank is an essential source of 
information and recommendations 
for the collection of biospecimens 
and for their annotation, storage, 
processing, and flow from the par-
ticipant to the laboratory where they 
will be analysed.
to confirm with the recipient before 
the shipment that someone will be 
available to receive the samples.
When shipping biospecimens 
internationally, the sender must be 
aware of the requirements and reg-
ulations in the destination country 
before initiating the shipment, and 
must ensure that the consignment 
adheres to these regulations.
It is important to select an ap-
propriate shipping company. Some 
companies offer more dedicated 
services for biospecimens, such as 
refilling of dry ice, handling of cus-
toms paperwork, and step-by-step 
monitoring and tracking.
3.10 Biobank workflow
Fig. 29 shows the sequence and the 
flow of information, data, and bio- 
marking, according to the category 
in which the specimens fall. For Cat-
egory A, Packing Instruction P620 
applies. For Category B, Packing 
Instruction P650 applies. Detailed 
instructions are described in the 
IATA Dangerous Goods Regulations 
(IATA, 2015c). All packages must 
have shipper details and consignee 
details (name of institute, address, 
contact name, email, and telephone 
number).
3.9.4 Constraints
When preparing to transport biospec-
imens, it is important to consider ship-
ping time, distance, climate, season, 
method of transportation, and regula-
tions, as well as the type and num-
ber of biospecimens to be sent and 
their intended use. It is also important 
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Fig. 29. Biobank workflow.
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4.1 Processing of blood 
specimens
If serum and plasma samples are 
being collected, the blood should 
be centrifuged as soon as possible 
after blood collection and separated 
immediately after centrifuging so that 
the samples can be frozen as soon as 
possible. This is critical for time-sen-
sitive samples for protein studies, for 
example. For the processing of blood 
specimens, the following protocols 
are recommended.
4.1.1 Filter paper dried blood 
spot collection, processing, 
storage, and shipment
Dried blood spot (DBS) is an easy 
and inexpensive means of collection 
and storage of peripheral blood spec-
imens in settings where collection 
and storage of plasma is not optimal. 
DBS can be used for molecular biol-
ogy techniques and other diagnostic 
assays. The cost and difficulty of cold 
chain shipping of plasma samples are 
greatly reduced by the use of DBS, 
which can be shipped as non-dan-
gerous goods.
Always wear gloves when han-
dling filter papers, and hold them 
only by the upper corner, marked 
out for labelling. Do not allow the 
card to come into contact with any 
unclean surface (e.g. bench, base of 
hood).
The procedure should be per-
formed in accordance with the relevant 
health and safety practices specific 
to specimen handling and waste dis-
posal. A minimum level of training is 
required to perform the procedure.
Reagents and materials required:
•  finger prick device (e.g. Unistik 2 
device; Fisher Scientific, 22-0227);
•  alcohol swab;
•  Whatman Protein Saver Card (e.g. 
Whatman, 903; 10534612);
•  gas-impermeable storage bag (e.g. 
Fisher Scientific, NC9307519);
•  desiccant pack (e.g. Whatman, 
10548234);
•  humidity indicator cards (e.g. Multi-
sorb Des Manufacture, MS200032);
•  card drying rack (e.g. VWR, 89015-
592) (optional; cards can be placed 
on a dry worktop if a drying rack is 
not available);
•  gloves, preferably powder-free; and
•  sample label.
4.1.1.1 Collection of DBS from 
finger prick
i.  Disinfect the selected site and 
prick it using a lancet/needle.
ii.  Uniformly saturate the entire circle 
by quickly and gently touching, 
not pressing, the puncture site to 
the filter paper.
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iii.  Note: Do not touch the Whatman 
card at any stage of collection.
iv.  After the collection of five blood 
spots, clean the site and leave it 
unbandaged.
v.  Allow the blood spots to air-dry, 
without the flap covering the 
spots, in a clean dry place that is 
protected from rodents or insects 
and direct sunlight, for at least 
4 hours (overnight drying may 
be needed in areas with higher 
humidity).
vi.  Do not heat or stack DBS cards 
or allow them to touch other 
surfaces during the drying pro-
cess.
vii.  Tuck in the flap of the card as 
indicated on the card.
viii.  Clearly label the card with the pa-
tient identifier and date, or label it 
with a prepared barcode label.
ix.  Be sure the DBS card is com-
pletely dry before packing.
x.  Insert the DBS card into a gas-im-
permeable plastic bag containing 
a desiccant pack and a humidity 
indicator. Do not store more than 
one card per bag.
xi.  Ensure that the patient identifier 
and date (or the prepared bar-
code label) are on the outside of 
the bag as well as on the DBS 
card.
xii.  Seal the plastic bag.
xiii.  Place the sealed bag containing 
the DBS card in a clean, dry area 
of the laboratory with no exposure 
to direct sunlight, free of insects 
or rodents, and where ambient 
temperatures will not exceed 
30 °C.
xiv. The room should be temperature- 
and humidity-controlled (temper-
ature of 20–22 °C and humidity of 
not more than 22%).
xv.  Check the desiccant pack before 
shipment of the DBS card and 
replace it if the colour of the hu-
midity indicator has changed from 
blue to pink or colourless.
xvi. Ship the DBS cards at ambient 
temperature.
4.1.1.2 Preparation of DBS from 
EDTA, ACD, or heparin tubes
DBS can also be prepared from 
EDTA, ACD, and heparin blood tubes.
i.  Before starting, mix vacutainers 
containing anticoagulated blood 
by inversion.
ii.  Wipe the top of the vacutainer 
with 70% ethanol before opening 
the lid.
iii.  Using a micropipette, apply 40 µL 
of blood onto the circle on the 
DBS card.
iv.  Air-dry the filter paper thoroughly 
by following step v above (Sec-
tion 4.1.1.1), and continue with the 
rest of the protocol as described 
above.
4.1.1.3 Shipping of DBS cards
DBS are classified as “Exempt Bi-
ological Specimens” according to 
the ICAO and IATA shipping regula-
tions. DBS bags should be shipped 
in courier envelopes or boxes under 
ambient conditions according to 
the triple packaging system (see 
Section 3.9.2).
i.  Provide a shipping manifest for 
all boxes. The shipping manifests 
must exactly match the label in-
formation and the order in the as-
sociated shipment, including the 
global specimen IDs.
ii.  Provide a box map for all boxes. 
The box maps must exactly match 
the label information and the order 
in the associated shipment, includ-
ing the global specimen IDs.
iii.  Record the courier service and 
the courier air bill number on the 
specimen shipment notice.
iv.  Advance notification of shipment 
must be made to the recipient.
4.1.2 Whole blood
Whole blood is to be prepared from 
EDTA tubes. The anticoagulated 
blood can be snap-frozen as it is. 
If the blood cells are needed intact, 
DMSO is needed to keep them alive 
while freezing.
i.  Dispense 50 μL of DMSO into two 
1 mL sterile cryovials.
ii.  Invert the EDTA tube twice, and 
then add 450 μL of blood to each 
cryovial.
iii.  Invert the cryovial to mix the 
whole blood with the DMSO. 
Note: DMSO is cytotoxic at room 
temperature; therefore, as soon 
as it is mixed with blood, it should 
be placed in a controlled-rate 
freezer.
iv.  Transfer to −80 °C after at least 
4 hours.
4.1.3 Plasma
Plasma collected in EDTA or ACD 
tubes can be used for bioassays, 
plasma DNA isolation, proteomic 
analysis, and biomarker discovery.
i.  Spin the vacutainer (about 9 mL) 
at 815g for 10 minutes at 4 °C to 
separate plasma from blood cells.
ii.  After wiping each tube with 
70% alcohol, remove about 3  mL 
of plasma. (The tube can be 
retained for white blood cell 
extraction.)
iii.  Transfer to a labelled 15 mL tube, 
and centrifuge at 2500g for 10 
minutes at 4 °C.
iv.  Aliquot plasma into 1 mL labelled 
cryovials (three or four aliquots).
v.  Place in LN2 dewar to snap-
freeze.
vi.  Store at −80 °C or in LN2.
The purpose of double-spinning 
the plasma is to remove all cellular 
contaminants so that the plasma is 
suitable for plasma DNA analysis. 
Therefore, it is extremely important 
not to disturb the buffy coat after the 
first spin and any pellet after the sec-
ond spin.
4.1.4 Platelet-poor plasma
Platelet-poor plasma can be used for 
the isolation of plasma DNA (from 
EDTA tubes).
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i.  Spin blood at 3200g for 12 min-
utes at room temperature.
ii.  Pipette off plasma using a plas-
tic Pasteur pipette. Transfer into 
a tube.
iii.  Spin plasma at 2000g for 10 min-
utes at 4 °C.
iv.  Aliquot into 1 mL aliquots in la-
belled cryovials.
v.  Store at −80 °C.
4.1.5 Buffy coat cells
The buffy coat is a thin, greyish-white 
layer of white blood cells (leukocytes 
and lymphocytes) and platelets cov-
ering the top of the packed red blood 
cells after centrifugation at 450g 
(from EDTA- or ACD-containing 
blood tubes).
i.  After having spun the blood, 
take the buffy coat off with about 
100 μL of plasma using a dispos-
able sterile Pasteur pipette; be 
careful not to lift red blood cells.
ii.  Lyse the remaining red blood cells 
by addition of red blood cell lysis 
buffer at room temperature.
iii.  Spin the tube at 450g for 10 min-
utes at room temperature.
iv.  Resuspend the pellet.
v.  Aliquot as appropriate into la-
belled cryovials.
vi.  Place in LN2 to snap-freeze.
vii.  Store in LN2.
4.1.6 Blood pellets (white 
blood cells)
Blood pellets can be used for the 
isolation of DNA (from EDTA or ACD 
tubes).
i.  Transfer blood from the original 
tube to a labelled 50 mL tube.
ii.  Fill the tube with Tris-EDTA buff-
er (formula) and mix vigorously. 
Place on ice for 5–10 minutes.
iii.  Spin at 1200g for 10 minutes.
iv.  Carefully pour off the supernatant 
into a waste container containing 
chlorine bleach. Briefly vortex 
the pellet and add 50  mL of Tris- 
EDTA buffer. Shake vigorously.
v.  If division of the sample is nec-
essary, at this point pour 25 mL 
of the sample into another centri-
fuge tube.
vi.  Spin both tubes at 1200g for 10 
minutes.
vii.  Repeat the washing if red blood 
cells persist.
viii.  Carefully pour off the supernatant.
ix.  Using a swirling motion, remove 
the pellet with a pipette and trans-
fer it to a labelled cryovial.
x.  Store at −80 °C or in LN2 until 
further use.
As an alternative, red blood cells 
can be lysed by using an ammoni-
um-containing lysis buffer.
4.1.7 White blood cells
White blood cells collected in EDTA 
or ACD tubes can be used for DNA 
extraction and the creation of cell 
lines.
i.  Transfer the remaining blood 
from the plasma spin to a labelled 
50 mL tube containing 10 mL of 
RPMI 1640.
ii.  After swabbing the lid of this tube 
with alcohol, aliquot 3 mL of Ficoll 
into each of two clearly labelled 
15 mL tubes.
iii.  Carefully layer 9 mL of diluted 
blood onto each tube of Ficoll. 
Treat gently, and do not mix, but 
spin as soon as possible.
iv.  Spin at 450g for 30 minutes. Note: 
When centrifuging, do not use the 
brake.
v.  Remove most of the top layer 
(RPMI 1640) using a 1 mL Ep-
pendorf tip, and discard about 
3–4 mL into a waste container 
containing chlorine bleach.
vi.  Collect white blood cells with the 
same Eppendorf tip using a swirl-
ing motion to “vacuum up” white 
blood cells. Do not take too much 
Ficoll (third layer), because it is 
toxic to the cells. Place the white 
blood cells into a labelled 15 mL 
tube containing 10 mL of RPMI 
1640.
vii.  Spin at 450g for 10 minutes.
viii.  Pour off the supernatant into a 
waste container containing chlo-
rine bleach. Add 3 mL of cold 
freezing mix (10% DMSO, 20% 
fetal calf serum [FCS], RPMI 
1640) and resuspend.
ix.  Dispense the white blood cells 
into three 1 mL labelled cryovials 
that have been sitting on ice.
x.  Place on ice. Place vials in a 
controlled-rate freezer so as to 
cryopreserve cells under condi-
tions that maintain cell viability. 
This should be done as soon as 
possible, because DMSO is toxic 
at room temperature.
xi.  Transfer on a weekly basis to LN2 
tanks.
Instead of a separation based on 
Ficoll, a Percoll separation can be 
used.
4.1.8 Serum
The blood is collected into tubes 
without addition of anticoagulants. 
Then, two phases are distinguish- 
able: a solid phase containing fibrin 
and cells, and a fluid phase contain-
ing the serum.
This process should be complet-
ed after 30 minutes at room temper-
ature, after which the process de-
scribed below should start.
i.  Spin blood at 1500g for 10 min-
utes at room temperature.
ii.  Aliquot 1 mL portions of the su-
pernatant into labelled cryovials.
iii.  Place into LN2 dewar or dry ice to 
snap-freeze.
iv.  Transfer to −80 °C freezer or LN2.
4.2 Processing of solid tissue
Careful and well-documented pro-
cessing of tissue specimens is cru-
cial to the overall usefulness of the 
biobank as a resource for scientific 
research. Detailed records of the 
first steps in the process of sample 
handling include the times of an-
aesthesia administration, ligation of 
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vessels, and specimen removal from 
the patient.
These factors are important to 
assess tissue quality, because they 
affect the quality of the resulting bio-
molecules. The most commonly de-
scribed factor that has an impact on 
tissue quality is the warm ischaemia 
time, which is the period from when 
the blood supply is ligated until the 
specimen is placed in fixative in the 
pathology laboratory. Studies have 
demonstrated that changes in both 
RNA and protein occur during this 
time (Dash et al., 2002).
These protocols for collecting 
and freezing tissue samples were 
developed within the European Hu-
man Frozen Tumour Tissue Bank 
(TuBaFrost) project (Riegman et al., 
2006b) and the Standardisation and 
Improvement of Generic Pre-ana-
lytical Tools and Procedures for In 
Vitro Diagnostics (SPIDIA) project 
(Malentacchi et al., 2015).
These recommended protocols 
contain choices and recommen-
dations for preserving solid tissue, 
and describe the roles of key peo-
ple involved in the process. Consult 
the CEN norms for more detailed 
information on the processing of 
snap-frozen tissue and FFPE sam-
ples for protein DNA and RNA isola-
tion (CEN/TS 16826-1–2 and CEN/
TS 16827-1–3).
4.2.1 Snap-freezing
Snap-freezing is the process by 
which samples are lowered to tem-
peratures below −70 °C very rapidly 
using dry ice or LN2. This method 
can provide excellent sample integ-
rity and a wide array of options for 
tissue analysis, including extraction 
of proteins, RNA, and DNA for use 
in research diagnosis. Before tissues 
are stabilized by freezing, the protein, 
RNA, and DNA profiles can change, 
and these changes depend on the 
duration of warm and cold ischaemia 
and the ambient temperature before 
freezing. All the different pre-analyt-
ical conditions and durations should 
be documented.
4.2.1.1 Safety
All procedures should be carried out 
in accordance with the local codes of 
practice. Working with LN2 and iso-
pentane is hazardous; all procedures 
must comply with local safety rules 
specific to these chemicals. All tissue 
must be handled as if it is potentially 
infectious.
4.2.1.2 Hospital ward
Consent must be obtained from the 
patient before surgery (if applicable, 
according to the law and procedures 
in the country where the samples are 
being collected).
4.2.1.3 Operating theatre
i.  Deliver the notification of tissue 
collection (and the consent form, 
if needed) to the surgeon, or high-
light on the operating list.
ii.  The surgeon should:
a.  complete the pathology form (if 
possible, in advance);
b.  perform the operative proce-
dure and record the time of ar-
terial clamping and of excision 
of the specimen; and
c.  place the specimen in a la-
belled sterile pot or bag and 
put it on ice.
iii.  The operating theatre staff should 
send the fresh tissue specimen 
to the pathology department 
immediately.
4.2.1.4 Histopathology 
department
i.  Notify the pathologist and the tis-
sue bank research technician (if 
not already present).
ii.  Check the paperwork and allo-
cate a pathology number to the 
specimen as routine.
4.2.1.5 Role of the pathologist
i.  Macroscopically describe the 
specimen as usual.
ii.  Using clean instruments and on a 
clean surface (sterile foil or clean 
dissection board), dissect the tis-
sue specimen. Clean or change 
instruments between dissecting 
normal tissue and tumour tissue.
iii.  Take representative parts of tis-
sue for routine diagnosis (for fixa-
tion and embedding) as a priority, 
and decide whether there is suf-
ficient material available for the 
tissue bank.
a.  Supply the research technician 
with a tissue sample or sam-
ples for biobanking representa-
tive parts of the lesion, normal 
tissue, and pre-malignant con-
ditions.
b.  Perform QC of frozen tissue 
and annotation.
4.2.1.6 Role of the technician
i.  Prepare the tissue sample for 
snap-freezing on a clean sur-
face and using clean instruments; 
change instruments between pre-
paring normal tissue and tumour 
tissue. The minimum volume of 
tissue for snap-freezing is ap-
proximately 0.5 cm3, although the 
amount of tissue available will dif-
fer depending on the sample site. 
Smaller fragments should still be 
snap-frozen and stored in the tis-
sue bank; if there is sufficient ma-
terial, freeze duplicate samples.
ii.  Pre-cool the freezing medium 
isopentane  (2-methylbutane) until 
opaque drops begin to appear in 
the isopentane and the solution 
becomes misty; this will bring the 
isopentane towards its freezing 
point (−160 °C), the optimal freez-
ing point for the tissue. Options:
a.  LN2: suspend a vessel of iso-
pentane in LN2.
b.  Dry ice: add dry ice (cardice) to 
the isopentane until a slush is 
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formed, or suspend a vessel of 
isopentane in dry ice.
iii.  Label cryovials, cryomoulds, or 
cryostraws with a barcode and/
or sequential code (depending on 
local laboratory practice). Use a 
waterproof pen with ink that is 
able to withstand long-term stor-
age at low temperatures. The 
sequential code is the local in-
ventory code and must not relate 
to the pathology number or other 
identifiers. If a barcode is used, 
readable recognition must also 
be included to make the sample 
identifier readable at institutions 
where there are no barcode 
readers.
iv.  Record the local sequential code, 
the pathology number, the date, 
the lag time from arterial clamp-
ing and excision to freezing, 
and the type of tissue (the site, 
and also whether the sample is 
tumour, normal, and/or pre-ma-
lignant) in the inventory book. If 
a barcode system is in use, the 
barcode can be scanned into the 
LIMS and the above-mentioned 
data recorded.
v.  Freeze directly in isopentane. Do 
not remove the tissue from the 
isopentane until freezing is com-
plete (5 seconds or less, depend-
ing on size), but ensure that the 
sample does not crack. Remove 
the sample from the isopentane 
and enclose it in the labelled cryo- 
vial. It is good practice to strive 
to snap-freeze all tissue within 
30 minutes of excision from the 
patient. Tissue subject to a delay 
of up to 2 hours should still be col-
lected and the delay noted with-
in the local inventory database. 
Options for freezing:
a.  Embed the tissue samples in 
OCT compound and freeze in 
isopentane, or freeze directly 
in isopentane. The isopen-
tane used is cooled either by 
suspension in LN2 or through 
addition of dry ice.
b.  Orientate the tissue on a 
piece of cork and an equally 
sized piece of Whatman paper 
soaked in physiological salt 
solution.
c.  If the cryostraw system is used 
to introduce a carrot of tissue 
into the straw, thermally seal 
each extremity and place in 
LN2.
4.2.2 Storage of tissue
Storage of tissue can be done ac-
cording to different protocols accord-
ing to the equipment available in the 
facility. Options for storage:
i.  Transfer the snap-frozen sam-
ple from the isopentane to a 
pre-chilled storage container for 
transfer to either a locked −80 °C 
freezer or a LN2 storage facility 
in the liquid or vapour phase. For 
storage for longer than 5 years, 
LN2 in the liquid or vapour phase 
is recommended.
ii.  Place cryostraws in a designat-
ed visotube within a goblet (re-
movable LN2 storage elements) 
and place in the locked LN2 
repository.
a.  Store duplicate samples in a 
different storage facility if this 
is available.
b.  Check the backup system for 
the storage repository – either 
a backup freezer running con-
stantly or adequate supplies 
of LN2.
c.  Record the storage details 
in the inventory system, and 
check earlier data that were 
entered. At a minimum, the 
information recorded will in-
clude the inventory number 
(local sequential code), the 
location, the pathology num-
ber, the type of tissue (the site, 
and also whether the sample 
is tumour, unaffected/normal, 
and/or pre-malignant), the lag 
time between excision and 
freezing, and the date.
4.2.3 Storage of FFPE blocks 
and slides
i.  FFPE blocks and sections mount-
ed on slides can be stored at room 
temperature. Prevent exposure of 
blocks to sun or extreme temper-
ature variation or humidity.
ii.  Store blocks in moisture-resistant 
cardboard boxes or plastic stor-
age boxes.
iii.  Transfer details to the computer-
ized database system.
iv.  Update the database when sam-
ples are moved or depleted.
4.2.4 Formalin fixation
Formalin fixation is standard practice 
in most routine histopathology labo-
ratories. The following guidelines 
address specific issues related to 
preservation of formalin-fixed spec-
imens in biobanks. Table 6 provides 
information on the composition of 
neutral buffered formalin.
i.  Tissue specimens should not be 
bigger than 3 cm × 2 cm × 0.5 cm.
ii.  Specimens should be fixed in 
fresh 10% neutral buffered for-
malin for a minimum of 4 hours 
and a maximum of 48 hours, after 
which they should be embedded 
in paraffin in accordance with 
conventional techniques.
iii.  All reagents should be DNase- 
and RNase-free (e.g. prepared us-
ing  diethylpyrocarbonate [DEPC] 
water).
iv.  Fixation media, such as Bouin’s 
solution, that contain picric acid 
should be avoided, because this 
compound interferes with subse-
quent PCR analysis of extracted 
nucleic acids.
v.  Alcohol fixation may be used as 
an alternative to formalin fixation. 
For this, tissue is placed into 70% 
alcohol (diluted with DEPC water) 
for a minimum of 4 hours.
Because of the chemical hazards 
of formalin, it can be desirable to use 
alternatives to formalin as a routine 
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fixative. However, the effect of long-
term storage with these alternative 
fixatives on the desired macromole-
cules is not always known and should 
be established empirically.
4.2.5 RNAlater
This substance protects RNA in fresh 
specimens. It eliminates the need 
to immediately process or freeze 
samples.
4.2.5.1 Tissue
Cut the tissue to be smaller than 
0.5 cm in at least one dimension, 
and then submerge the tissue in 5 vol-
umes of RNAlater (e.g. a 0.5 g sample 
requires about 2.5 mL of RNAlater).
4.2.5.2 Cells
Resuspend the pelleted cells in a 
small volume of phosphate-buffered 
saline (PBS) before adding 5–10 
volumes of RNAlater.
4.2.5.3 Storage
RNAlater-treated tissue and cell sam-
ples can be stored at 4 °C for 1 month, 
at 25 °C for 1 week, or at −20 °C  for 
an indefinite period. For RNA isola-
tion, simply remove the tissue from 
RNAlater and process.
4.2.6 Shipment of tissues and 
slides
FFPE tissues and slides are shipped 
at ambient temperature in accor- 
dance with the established shipment 
guidelines and protocols of the send-
ing and recipient institutions. Please 
refer to Section 3.9 for more details.
4.2.7 Quality control for tissue 
samples
i.  Ensure that the reagents have 
not expired and are of the correct 
composition and volumes.
ii.  Keep high-quality records on all 
variables related to specimens, 
FFPE tissues, and slides, includ-
ing the time of tissue collection, 
the processing time, and the pe-
riod of storage before shipment 
and/or use.
4.2.8 Data to be recorded
i.  Date and time of tissue collection.
ii.  Number of unprocessed samples, 
FFPE blocks, and slides prepared.
iii.  Date and time of shipping.
iv.  Any variations or deviations from the 
protocol, problems, or issues re- 
lated to the collection and storage.
4.3 Processing of urine and 
buccal cells
The following protocols for process-
ing of urine and buccal cells contain 
recommended procedures.
4.3.1 Urine
i.  Plastic or glass containers for 
collection of urine should be 
clean and dry, should have a 50–
3000 mL capacity, a wide mouth, 
and a leakproof cap, and should 
be clearly labelled.
ii.  When in transit, urine collections 
should be maintained on ice or 
refrigerated.
iii.  Urine should be aliquoted accord-
ing to the volume needed for anal-
ysis or storage.
iv.  Depending on the analyte to be 
measured, a preservative may be 
added during collection or before 
aliquoting.
v.  Store urine at −80 °C or below in LN2.
4.3.2 Buccal cells
i.  A collection kit (containing mouth-
wash, a 50 mL plastic tube, a 
Table 6. Composition of neutral buffered formalin and 70% ethanol
Composition Total volume
10% neutral buffered formalin (in 40% formaldehyde) 100 mL
100% formaldehyde 37–40 mL
Na2HPO4 (anhydrous) 6.5 g
NaH2PO4 4.0 g
Distilled water 900 mL
70% ethanol  
100% absolute alcohol 70 mL of absolute alcohol + 30 mL of water 100 mL
96% ethanol 73 mL of 96% ethanol + 27 mL of water 100 mL
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plastic biohazard bottle, and 
courier packaging) is mailed or 
given to the participant, along 
with an instruction sheet. The par-
ticipant is to brush their teeth as 
usual, rinse their mouth out well 
with water twice, and then wait 2 
hours. The participant should not 
eat or drink anything other than 
water during this time.
ii.  After 2 hours, 10 mL of commer-
cial mouthwash should be poured 
into the tube, and then 10 mL of 
tap water should be added. This 
diluted mouthwash should be 
placed into the mouth (without 
swallowing) and swished around 
vigorously for 30 seconds.
iii.  The mouthwash should then be 
spat back into the plastic tube, and 
the tube should be sealed tightly.
iv.  The sample should be sent back 
to the biobank immediately for 
processing, or stored at 4 °C un-
til it is sent, but it should be sent 
within 24 hours.
v.  When the sample arrives at the 
laboratory, transfer the mouth-
wash to 15 mL conical test tubes.
vi.  Add 35 mL of Tris-EDTA to the 
mouthwash sample and spin at 
450g for 5 minutes.
vii.  Decant the supernatant and dis-
card.
viii.  Wash the cells twice, each time 
with 45 mL of Tris-EDTA.
ix.  Resuspend the cell pellet in 50 μL 
of Tris-EDTA and transfer to 2 mL 
labelled cryovials.
x.  Store the sample at −80 °C or in 
LN2.
Note: Buccal cells can also be 
collected with other means, such as 
brushes.
4.4 Collection and processing 
of saliva
A research consortium at the Univer-
sity of California, Los Angeles was 
funded by the United States National 
Institute of Dental and Craniofacial 
Research to investigate the human 
saliva proteome. The protocol for col-
lection and processing of saliva is de-
rived from the consortium’s Salivary 
Proteome Handbook Procedures and 
Protocols (Hu et al., 2007).
i.  Saliva collection should be done 
in the morning (aim for 10:00–
11:00 am if possible). Ask the 
subject to refrain from eating, 
drinking, or oral hygiene proce-
dures for at least 1 hour before 
the collection.
ii.  The subject should be given 
drinking water (bottled) and asked 
to rinse their mouth out well (with-
out drinking the water).
iii.  Five minutes after this oral rinse, 
the subject should be asked to 
spit whole saliva into a 50 mL ster-
ile centrifuge tube. The subject 
should refrain from talking. It is 
better for the subject to drop their 
head down and let the saliva run 
naturally to the front of the mouth, 
hold this position for a while, and 
spit into the tube provided. The 
subject will spit into the collection 
tube about once a minute for up 
to 10 minutes. The goal for each 
whole saliva donation should be 
about 5 mL. Require that the tube 
be placed on ice while collecting 
whole saliva. Remind the subject 
not to cough up mucus, so that 
saliva is collected, not phlegm.
iv.  For the collection of subman- 
dibular saliva, use 2  ×  2-inch cot-
ton gauze to block the opening 
of each parotid duct. Dry up the 
floor of the mouth, and block the 
openings of the sublingual gland 
(both sides), and have the sub-
ject raise their tongue slightly to 
elevate the opening to the sub-
mandibular gland. Begin to collect 
submandibular saliva by using a 
sterilized Wolf device. A sterilized 
and disposable yellow tip (for pi-
pette P200) should be connect-
ed into the device and changed 
after every collection. During the 
collection, at 2-minute intervals, 
a few grains of citric acid powder 
should be swabbed with a moist-
ened cotton applicator onto the 
lateral dorsum of the tongue to 
stimulate the secretion. Aim to 
collect at least 200 μL of subman-
dibular saliva.
v.  For the collection of sublingual 
saliva, the protocol is similar to 
that described above for collec-
tion of submandibular saliva. The 
only difference is that the duc- 
tal orifices of the submandibular 
gland are blocked off. Aim to col-
lect > 100 μL of sublingual saliva 
every time.
vi.  For the collection of parotid saliva, 
use a parotid cup to collect the sa-
liva. Parotid cups may be placed 
bilaterally if the clinical investiga-
tor so chooses. This will enable 
the simultaneous collection from 
each parotid gland. The citric acid 
stimulation should be performed 
as described above. Aim to col-
lect > 1 mL of parotid saliva. The 
first 0.1 mL of parotid saliva col-
lected should be discarded, to 
ensure that fresh parotid saliva 
is obtained.
 Note: The collected samples 
should be kept on ice at all times 
before processing.
vii.  For sample processing using pro-
teinase inhibitors, to each 100 μL 
of saliva:
a.  Add 0.2 μL of proteinase inhibi-
tor cocktail from standard stock 
solution (Sigma, P8340), and 
invert gently.
b.  Add 0.3 μL of sodium ortho-
vanadate (Na3VO4) (Sigma, 
S6508) from standard stock of 
400 mM, and invert gently.
viii.  Centrifuge the specimens at 
2600g for 15 minutes at 4 °C (if 
you note that incomplete separa-
tion has occurred, increase the 
spin time to 20 minutes). Then:
a.  Remove the supernatants from 
the samples and label them 
with the term “super”, which 
stands for the supernatant 
phase of the saliva.
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b.  Taking care not to disturb the 
pellet and keeping the pellet as 
is in the original tubes, label the 
original tubes as “pellet”.
ix.  Freeze the samples at −80 °C.
4.5 Processing of cervical 
cells
In a Pap smear test, a sample of 
cells is taken from the uterine cervix 
using a wooden spatula or a brush, 
smeared onto a slide, and examined 
under a microscope for abnormal 
cells (precancer or cancer). This 
protocol is a selected protocol from 
diverse collection procedures.
Note the following:
i.  It is best not to take a smear from 
a woman who is actively men-
struating or has symptoms of an 
acute infection. Slight bleeding is 
acceptable.
ii.  Pregnancy is not an ideal time for 
a Pap smear, because it can give 
misleading results.
4.5.1 Taking the sample of 
cells
Insert the long tip of the spatula into 
the cervical os, and rotate the spatula 
through a full circle (360°). If the cer-
vical broom brush is used, place the 
tip of the brush into the cervical os, 
and rotate the brush gently through 
three 360° circles.
4.5.2 Taking the Pap smear
i.  Smear both sides of the spatu-
la (or the contents of the brush) 
onto the glass slide with one or 
two careful swipes. If any abnor-
malities are seen outside the area 
sampled, take a separate speci-
men and smear it onto another 
slide.
ii.  Immediately fix each slide. Either 
use spray fixative, at a right an-
gle to, and at a distance of 20 cm 
from, the slide, or immerse the 
slide in a container of 95% eth-
anol for at least 5 minutes. If the 
slide is not fixed immediately, the 
cells will dry and become mis-
shapen; it will then not be possi-
ble to read the slide accurately 
in the laboratory.
iii.  Gently close and remove the 
speculum.
iv.  Place all used instruments in 
decontamination solution.
4.5.3 After taking the smear
i.  Label the frosted edge of each 
slide carefully.
ii.  On the patient record, note and 
illustrate any features you have 
noted: visibility of the transforma-
tion zone, inflammation, ulcers or 
other lesions, or abnormal dis-
charge. Note whether other sam-
ples were taken, for example Pap 
smears of other areas, and if the 
woman has been referred else-
where, note to whom and when.
4.6 Processing of hair and 
nails
These protocols are recommended 
for collecting hair or nail specimens.
4.6.1 Hair
Head hair may be collected as follows.
i.  Along an imaginary line drawn 
across the middle of the back of 
the head from the centre of one 
ear to the centre of the other, 
gather a lock of hair at least the 
thickness of a pencil, and tie it 
together near the root end (near 
the scalp) using a small string or 
a rubber band.
ii.  Cut the hair as close to the scalp 
as possible without cutting the 
scalp.
iii.  Maintain the horizontal position of 
the hairs in the bundle by wrap-
ping the cut section in aluminium 
foil or plastic wrap.
iv.  Indicate the root end and the tip 
end by marking the foil or plastic 
wrap with a permanent marker or 
with a paper label. Do not use 
tape on the hair itself.
v.  Place the specimen in a clean, 
dry, labelled paper envelope for 
shipment to the laboratory. Note 
whether bleaches, hair dye, or 
medications (e.g. selenium or 
minoxidil) were used.
Please note that hair from oth-
er sources (pubic, axillary, beard, 
moustache, chest, etc.) may also 
be analysed if head hair is not 
available.
4.6.2 Nails
A clean pair of nail clippers should 
be used. To clean nail clippers thor-
oughly, they should be rubbed with 
alcohol swabs. Nails should be clean 
of all polish, dirt, and debris. Nail clip-
pings from each finger or toe should 
be collected and packaged sepa-
rately in plastic bottles. Each bottle 
should be labelled with the mass of 
the nail collected and its source (e.g. 
right index finger) (NMS Labs and 
ExperTox).
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A1.1 Definitions
1.1  The IARC Biobank (IBB): the IBB is a centralized biological resource storage facility for samples collected 
from studies conducted worldwide by IARC in collaboration with international partners (http://ibb.iarc.fr/).
1.2  The Laboratory Services and Biobank Group (LSB): LSB is responsible for the management of the IBB. The 
Group also provides services in pre-analytical sample processing and shipment.
1.3  Biological resources: include human tissues, cells, biological fluids/derived products, and associated sample 
quality data.
1.4  Sample collections: include biological resources based on common characteristics (e.g. sera from individuals 
from a population-based study; a clinical collection of breast cancer tissues).
1.5  Associated data: include anonymized data associated with biological samples, sample annotations, and data 
on sample quality.
1.6  Steering committee for multicentre studies: the steering committee has a coordinating role for a particular 
study, with responsibilities for coordinating research activities, including with regard to use of the study’s 
biological resources.
1.7  IARC Principal Investigator (PI): the PI is the IARC scientist who is responsible for the sample collection at 
IARC.
1.8  IARC Custodian (CU): the CU is the IARC scientist to whom the responsibility for the sample collection was 
assigned after the departure of the original IARC PI.
1.9  Biobank Steering Committee (BSC): the BSC is the committee that oversees the biobanking activities at IARC.
1.10  Biobank Application sub-Committee (BAC): the BAC is the sub-Committee appointed by the BSC to assist in 
the handling of requests for human sample access.
1.11  IARC Ethics Committee (IEC): the role of the IEC is to provide ethical evaluation of all IARC projects within 
its competence (http://ethics.iarc.fr/).
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1.12  Requestor: the requestor is a scientist affiliated with a public research institution or organization based in any 
country who is applying to access IARC sample collections for the purpose of research.
1.13  User: the user is a requestor who has received the necessary approvals to access IARC samples.
1.14  Material Transfer Agreement (MTA): the MTA is an agreement developed and signed between IARC and 
the host institute of the requestor, which governs the terms and conditions under which the parties will 
collaborate.
1.15  Study results: all laboratory results obtained from the use of IARC samples.
A1.2 Sample access: principles and policies
A1.2.1 Introduction
The IARC Biobank (IBB) comprises one of the largest and most varied collections of cancer-related samples in the 
world. The IBB is publicly funded by IARC Participating States and research grants and hosts more than 50 different 
studies, led or coordinated by IARC scientists.
Over the years, IARC has developed or coordinated a considerable number of large molecular epidemiological 
studies involving specimen collections. These studies are extremely diverse in their size, design, and governance 
and in the type of biomarker analyses involved. Study designs include case series, prevalence studies, case–control 
studies, and cohort studies. Most of the samples in the IBB are body fluids, including plasma, serum, and urine as 
well as extracted DNA samples.
A table of biospecimens stored at IARC is available on the IBB website (http://ibb.iarc.fr/docs/collection_table.pdf). 
The table provides details of sample origin, primary study design, key words describing the collection, and the name 
of the IARC PI/CU to contact for further information by potential requestors.
The IBB includes, as part of its governance structure, the Biobank Steering Committee (BSC) and the IARC 
Ethics Committee (IEC). The BSC oversees the IBB and provides advice to the Director in terms of the strategic 
development of IARC biobank activities. The IEC provides ethical guidance and evaluates all IARC projects within 
its competence.
A1.2.2 Guiding principles
The mission of IARC includes promoting cancer research internationally. As a publicly funded international organization 
with a mandate for collaborative research, IARC wishes to ensure that biospecimens stored within the Agency are 
being put to the best possible use. Within this context, the samples stored at IARC are available for research projects 
consistent with IARC’s scientific goals and the IARC/WHO legal and ethical standard practices.
The principle of access means that samples and data entrusted to the Agency should be put to best possible scientific 
use taking into account the best interest of the participants and for public benefit. In particular, IARC PIs and CUs 
are encouraged to identify new potential uses and users of the resources and to make cancer researchers worldwide 
aware of these progressions in scientific research.
Access to and use of IBB biological samples are governed by the following principles:
•  As an overarching principle, the biological samples stored under the Agency’s custodianship in the IBB remain the 
property of the national collaborating centre as the original source, unless otherwise specified under a separate 
agreement. Consequently, access to IBB biological samples for third parties will only be granted by IARC after 
consultation and agreement with the relevant national centre and the IARC PI/CU as applicable.
•  Applications by requestors for access to IARC’s biological samples will be required to follow the sample request 
procedure described below.
•  The confidentiality and data protection principles of IARC also apply to the IBB by maintaining participants’ 
confidentiality and anonymity; the rights, privacy, and consent of participants must be protected and respected at 
all times.
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•  IBB biological samples will be made available for use in a timely and responsible manner taking into account the 
need to ensure data validity and sample integrity.
•  IBB biological samples can only be used for research and non-profit purposes.
•  All extensions to the use of human biological material beyond the aims and objectives for which samples were 
initially collected and provided, subject to the above-mentioned overarching principle, must also be approved by 
the IEC and be in line with the medium- and long-term objectives of IARC.
•  To ensure ongoing enrichment of the IARC biological sample collections, users will be required to provide IARC 
with the results arising from specific analyses (including biological sample analysis, derived variables, etc.) carried 
out using the data and/or samples provided by the IBB, unless otherwise specified in a previous agreement.
•  Management for access purposes will be cost-neutral to the IBB; requestors will contribute to the cost of sample 
retrieval, pre-analytical processing, and shipment according to standard costs published by the IBB.
•  IARC reserves the right to refuse any request without a necessity to provide justification for decisions made, although 
appropriate feedback will normally be provided regarding a refusal for access.
A1.3 Limits on the use of IBB biological samples
IBB biological samples can only be used for research and non-profit purposes by investigators affiliated with public 
sector research organizations. Access may be denied for certain specific reasons, for example:
•  The available sample volume is insufficient for delivery of samples without compromising the future scientific value 
of the collection.
•  The project overlaps with ongoing or planned projects or analyses, leading to unnecessary duplication of work and 
a waste of materials and other resources.
•  The scientific quality of the project is considered inadequate. Scientific quality and ability to administer the project 
will be more specifically considered by the IARC PI/CU and the IEC. The applicant will have to show evidence of 
expertise, resources, and financing for the successful completion of the project.
•  There are ethical or legal issues with the proposal, including, for example, when the proposed use is not consistent 
with the specified purpose of the specimen collection in the original informed consent.
•  The proposed project is in contradiction with IARC’s mission and goals towards public health or against the above-
mentioned guiding principles.
A1.4 Procedure for accessing IARC biological resources and monitoring
A1.4.1 Sample request procedure
Access to IARC biological samples is a six-step procedure, summarized in Fig. A1.1.
Step 1: Requests for accessing IARC biospecimens should be initially directed to the IARC Biobank (ibb@iarc.fr). 
The requestor will be required to complete a Project Application Form (CIRC 66 11/2013) and a Partner Profile Form 
(CIRC 67 11/2013) to provide information on project, requestor, and requesting institute.
Step 2: After review of the Project Application Form and Partner Profile Form, the IARC Biobank submits the request 
to the IARC PI/CU, to assist in the handling of the request.
Step 3: The IARC PI/CU will carry out an initial review of the request for recommendation to the BSC/BAC.
•  In the case of multicentre studies with already defined procedures, the IARC PI/CU will contact the steering committee 
of the study, when there is one in place (e.g. the steering committee for the European Prospective Investigation into 
Cancer and Nutrition [EPIC] study). The relevant steering committee will review the request according to its established 
protocol and provide feedback through the IARC PI/CU.
Step 4: Once the request has been approved by the BSC/BAC, or the relevant steering committee when appli-
cable, the requestor is informed. The IARC Ethics Questionnaire must then be submitted to the IEC for ethical 
approval.
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Fig. A1.1.  Sample request procedure. BAC, Biobank Application sub-Committee; BSC, Biobank Steering Commit-
tee; CU, IARC custodian; IEC, IARC Ethics Committee; PI, IARC principal investigator.
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Step 5: Subject to ethical approval by the IEC, a Biobank Request Form (CIRC 68 11/2013) must be completed by 
the requestor and sent to the IARC Biobank, together with all required supporting documents; these will enable the 
IARC Biobank to prepare the requested samples and the related MTA (using form CIRC 41 04/2013).
Step 6: Upon receipt of the signed MTA and payment of relevant sample access charges, the IARC Biobank will 
proceed with shipment of the samples for the project.
A1.4.2 Monitoring and follow-up
In order for the IARC Biobank to monitor use of IARC biological resources, the requestor will be required to submit 
a Project Progress Report (using form CIRC 69 11/2013) on a 6-monthly basis after samples have been sent.
A1.5 Responsibilities of the requestor/requesting institution
In submitting requests to access IARC biological resources, requestors have the following responsibilities.
A1.5.1 Requesting and receiving
Requestors should:
•  be affiliated to a recognized academic or other public research organization;
•  follow the sample request procedure described above, and accept the provisions and general principles contained 
in the present policy;
•  pay all sample access charges as invoiced by the IARC Biobank; and
•  comply with any request to discard sample(s) if notified by IARC that subject(s) have withdrawn permission for the 
use of donated sample(s).
A1.5.2 During the study
Requestors should:
•  accept and undertake research in the context of the ownership of samples and data as stipulated in the IARC MTA 
(CIRC 41 04/2013);
•  provide plans for publication of the study results in peer-reviewed journals within 1 year of reception of the samples 
(or provide clear justification for the requirement of a longer period);
•  report on progress made within the project (using form CIRC 69 11/2013), every 6 months until the study has been 
completed and remaining samples, if any, have been destroyed or returned to IARC (as is stipulated in the MTA); and
•  ensure compliance with the terms and conditions of the MTA; users found to be in breach of the MTA will be denied 
future access to the IARC biological resources.
A1.5.3 At the end of the study
Requestors should:
•  report on the outcome of the study upon completion, including publications (using form CIRC 69 11/2013);
•  return any unused samples to IARC, unless otherwise stated in the MTA (CIRC 41 04/2013); and
•  provide IARC with a copy of the results generated within the project through use of the IARC biological resources 
(raw data or other relevant format agreed upon with IARC) within 6 months of publication.
A1.6 Acknowledgement in publications
Full acknowledgement of the sources of all biological resources must be included in any publications that arise from 
access to and use of the IBB resources. All publications must include at a minimum the following acknowledgement: 
“The research was made possible using the data/samples provided by the IARC Biobank.” In addition, where applicable, 
the acknowledgements must refer to the original sample source centre as well as the source of funding. Specific 
authorship rules may apply in some instances; these will be agreed upon on a case-by-case basis.
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A1.7 Reference documents
7.1  IARC Policy on Access to Human Biological Materials (IARC/Access Policy/Group-BSC/EN/11/2013):  
http://ibb.iarc.fr/docs/iarc-policy-access.pdf
7.2 Project Application Form (CIRC 66 11/2013): http://ibb.iarc.fr/docs/IBB_ProjectForm.dot
7.3 Partner Profile Form (CIRC 67 11/2013): http://ibb.iarc.fr/docs/IBB_PartnerForm.dot 
7.4 IARC Ethics Questionnaire: http://ethics.iarc.fr/Submission/index.php
7.5 Biobank Request Form (CIRC 68 11/2013): http://ibb.iarc.fr/docs/IBB_RequestForm.dot
7.6 MTA Form (CIRC 41 04/2013): http://ibb.iarc.fr/access/index.php
7.7 Project Progress Report Form (CIRC 69 11/2013): http://ibb.iarc.fr/docs/IBB_ReportForm.dot
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These guidelines are made up of the following three sections: design decisions; guidance for broad consent participant 
information sheets and consent forms; and links to biobank-specific templates for participant information sheets and 
consent forms.
A2.1 Design decisions
This section contains useful points to consider when designing participant information sheets and consent forms 
for biobanks.
A2.1.1 Where do I start?
The templates for participant information sheets and consent forms listed in Section A2.3 are a good place to start 
to get an idea of the general contents of participant information sheets and consent forms.
A2.1.2 Will I provide the participant information sheet and the consent form as separate 
documents?
It is common practice to provide these documents separately, and this may be the most practical solution for biobanks 
in terms of the storage and distribution of these documents. However, in clinical trials that involve biobanking, the 
two documents are often combined, which ensures that the participant information sheet and the consent form used 
are stored together.
A2.1.3 Will I require that the participants initial or tick the boxes on the consent form?
It is recommended that biobanks follow best practice in clinical trials, which requires that participants initial the boxes 
on the consent form. It is worth making this requirement clear on the consent form itself.
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A2.1.4 Will I provide opt-in/opt-out statements on the consent form?
The most critical thing to consider before providing opt-in/opt-out statements is whether the biobank can support 
this. For example, allowing the participant to opt out of research that involves animals but not being able to enforce 
this when distributing samples will cause problems for the biobank. The most common problem is that the biobank 
database does not record the participant’s decisions, resulting in a time-consuming search for the consent form each 
time a sample is distributed. If opt-in/opt-out statements are provided, add two boxes, marked with “yes” and “no”, 
to the consent form so that it is clear that these statements are optional. See the information on dynamic consent in 
Table A2.2 for examples of possible opt-in/opt-out statements.
A2.1.5 Should I consider what might happen to the samples in the future?
It is very important that when the participant information sheets and consent forms are being developed, the biobank 
should carefully consider the possible future use of the samples and data, so that the biobank can inform the participant 
at the outset and will not need to re-contact them for further permissions. Some examples of areas to consider are: 
issues that are potentially ethically or legally challenging, such as transfer of samples or data across national borders 
or use of samples and data by commercial researchers (see the recommendations in Section 3.1.2.3); return of 
results and incidental findings (see Section 3.1.4); access to and sharing of samples and data (see Section 3.1.5); 
when participants might need to be re-contacted; and whether the participants need to receive information or give 
consent via an interpreter. If an interpreter is needed, lines may need to be added to the consent form to allow the 
interpreter to sign the form.
A2.2 Guidance for broad consent participant information sheets and consent forms
Table A2.1 provides information on the headings that would be expected on a biobank participant information sheet 
aiming for a broad consent approach. The optional sections apply only to specific types of biobanks or specific types 
of research being conducted.
Table A2.1. Sections for inclusion on a biobank participant information sheet, indicating whether these are optional 
or mandatory; the initial statements or questions can be used as titles in the participant information sheet
Section Mandatory or optional?
Why are human tissues and body fluids vital for research? Mandatory
What is the purpose of the biobank?
Answering questions such as:
• What is the aim of the biobank?
• Is the biobank disease-specific?
• Is unspecified future research (secondary use) planned? 
Mandatory
Who has approved the research? Mandatory
Why am I being invited? Mandatory
What will happen if I agree to participate?
Answering questions such as:
• Is access to medical or other health-related records planned?
Mandatory
Will my samples be used in genetic research? Mandatory
What are the benefits and risks of taking part? Mandatory
Who will have access to my samples and data?
Answering questions such as:
•  Can the samples and/or data be transferred to/used by/shared with other researchers/biobanks/institutions? 
– Is this individual-level/aggregated/genetic data? 
– Will the samples be shared?
• Can the samples and/or data be transferred to/used by/shared with researchers in other countries?
• Will the data be included in a public database?
• Can the samples be accessed by commercial organizations? 
Mandatory
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Section Mandatory or optional?
How will my samples and data be stored?
Answering questions such as:
• What are the privacy/data protection mechanisms?
Mandatory
How long will my samples and data be stored? Mandatory
Will I find out results of the research?
Answering questions such as:
• Will any results (general or individual) be returned to the participant?
• How will any return of results take place?
• What options does the participant have?
Mandatory
What if I change my mind?
Answering questions such as:
• What withdrawal options are there?
• What happens to samples and/or data after withdrawal?
Mandatory
Contact details for the biobank Mandatory
Will my cells or tissue be used for research involving animals? Optional
Will my cells or tissue be used to create cell lines? Optional
Will my cells or tissue be used for research linked to reproduction? Optional
Can I donate cells or tissues after death? Optional
Will I receive any compensation for being involved? Optional
Detailed explanations about tissue, cells, and DNA:
Human cells and tissues
DNA and genes
How cells and tissue are collected
Use of human tissue and fluids for medical education and audit
Details for specific types of tissues or donors (e.g. stem cells, healthy donors)
Optional
Detailed information about biobank governance
Answering questions such as:
•  What type of committee reviews applications for access to biobank samples and/or data, and who serves on 
this committee?
•  What type of contracts must those accessing the biobank samples and/or data complete (e.g. Material 
Transfer Agreements)?
• How is the biobank governed?
Optional
Detailed information for postmortem donors Optional
Information about whether samples and/or data are collected from vulnerable persons or populations and how 
that works
Answering questions such as:
• Can samples and/or data be used after children participating in the study become adults?
Optional
Preferences for re-contact (see Table A2.2) Optional
Table A2.1. Sections for inclusion on a biobank participant information sheet, indicating whether these are optional 
or mandatory; the initial statements or questions can be used as titles in the participant information sheet (continued)
Table A2.2 provides information on the consent statements that might be expected on a biobank consent form 
aiming for a broad consent approach. Some of these consent options may be required by the legal system in a 
particular country, for example the need to gain specific consent to access medical records. In addition, legal 
requirements may mean that consent is needed to transfer samples or data across national borders if this may 
occur in the biobank. Opt-in/opt-out statements should be included only when these are recordable, actionable by 
the biobank, and practicable.
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Area Example of statement on consent form (italic means that text must be adapted)
The participant confirms that they have read and understood  
a particular participant information sheet
I have read and understood the information pamphlet [version/date].  
I have had the opportunity to consider the information it contains and 
to ask all the questions I had. I have obtained satisfactory answers to 
my questions.
The participant confirms that they have had the risks and benefits of 
participation explained to them
The risks and benefits of my participation have been explained to me.
The participant understands that participation in the research is 
voluntary
I understand that my participation is voluntary. I am free to withdraw 
at any time, without giving any reason.
Use of samples and data by commercial researchers I understand that some of these research projects may be carried out 
by commercial organizations and that I will not benefit financially if 
this research leads to new treatments or medical tests.
Use of samples for genetic research These samples may be used for genetic research.
Access to medical records I give permission for information about me, provided by me or found 
in my medical and other health-related records, to be supplied to and 
stored by [name of biobank] for research purposes.
or
I give permission for access to my medical and other health-
related records, and for long-term storage and use of this and other 
information about me, for health-related research purposes (even 
after my incapacity or death). 
Contacting general practitioner for information My general practitioner can be contacted for information relevant to 
my condition and current treatment.
Possible opt-in/opt-out statements (to be used when these are recordable, actionable by the biobank, and practicable)
Re-contacting participants to ask for further information or about 
participation in new studies
We may like to re-contact you in the future to ask for further samples 
or information that may be of use to researchers, or for further 
permissions relating to the use of the samples and information you 
have already donated.
I agree that [name of biobank] may re-contact me in the future to ask 
me to provide additional samples or information related to [name of 
biobank] or to invite me to participate in a new study. I understand 
that this does not oblige me to provide the samples or to participate 
in further research.
Re-contacting participant with information arising from the study
The text included here in the consent form will depend on the 
biobank’s policy in relation to return of study results
These are the areas where permission may be requested, if relevant:
A.  Agreement or opt-in/opt-out to receiving general research project 
results, for example in the form of a newsletter or email.
B.  Agreement or opt-in/opt-out to receiving the results of any physical 
examination conducted as part of the sample or data collection, 
in which case also briefly explain the circumstances under which 
this may take place and the mechanisms by which it would be 
achieved.
C.  Agreement or opt-in/opt-out to receiving the results of any tests for 
infectious diseases conducted on the samples. Briefly explain the 
related circumstances and mechanisms, as in B.
D.  Agreement or opt-in/opt-out to receiving individual-level research 
results or other incidental findings arising from the research. 
Briefly explain the related circumstances and mechanisms, as in B.
Transfer of samples or data across national borders Do you give permission for samples to be sent to centres outside 
[name of country]?
Experiments involving animals Do you give permission for your samples to be used in experiments 
using [animal type, e.g. rodents (rats or mice)]?
Creation of cell lines from the tissue These samples may be used to create cell lines.
Table A2.2. Items for consideration on a biobank consent form, including options that may be provided as consent 
statements and possible opt-in/opt-out statements
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A2.3 Links to biobank-specific templates for participant information sheets and consent forms
The documents and links listed below can be used as reference materials to produce biobank participant information 
sheets and consent forms.
1. World Health Organization (WHO):
 • WHO Informed Consent Form Templates: http://www.who.int/rpc/research_ethics/informed_consent/en/
 •  WHO Informed Consent Form Template for Consent for Storage and Future Use of Unused Samples: 
http://www.who.int/entity/rpc/research_ethics/Informed%20consent%20for%20sample%20storage.doc?ua=1
2. Public Population Project in Genomics and Society (P3G):
 •  P3G-IPAC Generic Clauses/Agreements Database, to assist researchers in building documents: http://www.
p3g.org/resources/ipac
 •  P3G Generic Information Pamphlet and Consent Form (2014): http://www.p3g.org/system/files/biobank_toolkit_
documents/P3G%20Generic%20Info%20Pamphlet%20and%20Consent%20Form%20for%20Biobanks_0.pdf
3. Global Alliance for Genomics and Health (GA4GH):
 •  Consent tools in relation to international data sharing: http://www.p3g.org/sites/default/files/site/default/files/
GA4GH-Consent%20Tools-FINAL%20%281%29.pdf
4. Human Heredity and Health in Africa (H3Africa):
 •  H3Africa Guidelines for Informed Consent (2013), guidance for designing consent materials for genomic 
research in African contexts: http://h3africa.org/images/FinalPoliciesDocuments/H3A%20WG%20Guidelines%20
Informed%20Consent_FINAL_01082013.pdf
5.  Beskow LM, Friedman JY, Hardy NC, Lin L, Weinfurt KP (2010). Developing a simplified consent form for 
biobanking. PLoS One. 5(10):e13302. http://dx.doi.org/10.1371/journal.pone.0013302
6. Strategic Tissue Repository Alliances Through Unified Methods (STRATUM) project:
 •  Consent Models Work Package tools, including a two-page combined participant information sheet and consent 
form template and an in-depth biobank participant information sheet template: http://stratumbiobanking.org/
consent.html
7. UK Biobank:
 •  Consent form: http://www.ukbiobank.ac.uk/wp-content/uploads/2011/06/Consent_form.pdf
 •  Participant information sheet: http://www.ukbiobank.ac.uk/wp-content/uploads/2011/06/Participant_information_
leaflet.pdf?phpMyAdmin=trmKQlYdjjnQIgJ%2CfAzikMhEnx6
8. Children’s Cancer and Leukaemia Group (CCLG):
 •  Information sheets for involving children in biobank research: http://www.cclg.org.uk/tissue-bank/information-
for-patients
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This template is based on Public Population Project in Genomics and Society (P3G) database resources.
General considerations
•  The information brochure and consent form should be clear, in plain language, easy to read, and written in large 
fonts (size may vary according to the target population). The date of the version of the form should be identified 
in the footer, and pages should be numbered “Page x of y”. In the information pamphlet, the term “you” should be 
used to refer to potential participants. In the consent form, the term “I” should be used.
•  Researchers should follow a culturally sensitive process of providing information to obtain participants’ consent. In 
particular, in some communities, obtaining the agreement of local community leadership for the proposed research 
is mandatory and this agreement should be sought before the preparation of consent forms and before obtaining 
the consent of any participant from that community. In addition, the degree of autonomy that individuals have may 
vary between cultures. In preparing for the consent process, the researcher must therefore consider applicable 
norms and traditions.
•  Other considerations may be specific to certain populations (e.g. research involving children, vulnerable populations), 
and additional requirements may apply to the consent process. Researchers should ensure that all such specific 
requirements are taken into account when preparing consent materials.
The following text presents generic template language in the preparation of biobanking consent forms for adult 
participants (italic means that text must be adapted).
annex 3. 
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[Insert logo and letterhead of biobank]
INFORMATION PAMPHLET AND CONSENT FORM FOR PARTICIPANTS
[Name of biobank/Title of study]
[Name of Principal Investigator]
[Name of organization]
[Names of funders and sponsors]
[Contact information]
Preamble
We are inviting you to take part in the creation of a resource for research called [identify biobank/title of study]. Your 
participation is voluntary. Before you decide whether or not to participate and sign the consent form, please take your 
time to read this information pamphlet. This document may contain information or words that you do not understand. 
Please ask us if there is something you do not understand, or if you would like more information. It is important that 
you fully comprehend what participation in this project entails.
1. Nature and objectives of the study
[Describe the study purpose, in addition to the current and future scope of research.]
The [identify biobank/title of study] is a resource that contains biological materials, such as DNA samples, in 
addition to health/lifestyle information and personal information (data) on a large number of people over time. It 
has been set up so that it can be used in the future as a resource for researchers undertaking a wide range of 
medical research.
Optional clauses
- If applicable, provide specific information as to “large number of people involved”;
- If applicable, specify types of future “medical research” (e.g. specific disease/research area).
This [biobank/study] has two main aims. The first aim is to gain a better understanding of the interactions between 
genes, the environment, and our lifestyle that influence our health or cause diseases. The second aim is to use this 
understanding to develop new drugs, genetic tests, and treatments, and to create public health strategies that will 
benefit everyone.
Your participation in this project involves you giving broad consent. This means that you allow your personal information 
and samples to be used for a variety of future medical research approved by an ethics committee, but which cannot 
be specified at the present time.
Optional clauses
-  If applicable, specify types of medical research that will use the biobank (e.g. specific disease/
research area). If other types of research are indicated, add: “Some future types of research may 
require your specific consent.”
-  If data linkage is planned, add: “Your personal data will have to be regularly updated by being linked 
to your medical record and other sources of administrative health information. If, after reading this 
information pamphlet, you do not agree to any of these aspects, you should not take part.”
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2. Prospective participants
[Outline the total number of expected participants, and explain why the individual was selected to participate.]
The [biobank/study] involves the participation of [number] people between [age] and [age] years of age from [region].
You have been chosen from [identify database, registry, etc.] to be invited to participate.
Optional clauses
- If applicable, specify targeted disease or specific illness.
-  If applicable, add: “You are being asked to participate because you are a patient at [name of hospital/
institution]” or “You have been identified by your personal doctor as someone who is in the correct 
age bracket and meets the relevant criteria to participate.”
However, please note that you should not participate if [enumerate exclusion criteria].
3. Researchers and institutions conducting the study
[This section should also disclose any conflicts of interest.]
The [biobank/study] is a research effort led by [identify institution(s)]. This institution is responsible for the practical 
aspects, such as data collection and secure storage of samples and data. It will be the point of contact for you, 
and for the researchers who use the biobank. The person who has overall responsibility for the management of the 
biobank is [name of executive director]. If you need to contact the biobank for any reason, please telephone [name] 
at [telephone number], email [email address], or write to [mailing address].
The [biobank/study] is supported by [identify institution(s)] and is funded by [name(s) of sponsor(s)/government 
agency]. The [name of study] has received approval from [name of research ethics committee].
4. What does participation involve?
[Outline study procedures; what participants are expected to do throughout the course of the study; include types of 
information being gathered (samples and data); amount of information being gathered; tests to be performed (manner 
of acquiring samples); questionnaires; length of time; location, etc.]
If you choose to participate, you will be asked to:
(1) Undergo a physical assessment, which involves you:
•  attending an appointment at [insert location], which will last approximately [insert duration of appointment];
•  providing a [insert sample type (e.g. blood, urine, saliva)] sample of [insert amount/measures of samples taken], 
which the biobank will store;
•  answering a questionnaire on [insert topics (e.g. your health and lifestyle, family, and medical history)] that will 
take approximately [insert length of time]; and
•  allowing our staff members to perform basic measurements, including [insert measurement types (e.g. measuring 
your weight, height, and blood pressure)].
The physical assessment will be conducted by [qualified health professionals (e.g. nurses, physicians)]. In total, it 
should take approximately [insert duration of entire assessment].
(2)  Allow your samples and data to be stored and used in coded form by researchers for many years [if applicable, 
specify length of time].
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Optional clauses
-  If applicable, add: “Allow your personal information contained in your administrative health records 
to be accessed now and in the future.”
-  If applicable, add: “We may continue to access these records even if you become unable to make 
decisions for yourself or after your death.”
5. Study risks
[List possible disadvantages or risks (e.g. discomfort, malaise, stress, transportation costs, time).]
Your participation entails few risks. The physical assessment involves little risk. The taking of a blood sample for DNA 
analysis may cause some bleeding, bruising, dizziness, and/or discomfort. You should be aware that certain physical 
measurements that will be taken [e.g. your weight] and/or some of the questions you will be asked in the questionnaire 
may be personal in nature. The storage of your samples and the extraction of DNA involve minimal risk, because 
rigorous security measures are in place (as described below) and all samples will be kept in a high-security facility.
Unless required by law or a court order, access to this information will not be offered to third parties such as employers, 
insurance companies, or family members. Only authorized staff members will have access to your information. For 
requests for access by researchers, they will not be given any information that would allow them to identify you. The 
utmost care will be taken to ensure the confidentiality of all data.
6. Potential study benefits
You will not directly benefit by taking part in this study, because the most important health benefits will be realized 
many years from now. Rather, your participation will contribute to the advancement of scientific knowledge and help 
future generations, because your participation is expected to improve our understanding of genetic and non-genetic 
factors that affect the health of the population.
However, any immediate, life-threatening condition will be reported to you immediately so that you can obtain 
emergency care.
7. Privacy and confidentiality
[Specify who will have access to the participants’ personal information and the types of information.]
The information in your file could include your past and present medical history, in addition to information about your 
life and test results from examinations and procedures done during this study. Your file could also contain information 
such as your name, sex, date of birth, and ethnic origin.
All information collected about you will remain confidential. No one will have access to your directly identifying 
information, that is information that identifies you through specific identifiers such as your name, your social insurance 
number, and your personal health number.
To protect your privacy, your information will be coded. “Coded” means that your information has been stripped of 
any direct or indirect identifiers, which are replaced by a numerical code. A list that links the coded information with 
your identity will be kept secure, to allow for your re-identification in certain circumstances. Your unique code will 
enable us to link the information from different data sets to you, but at the same time, will enable us to keep your 
identity confidential when we give your data to other researchers to use.
While study information could be printed in journals or shared with other people at scientific meetings or for teaching 
purposes, it will not be possible to identify you. Your identity will be kept confidential. All data will be presented as 
group data, rather than individual data.
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Also, specific rules regulate access to your data and samples by researchers. Researchers will not have access to 
any of your personal information.
8. Access to your data and samples
Only approved research studies can gain access to your coded data and samples, in order to protect your privacy. 
An approved researcher can be from [outline the approved users as per access policy (e.g. academia, a charitable 
organization, a private company, or a public institution)]. All projects must be approved by the [identify the access 
committee], who will essentially review whether the proposed study has received prior scientific and ethical approval by 
the relevant committees, and that the study fits within the purpose of the biobank and meets other general requirements.
Researchers have to sign agreements that control their access to data and samples, and they are not permitted 
to disclose or transfer data or samples to anyone else or to use them for purposes other than those agreed to. 
Researchers must also agree that they will not attempt to re-identify you from your data and samples and should 
immediately report any re-identification of participants to the biobank.
We also expect to receive access requests from overseas researchers and international collaborators. These 
researchers must follow the same procedures as all other researchers. All access is subject to the strictest scientific 
and ethical scrutiny, as described above.
When transferred samples are no longer needed for the purpose for which they were given to researchers, researchers 
must [return them to the biobank or destroy them]. Researchers must also return their research results to the biobank, 
so that those results are available for other researchers to use in the future. This facilitates future research and 
enriches the database of the [name of biobank].
9. Storage of your data and samples
[Specify where the data and samples will be stored (location) and how long they will be stored.]
Your data and samples will be stored in a database at [name of institution/hospital and location]. This is a secure 
facility, meeting international security and safety standards for laboratories. Also, in order to keep your information 
confidential, numerous safeguards are in place. In particular, we will:
•  remove personal identifiers such as your name or date of birth from your samples and records;
•  assign codes to your samples and records;
•  keep your personal details separate from your data and samples;
•  use stringent security measures to prevent unauthorized use, including strict access controls, computer security 
and data encryption techniques, confidentiality agreements, and staff training;
•  hold information in secure databases, which can be accessed only by the authorized staff members and by approved 
researchers, who will only have access to coded information; and
•  have a decoding step that will allow us to re-link your personal details with your samples and information, should 
you want to withdraw from the study or in order to make sure that the database records are correct.
Your samples and data will be kept for a period of [identify period of conservation (e.g. number of years)]. After this 
period, your samples and data will be [destroyed or transferred], unless an ethics committee decides otherwise.
Optional clause
If samples and data are transferred at the end of the period of conservation, specify where the data 
and samples will be transferred [name of biobank].
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10. Withdrawing from the study
[Indicate treatment (planned use and storage procedures) of already collected data/samples.]
You may choose whether or not you wish to take part in this study. If you choose to take part now, you can change 
your mind later and withdraw, meaning stop participating at any time and for any reason.
You can withdraw by [indicate ways for participant to signal their withdrawal (e.g. by telephone, by email, by mail, 
and whom to contact)]. You will receive a letter confirming your withdrawal.
If you withdraw, your identifiable samples and the data derived from your samples and other personal information 
will be destroyed if possible. Data that are already being used for research cannot be destroyed or removed.
The code that enables us to re-link your samples and personal information will be deleted so that no further information 
about you will be collected. Only your signed consent form and a copy of the letter confirming your withdrawal will 
be kept as a record of your wishes. Such a withdrawal will prevent information about you from contributing to further 
research and analyses.
11. Return of research results
[Outline the biobank’s policy as to returning results, including the results from the laboratory assessment and physical 
assessment, general research results, individual research results, and incidental findings. If the biobank’s policy is 
to return individual results, indicate who has the obligation of returning these results and for how long.]
(a) Results from laboratory assessment and initial physical assessment
You can choose to immediately receive the results of your physical assessment, such as [specify results that can be 
returned], from your [type of assessment (e.g. BMI, ECG, blood pressure)]. These results will be provided with the 
appropriate explanations (e.g. your measurements alongside “standard measures”). You can decide whether you want 
these measurements sent to you or not.* If, during the physical assessment, we find something that we feel should be 
explored further, we will advise you to see your personal doctor, because the assessment is not a clinical check-up.
Optional clause
* If applicable, add: “You can ask that they be sent to your personal doctor.”
(b) General research results
General research results, meaning aggregate results derived from the analysis of the data and samples of research 
participants, will also be made available to participants, researchers, and any other people who might be interested 
through [state format (e.g. website, newsletter)]. This is done to make data more readily available to researchers 
and encourage medical advances. Such data will not have any identifiers that will enable anyone to link the data 
to you. You can access these results through the biobank [specify how/where participants can find these results].
(c) Individual research results and incidental findings
Individual research results are results discovered during the course of research that concern you and have potential 
health or reproductive consequences.
Incidental findings are unforeseen findings about you that have potential health or reproductive consequences. 
Although they were discovered during the course of research, they are outside of the study objectives.
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Alternative clauses
Alternative clause 1: “We will not return any individual research results or incidental findings to you”; 
or
Alternative clause 2: “With your consent, we will return individual research results or incidental 
findings to you when they are scientifically valid, they are clinically significant, and there is a recognized 
therapeutic or preventive measure or way of changing the clinical course of the disease or condition. 
These results will be returned to you by [e.g. the Principal Investigator, a qualified health professional] 
for a period of [number of years]. After this period, the biobank will no longer return individual research 
results to you.”
12. Re-contact
With your permission, we may re-contact you to invite you to update your questionnaire or to provide additional 
samples or to be involved in new research projects by other researchers that could require additional physical 
assessments, tests, and questions.
13. Compensation
[Include travel expenses and the procedure for reimbursement.]
Alternative clauses
-  If compensation is not offered, add: “Your participation is on a voluntary basis. You will not be 
compensated for your participation.”
-  If compensation is offered, add: “Your participation is on a voluntary basis. However, as compensation 
you will receive [specific amount] for [type of visit (e.g. a visit to the clinic or a home visit], travel 
expenses, and other inconveniences related to your participation.”
14. Possible commercialization
[Explain the potential uses of data and samples, including the development of intellectual property and commercial 
uses.]
[Identify biobank or specific committee] has been set up as the [guardian/owner/custodian] of the database and 
sample collection. The use of your data and samples might someday lead to the commercialization of a medical 
or genetic test or product. This may be done by a university or hospital, a commercial company, or both working in 
partnership. This means that researchers, including, potentially, commercial companies, may benefit financially. You 
will not derive any personal financial advantage from this commercialization.
15. Closure of the biobank
[Explain what will happen upon the closure of the biobank, whether the closure is scheduled or unplanned.]
If the [name of biobank] were to close for whatever reason, [see Alternative clauses].
Alternative clauses
Alternative clause 1: “all of the research results and information will be put into an archive that will 
be overseen by the [identify committee]”;
Alternative clause 2: “all of the samples and data will be destroyed”; or
Alternative clause 3: “all of the samples and data will be transferred to [identify existing biobank]”.
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16. Your questions or concerns
If you have any questions or concerns, please contact [insert name of person] free of charge at [insert telephone 
number] or by mail/email at [insert mailing address and/or email address].
If you wish to make a complaint about any aspect of this study at any time, please contact [insert name of person] 
free of charge at [insert telephone number] or by mail/email at [insert mailing address and/or email address]. We 
take all comments seriously and will get back to you as soon as possible.
Thank you for considering taking part in this study!
88
[Insert logo and letterhead of biobank]
PARTICIPANT CONSENT FORM
[Name of biobank/Title of study]
Name of biobank: [insert name of biobank]
Investigator(s): [insert name(s) of investigator(s)]
Sponsor(s): [insert name(s) of sponsor(s)]
The goal of the [biobank/study] is [provide a brief summary of goal].
BY SIGNING THIS CONSENT FORM, I AGREE TO PARTICIPATE IN THE [BIOBANK/STUDY] AND DECLARE THAT:
  I have read and understood the information pamphlet [version/date]. I have had the opportunity to consider the 
information it contains and to ask all the questions I had. I have obtained satisfactory answers to my questions.
  The risks and benefits of my participation have been explained to me.
  I understand that my participation is voluntary. I am free to withdraw at any time, without giving any reason. This 
can be done by contacting [insert name] at [insert telephone number, email address, and/or mailing address]. 
I will receive a letter confirming my withdrawal.
  I understand that I will not receive any personal financial benefit from any possible commercialization of a test or 
product developed by using my data and samples.
  I understand that my participation does not entail any direct personal benefit. However, any immediate, life-
threatening condition will be reported to me immediately so that I can obtain emergency care.
  I understand that upon closure of the biobank, my data and samples will be [specify policy for closure: archived, 
destroyed, or transferred to another biobank].
  I understand that unless access is required by law, only approved researchers will have access to my coded data 
and samples. Access is subject to ethics approval and oversight.
  I understand that general research results, meaning aggregate results, will be made available to participants, 
researchers, and other people who might be interested through [specify format (e.g. website, newsletter)] in order 
to make data more readily available and encourage medical advances.
I AGREE TO:
  Undergo a physical assessment, including:
•  attending an appointment at [insert location], which will last approximately [insert duration of appointment];
•  providing a [insert sample type (e.g. blood, urine, saliva)] sample of [insert amount/measures of samples taken], 
which the biobank will store;
•  answering a questionnaire about [insert topics (e.g. my health and lifestyle, family, and medical history)]; and
•  allowing staff members to perform basic clinical measurements, including [insert measurement types (e.g. 
measuring my weight, height, and blood pressure)].
  Allow my coded data and samples of [insert sample type (e.g. blood, cells, DNA, urine, saliva)] to be used for 
various research purposes approved by the relevant research ethics committee.
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Optional clause
If specific disease/research area: “Allow my coded data and samples of [insert sample type (e.g. blood, 
cells, DNA, urine, saliva)] to be used for [specify disease/research area] approved by the relevant ethics 
committee. My approval will be required for other types of research.”
  Have my data and samples stored at [specify storage location] for [specify period of conservation]. All data and 
samples will be kept in a secure facility overseen by [insert name of individual or committee].
  Allow my data contained in administrative health records to be examined now and in the future. My records and 
samples will continue to be accessed even if I become unable to make decisions for myself or if I die.
Alternative clause
If applicable: “Allow my data contained in administrative health records to be examined now and in the 
future. If I die, my records and samples will no longer be used.”
RETURN OF RESULTS
(a) Results from laboratory assessment and initial physical assessment
Optional clauses
  I wish to receive the measurements or other results taken during the physical assessment and laboratory tests.
YES £     NO £
[OR]
  I wish to have the measurements or other results taken during the physical assessment and laboratory 
tests sent to my doctor.
YES £    NO £
(b) Individual research results and incidental findings
Alternative clauses
Alternative 1:
  I understand that I will not receive any individual research results or incidental findings.
Alternative 2:
  I agree to have individual research results and incidental findings returned to me when these results 
are scientifically valid, have clinical significance, and are actionable (there is a recognized therapeutic 
or preventive measure or way of changing the clinical course of the disease or condition).
YES £      NO £
RE-CONTACT
  I agree to be re-contacted by [identify biobank/study] to update my data (questionnaires or physical measures) 
or to provide additional data/samples.
 YES £      NO £
  I agree to be re-contacted by [identify biobank/study] to participate in new research projects conducted by other 
researchers that could require additional physical assessments, tests, questions, or samples.
 YES £      NO £
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CONFIRMATION BY INVESTIGATOR OR HIS/HER DESIGNEE
I described the [identify biobank/study], including the conditions of participation, to the participant. I explained the 
contents of the information pamphlet and consent form to the participant. Any questions were answered. I explained 
that participation was voluntary.
Investigator/Designee name ........................................................... Signed  .................................. Date ......................
 
Optional clause
TRANSLATOR INFORMATION (if applicable)
I was present during the meeting between [name of investigator/designee] and the participant. I translated, 
for the participant, the consent form and all information presented regarding the research project.
Translator name ................................................................... Signed  .................................. Date ......................
PARTICIPANT INFORMATION
I AGREE TO PARTICIPATE IN [BIOBANK/STUDY] AND WILL RECEIVE A COPY OF THIS CONSENT FORM 
AFTER I SIGN IT.
Name .............................................................................................................................................................................
 
Signed ............................................................................................................................................ Date ......................
THANK YOU FOR PARTICIPATING! FOR MORE INFORMATION, PLEASE CONTACT: [insert website, name of 
person to contact, telephone number, email address].
To file a complaint regarding your participation, please contact: [insert name of person to contact, telephone 
number, email address, and mailing address].
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This template is based on the IARC MTA template. The text presents generic template language (italic means that 
text must be adapted).
[Insert logo of Providing Institute]
MATERIAL AND DATA TRANSFER AGREEMENT – MTA/DTA
MTA/DTA Reference Number: [to be provided by [insert name of Providing Institute]]
Subject to the terms and conditions of this Agreement, the [insert name of Providing Institute] hereby agrees to 
provide, and the Receiving Institute hereby agrees to accept, the Materials and Information specified below for such 
Purposes of Use and subject to such Restrictions on Use as specified below.
In this Agreement, the following expressions shall have the following meanings:
1. “Providing Institute”:
[Insert name and full address of Providing Institute]
Contact: [insert name and contact details (including email address) of Providing Institute’s Principal Investigator]
2. “Receiving Institute”:
[Insert name and full address of Receiving Institute]
Contact: [insert name and contact details (including email address) of Receiving Institute’s Principal Investigator]
annex 4. 
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3. “Materials”:
[Insert precise description of Materials], held by [insert name of Providing Institute], and made available to the 
Receiving Institute hereunder in a quantity of [insert quantity to be provided by Providing Institute].
4. “Information”:
Any information, unpublished or otherwise, owned by [insert name of Providing Institute] and communicated to the 
Receiving Institute by [insert name of Providing Institute] during the term of this Agreement relating to the Materials, 
their production, properties, and/or experimental results observed using the Materials or any derivatives therefrom.
5. “Purposes of Use”:
The Materials and Information are provided for the following purposes, as more fully described in Appendix 2 (the 
“Research Project”):
[Insert a brief description of the purposes for which the Materials, and products incorporating or developed with the 
Materials, may be used.] [Add reference to a specific grant, etc. when appropriate.]
6. “Restrictions on Use”:
The Materials and Information shall not be used for any purpose other than the Purposes of Use.
In particular, the Materials and Information shall not be used for [insert any specific restrictions on use].
7. “Term of Agreement”:
This Agreement shall remain in full force and effect as from the date of its signature by both parties for a duration of 
[specify duration/may be based on project duration].
8. “Materials Charges”:
PLEASE KEEP THE APPLICABLE CLAUSE (1) AND DELETE THE REST.
8.1  As per price list The cost of sample retrieval, processing – including DNA extraction – packaging, and shipment 
will be charged by [insert name of Providing Institute] to the Receiving Institute at the latest rate [indicate where 
rate will be made available for informational purposes].
or
8.1  As per agreed unit price The cost of sample retrieval, processing – including DNA extraction – packaging, and 
shipment will be charged by [insert name of Providing Institute] to the Receiving Institute at the following agreed 
rate: [list unit price].
or
8.1 Lump sum amount The cost of sample retrieval, processing – including DNA extraction – packaging, and 
shipment will be charged by [insert name of Providing Institute] to the Receiving Institute for the total lump sum 
amount of [amount and currency in words].
or
8.1  Free of charge The sample retrieval, processing – including DNA extraction – packaging, and shipment will be 
provided free of charge.
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9. “General Conditions”:
The General Conditions attached hereto under Appendix 1 form an integral part of this Agreement.
This Agreement is duly signed on behalf of the parties as follows:
Signed for and on behalf of [Providing Institute]: Signed for and on behalf of Receiving Institute:
[Providing Institute] Responsible Scientist  Receiving Institute Responsible Scientist
Name  .................................................................  Name  ...................................................................
Title  ....................................................................  Title  ......................................................................
[Providing Institute] Authorized Official  Receiving Institute Authorized Official
Name  .................................................................  Name  ...................................................................
Title  ....................................................................  Title  ......................................................................
Date  ...................................................................  Date  .....................................................................
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APPENDIX 1 – GENERAL CONDITIONS
1. Use
1.1  The Materials and Information are supplied by [insert name of Providing Institute] to the Receiving Institute solely 
for the Purposes of Use and subject to the Restrictions on Use as set out herein.
1.2  The Materials and Information shall not be used in human subjects, in clinical trials, or for diagnostic purposes 
involving human subjects without the written consent of [insert name of Providing Institute].
1.3  Other than for and within the Purposes of Use, and as specifically described in Appendix 2, the Materials and 
Information shall not be transferred, offered for sale, or otherwise used without the prior written agreement of 
[insert name of Providing Institute].
1.4  The Receiving Institute shall allow only parties who have a need to know for the Purposes of Use and who are 
bound by similar obligations of confidentiality and Restrictions on Use as contained in this Agreement to have 
access to the Materials and Information.
1.5  The Receiving Institute shall require any party handling and/or using the Materials and Information to comply 
with all relevant laws, rules, and regulations applicable to the use of such Materials and Information.
2. Confidentiality
2.1  The Information may incorporate confidential information of [insert name of Providing Institute]. Accordingly, 
if and to the extent that any such Information is clearly marked as “confidential”, the Receiving Institute shall 
during the Term of this Agreement and for a period of [insert number of years] years following its termination 
treat such Information as confidential and only disclose it under like obligations of confidentiality and Restrictions 
on Use as those contained herein. The Receiving Institute shall be deemed to have fulfilled its obligations if 
it exercises at least the same degree of care in maintaining confidentiality as it would in protecting its own 
confidential information.
2.2  The above-mentioned obligations of confidentiality shall not apply to Information which:
(i)  can be shown to have been known to the Receiving Institute at the time of its acquisition from [insert name 
of Providing Institute]; or
(ii)  is acquired from a third party, not in breach of any confidentiality obligation to [insert name of Providing 
Institute]; or
(iii)  is independently devised or arrived at by, on behalf of, or for the Receiving Institute without access to the 
Information; or
(iv)  enters the public domain otherwise than by breach of the undertakings set out in this Agreement.
2.3  In some cases, the Information may also incorporate confidential information pertaining to research participants 
having provided the Materials. The Materials provided to the Receiving Institute have been [coded or anonymized 
(provide description of data treatment here)]. If the Receiving Institute inadvertently receives information that 
identifies individual research participants, the Receiving Institute will take all reasonable and appropriate steps 
to protect the privacy and confidentiality of such information. This may require immediate destruction of the 
information on request of [insert name of Providing Institute]. The Receiving Institute agrees to make no intentional 
attempt to re-identify research participants through linkage of data or otherwise. The Receiving Institute will 
immediately report any identification of research participants to [insert name of Providing Institute].
3. Rights
3.1  Except for the rights explicitly granted hereunder, nothing contained in this Agreement shall be construed as conveying 
any rights under any patents or other intellectual property which either party may have or may hereafter obtain.
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3.2  [Insert name of Providing Institute] shall retain ownership of the Materials and Information and shall have the 
unrestricted right to use, assign, or distribute the Materials and Information to any third parties for any other 
purposes. The Receiving Institute acknowledges and agrees that nothing contained in this Agreement shall be 
deemed to grant to the Receiving Institute any intellectual property rights in any of the Materials or Information 
provided hereunder.
3.3  The Receiving Institute must not make intellectual property claims on Materials or Information derived directly from 
[insert name of Providing Institute]. However, the importance of downstream inventions made with [insert name of 
Providing Institute] Materials is recognized; patents on such inventions are permitted. In doing so, the Receiving 
Institute agrees to implement licensing policies that will not obstruct further research. The Receiving Institute will 
own all results, data, and inventions which arise under the Research Project described in Appendix 2.
  OPTIONAL ADDITIONAL CLAUSE: The Receiving Institute does, however, grant to [insert name of Providing 
Institute] a perpetual, non-cancellable, royalty-free, worldwide license, with right to sublicense, to use study 
results for all purposes.
4. Return of Individual-Level Results
OPTIONAL CLAUSES:
4.1  No return of individual-level results: Individual Research Results and Incidental Findings will not be returned 
to [insert name of Providing Institute].
or
4.1  Return of individual-level results: Participants in [insert name of Providing Institute] have consented to the 
return of Individual Research Results and Incidental Findings that are clinically significant, analytically valid, and 
actionable (i.e. treatable or preventable). If in the course of their research the Receiving Institute comes across 
such findings, they must be returned to the [insert name of Providing Institute].
5. Publications
5.1  Upon completion of the Research Project, the Receiving Institute will send to [insert name of Providing Institute] 
[specify: reports, enriched data, etc.]. The Receiving Institute must endeavour to publish results in an academic 
journal or in an open access database. The Receiving Institute agrees to acknowledge [insert name of Providing 
Institute] in any publication or presentation on work derived in whole or in part from the Materials and to supply 
[insert name of Providing Institute] with a copy or web address of any publication.
6. Warranties and Liabilities
6.1  [Insert name of Providing Institute] makes no warranty of the fitness of the Materials for any particular purpose 
or any other warranty, either express or implied. However, to the best of [insert name of Providing Institute]’s 
knowledge, the use of the Materials and/or Information within the Purposes of Use shall not infringe on the 
proprietary rights of any third party.
6.2  [Insert name of Providing Institute] will not be liable for damages related to the provision of Materials to the Receiving 
Institute. This includes but is not limited to damages in relation to inaccuracies, lack of comprehensiveness, or use 
of the Information and Materials and/or Information, or any delay or break in supply by [insert name of Providing 
Institute]. The Receiving Institute acknowledges that [insert name of Providing Institute] makes no guarantee that 
the Materials and/or Information are free of contamination from viruses, latent viral genomes, or other infectious 
agents. The Receiving Institute agrees to treat the Materials as if they were not free from contamination, to ensure 
that appropriate biosafety training is provided to research personnel, and to implement appropriate biohazard 
containment measures.
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6.3  The Receiving Institute agrees that, except as may explicitly be provided in this Agreement, [insert name of 
Providing Institute] has no control over the use that is made of the Materials or the Information by the Receiving 
Institute in accordance with the terms of this Agreement. Consequently, the Receiving Institute agrees that [insert 
name of Providing Institute] shall not be liable for such use.
7. Amendment, Extension, and Termination
7.1  Any amendment to this Agreement, including extension of the Term of Agreement, shall be valid only by written 
amendment executed by the duly authorized officers of both parties.
7.2  Notwithstanding the conditions set forth in this Agreement, in particular the Purposes of Use, Restrictions on 
Use, and Confidentiality obligations, either party may terminate this Agreement with sixty (60) days prior written 
notice to the other party.
7.3  When the Research Project is completed or this Agreement is terminated, whichever comes first, any unused 
Materials will either be destroyed in compliance with all applicable statutes and regulations or will be returned to 
[insert name of Providing Institute] by the Receiving Institute upon [insert name of Providing Institute]’s request.
8. Miscellaneous
8.1  Nothing in this Agreement shall be interpreted as establishing a partnership between the parties or establishing one 
party as the agent of the other or conferring a right on one party to bind the other, except as may be specifically 
set out herein.
8.2  Any dispute relating to the interpretation or application of this Agreement shall, unless amicably settled, be 
subject to conciliation. In the event of failure of the latter, the dispute shall be settled by arbitration. The arbitration 
shall be conducted in accordance with the modalities to be agreed upon by the parties or, in the absence of 
agreement, with the rules of arbitration of the International Chamber of Commerce. The parties shall accept the 
arbitral award as final.
8.3  This Agreement sets forth the entire understanding between the parties and supersedes any prior agreements, 
written or verbal.
APPENDIX 2 – RESEARCH PROJECT
[Provide description of project/work to be performed using the Materials and/or Information.]
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annex 5. 
Biobank, collection, 
study, and sample 
minimum data set and 
associated standards
Table A5.1. Minimum data set and associated standard available in BRISQ, SPREC, and MIABIS
Type of data set Data field Explanation of data field BRISQ Tier 1 SPREC MIABIS
Collection or study or biobank ID The unique ID or acronym of 
the study
NA NA Text value
Study or biobank Acronym Short name NA NA Text
Collection or study or biobank Name Name of the study in English NA NA Text
Collection or study or biobank Description Description of the study aim; 
recommendation maximum, 
2000 characters
NA NA Text
Study Principal 
investigator
Name of the person responsible 
for the study (e.g. the principal 
investigator)
NA NA Text
Collection or study Sex Sex of individuals can be one 
or more values
NA NA One or more values
Collection or study Age low Age of youngest donor NA NA Number
Collection or study Age high Age of oldest donor NA NA Number
Collection or study Age unit Unit of age NA NA Value can be in 
years, months, 
weeks, or days
Table A5.1 lists the minimum data set, which reduces the heterogeneity of sample-associated data and thus improves 
its quality. Such standardization enables biobanks to share samples in large studies and for research that requires 
samples from different sources.
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Type of data set Data field Explanation of data field BRISQ Tier 1 SPREC MIABIS
Collection or study Data categories Type of data that is associated 
with the collection or study
NA NA List of Yes/No 
values; also 
including whether 
biological samples 
are collected
Collection or study Material type Can be several values defining 
type of specimen
NA NA List of fluid or solid 
NCI definitions
Collection Storage 
temperature
— NA NA List of value ranges
Collection Collection type The type of collection; can have 
several values
NA NA List of collection 
types: case–control, 
cohort, longitudinal, 
etc.
Collection Disease Main disease of interest; can  
be more than one
NA NA Five subfields: 
ontology, ontology 
version, ontology 
code, ontology 
description, and 
free text
Collection or study or biobank Contact 
information
Contact information for the 
contact person
NA NA Eight subfields for 
contact name and 
contact information 
(telephone, email, 
and address)
Study Study design Design of the study NA NA List of collection 
types: case–control, 
cohort, longitudinal, 
etc.
Study Total number of 
participants
Number of participants 
recruited
NA NA Number
Study Total number of 
sample donors
Number of participants who 
provided samples
NA NA Number
Study Inclusion criteria Parameters to determine type 
of donor
NA NA List of values
Biobank Biobank URL Internet address of the biobank NA NA http address
Biobank Biobank juristic 
person
Person or entity legally 
responsible
NA NA Text value with name 
of juristic person
Biobank Biobank country Country of the biobank NA NA ISO standard letter 
code
Sample Sample ID Unique ID or acronym of the 
study
NA NA Text identifier or 
barcode
Sample Parent sample ID Specimen from which the 
sample was derived; only for 
aliquots or derivatives
NA NA Text identifier or 
barcode
Sample Type of sample Biological definition of the 
sample
Called 
“biospecimen 
type”; solid 
tissue, whole 
blood, serum, 
cells, etc.
Value list; 
different list and 
codes for solid 
and liquid
Called “material 
type”; list of fluid or 
solid NCI definitions
Sample Type of primary 
container
How the specimen was 
collected
Called “type of 
stabilization”; 
for fluids, 
analogous to 
SPREC, but for 
solids, SPREC 
calls this 
field “type of 
collection”
Value list; for 
solids, the field 
is called “type 
of collection” 
and the values 
are different
NA
Table A5.1. Minimum data set and associated standard available in BRISQ, SPREC, and MIABIS (continued) 
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Type of data set Data field Explanation of data field BRISQ Tier 1 SPREC MIABIS
Sample Pre-centrifugation 
delay
Time between collection and 
processing in hours
NA Value list NA
Sample Centrifugation Centrifugation speed (in g) and 
temperature
NA Value list NA
Sample Second 
centrifugation
Centrifugation speed (in g) and 
temperature
NA Value list NA
Sample Post-centrifugation 
delay
Time between centrifugation 
and storage in hours
NA Value list NA
Sample Long-term 
storage
Container and temperature NA Value list Called “storage 
temperature”; uses 
SPREC values and 
has additional value 
LN2
Sample Type of collection Biopsy, surgical, FNA, etc. Called 
“collection 
mechanism”
Value list NA
Sample Warm ischaemia 
time
Ranges in minutes NA Value list NA
Sample Cold ischaemia 
time
Ranges in minutes NA Value list NA
Sample Fixation type OCT compound, RNAlater, etc. Called “consti-
tution and 
concentration 
of preserva-
tive”; indicates 
formulations to 
maintain a non-
reactive state, 
but in BRISQ, 
also refers to 
fluid samples
Value list; in 
SPREC, only 
refers to solid 
samples
NA
Sample Fixation time Value ranges mostly in hours NA Value list NA
Sample Long-term 
preservation
Type of preservation Can include 
formalin 
fixation, 
freezing, and 
indication of 
temperature
Called “long-
term storage”, 
combining 
this value and 
the values 
of “storage 
temperature” in 
a single value list
NA
Sample Storage 
temperature
Temperature A temperature 
or range
Called “long-
term storage”, 
combining 
this value and 
the values 
of “storage 
temperature” in 
a single value 
list
NA
Sample Sampled time Time of sampling NA NA The time when the 
sample was taken
Sample Anatomical site The part of the body from which 
the sample was taken
Organ of origin 
or site of blood 
draw
NA Five values: name, 
version of ontology, 
anatomical code, 
description, and 
free text
Sample Biospecimen 
disease status
For tissue, the pathological 
status of the specific sample
Normal, 
diseased, 
normal adjacent
NA NA
Table A5.1. Minimum data set and associated standard available in BRISQ, SPREC, and MIABIS (continued) 
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Type of data set Data field Explanation of data field BRISQ Tier 1 SPREC MIABIS
Sample Clinical 
characteristics
— Available 
medical 
information
NA NA
Sample Vital status — Alive or 
deceased
NA NA
Sample Clinical diagnosis Clinical information Clinical 
evaluation 
based on 
anamnesis 
and physical 
examination
NA NA
Sample Pathological 
diagnosis
Pathological information Macroscopic 
and microscopic 
pathological 
evaluation
NA NA
Sample Collection 
mechanism
How the sample was taken; 
helps define also whether 
before or after treatment
FNA, pre-
operative blood 
draw, etc.
NA NA
Sample Storage duration Field recording the length of 
time that the sample has been 
stored
Time between 
acquisition and 
use
NA NA
Sample Shipping 
temperature
The temperature that 
is maintained during 
transportation
Temperature 
maintained 
during shipping
NA NA
Sample Composition 
assessment and 
selection
Criteria used for use; this field 
is mainly only after use in a 
specific research study
Criteria used for 
selection
NA NA
BRISQ, Biospecimen Reporting for Improved Study Quality; FNA, fine-needle aspiration; ISO, International Organization for Standardization; LN2, 
liquid nitrogen; MIABIS, Minimum Information about Biobank Data Sharing; NA, not applicable; NCI, United States National Cancer Institute; OCT, 
optimal cutting temperature; SPREC, Sample PREanalytical Code.
Table A5.1. Minimum data set and associated standard available in BRISQ, SPREC, and MIABIS (continued) 
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